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ABSTRACT
PROBING THE DOMAIN ARCHITECTURE AND STRUCTURAL DYNAMICS
OF CASPASE-6 FOR ITS SPECIFIC REGULATION
MAY 2017
KEVIN BULADLART DAGBAY, B.S., UNIVERSITY OF THE PHILIPPINES
MANILA
M.S., UNIVERSITY OF THE PHILIPPINES DILIMAN
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Jeanne A. Hardy
Caspases are cysteine aspartate proteases that direct programmed cell death in
multicellular organisms.

Activation of caspases is tightly regulated to secure

maintenance of cellular homeostasis. The aberrant regulation of caspases can
act

as

molecular

triggers

for

a

range

of

diseases

from

cancer

to

neurodegeneration. The detailed exploration of caspase structure, dynamics,
function, and regulation is crucial to better understand and precisely control their
cellular functions. This body of work specifically provides a multi-level
understanding of the unique structural dynamics and regulation of caspase-6, the
function of which is implicated in Alzheimer’s and Huntington’s diseases. A
detailed map of conformational flexibility of caspase-6 upon the five stages of
proteolytic activation revealed critical regions with discrete conformations that
offers a comprehensive scaffold for strategic design of therapeutics for
neurodegeneration. Meanwhile, the exploration on the natural mutations in
caspase-6 that have arisen from abnormally regulated tumor cells uncovered key
stabilizing interaction in regulatory region that appears to be exploited across the
family of caspases. In addition, the finding of ATP as a natural ligand of
procaspase-6 provides another layer of regulation to the already complex
caspase-6-associted signaling. Finally, the discovery of the most potent and
selective inhibitor of caspase-6 to date enabled specific regulation possible by
targeting a unique cysteine in the most diversified region in caspases.
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CHAPTER 1
APOPTOTIC CASPASE STRUCTRE, FUNCTION, REGULATION, AND
DISEASE IMPLICATIONS

1.1 Caspases in Programmed Cell Death
Multicellular organisms are composed of highly organized community of
cells. This exquisite cellular organization affords tight regulations in both cell
division and cell death necessary to maintain cellular homeostasis. Unwanted
cells undergo suicide through a mechanism known as an intracellular
programmed cell death, commonly referred to as apoptosis (from a Greek word
meaning “falling off,” as leaves from a tree) (Kerr et al., 1972). Morphologically,
apoptotic cell death is characterized by cell shrinkage, decrease in cell size, and
tightly packed cytoplasm with visibly dense chromatin organization. Although
apoptosis is typically associated with cell death, it has far-reaching influence on
key cellular processes in organismal development, cellular differentiation,
inflammation,

and

across

diverse

human

diseases

from

cancer

to

neurodegeneration.
A family of highly conserved cysteine aspartate proteases, also known as
caspases, is central to the execution of apoptosis. The momentous discovery of
the first caspase in the family, caspase-1, was initially described (Black et al.,
1989; Kostura et al., 1989) and further characterized by two independent
research labs (Cerretti et al., 1992; Thornberry et al., 1992). This cysteine
protease was originally given a name interleukin-1β-converting enzyme (ICE)
based on its ability to cleave interleukin-1β. Around that time, an essential gene,

1

Ced-3, in the roundworm Caenorhabditis elegans was reported to have roles in
programmed cell death during its development and shares greater than 24%
identity with ICE (Yuan et al., 1993). This marks for the first time a cysteine
protease was associated with programmed cell death. This finding inspired rapid
identification and characterization of other caspases in the family. Later on,
caspase-3 was identified to be the human homologue of Ced-3 (FernandesAlnemri et al., 1994). Thereafter, other caspases were identified and
characterized and an official nomenclature was established (Alnemri et al.,
1996). There are now 12 human caspases that are broadly classified based on
their function as either inflammatory (caspase-1, -4, and -5) or apoptotic. With the
exception of caspase-14, which appears to be a highly specialized enzyme
involved in the differentiation of corneocytes in the epidermis (Denecker et al.,
2008), caspases are further classified based on their entry into the apoptotic
cascades either as initiator (caspase-2, -8, -9, and -10) or executioner (-3, -6,
and -7).

1.2 The Essential Elements of the Apoptotic Pathway
Apoptotic signaling (Figure 1.1) showcases the death-inducing power of
caspases along with other factors that trigger their activation. Initiator caspase
activation typically involves the formation of signaling complexes such as DISC
(death-inducing signaling complex) (Muzio et al., 1998), the apoptosome (Cain et
al., 2000), or the PIDDosome (Tinel and Tschopp, 2004) following the so-called
extrinsic or intrinsic activation routes (MacKenzie and Clark, 2012). In the

2

extrinsic pathway, death ligands bind to death receptors to form a platform for
binding of initiator caspases through its DED (death effector domain) motifs in the
prodomain (Muzio et al., 1996) resulting in the oligomerization and subsequent
activation of procaspases (Muzio et al., 1998; Oberst et al., 2010). In the intrinsic
pathway, the exposure of the cell to various stimuli such as cytotoxic drugs, DNA
damage, reactive oxygen species (ROS) triggers the activation of procaspase-9
through formation of the apoptosome, a multiprotein complex dependent on the
binding of the cytochrome c, upon its release form the mitochondria, to the Apaf1 and the CARD (caspase recruitment domain) of caspase-9 (Bao and Shi, 2007;
Chu et al., 2001; Pop et al., 2006).

Figure 1.1 The Apoptotic Pathway
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The initiation steps from both extrinsic and intrinsic apoptotic pathways are
geared towards the activation of the initiator caspases that then activate the
downstream executioner caspases to ultimately induce cellular death through
series of proteolytic cleavage events of apoptotic targets. Clearly, the central
contribution of caspases in the apoptotic pathway is a determinant of life and
death of a cell, thus, underscoring the necessity to dissect every aspect of
caspase structure, function, activation, and regulation. In this way, when the time
comes we need to control these caspases for therapeutic reasons, we have the
necessary tools to do so.

1.3 The Structure and Activation Mechanisms of Caspases
Nature has been very clever in the design of the activation pathways for
these death-inducing caspases. Cells synthesize these caspases as inactive
precursors, known interchangeably as procaspases or zymogens, to avoid
unsolicited activation. It is only upon appropriate signal received by the cells that
these caspases are activated through chain of proteolytic cleavage events.
Moreover, these procaspases are organized to contain highly conserved
aspartate residues that are positioned in between the prodomain and large
subunit and in their intersubunit linker, which connects the large and small
subunits together (Figure 1.2). Positioning these aspartate residues in these
designated locations within procaspases ensures proper order of proteolytic
events to occur for their appropriate activation.
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Figure 1.2 The Structural Organization of Caspase
(A) Linear cartoon of procaspase-6 illustrating the prodomain (green), large
subunit (light gray), intersubunit linker (magenta) and small subunit (dark gray).
The active site Cys–163 is denoted by a dot. Arrows indicate proteolytic cleavage
sites. (B) Model of full-length procaspase-6 zymogen.

Initiator caspases generally exist as monomers and are subsequently
activated by dimerization, which is mediated by formation of molecular platform
(Bao and Shi, 2007; Chu et al., 2001; Muzio et al., 1996; Oberst et al., 2010; Pop
et al., 2006)
In contrast, executioner caspases exist as dimeric inactive zymogens and
are activated by limited proteolysis by initiator caspases. The proteolytic
cleavage at the intersubunit linker allows conformational change that brings the
two active sites of executioner caspase dimer together and forms a functional
mature caspase (Pop and Salvesen, 2009; Riedl and Shi, 2004). The activated
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executioner caspase can then cleave and activate other caspases creating a
productive feedback loop for sustained caspase activation.
Despite variations in the mode to activation, there are unifying biochemical
and structural features across the family of caspases. As enzymes, caspases
engage the Cys–His catalytic dyad in their active site from each monomer of a
homodimer (Figure 1.2) to cleave a peptide bond adjacent to an aspartate
residue at the P1 cleavage site in select protein substrates. Moreover, the active
site of caspases is composed of four mobile loops (L1, L2, L3, L4) that must be
properly oriented to afford binding and efficient catalytic turnover of the target
substrate. These mobile loops sample an ensemble of conformational states
throughout the lifetime of the protein that enable flexibility of caspases to
accommodate a spectrum of substrates and regulators.
Evidence for rearrangement in the mobile loops in caspase-6 along its
path

to

proteolytic

activation

has

been

suggested

by

protein

X-ray

crystallography. The procaspase-6 zymogen (Cao et al., 2014; Wang et al.,
2010), mature, unliganded caspase-6 (Baumgartner et al., 2009; Vaidya et al.,
2011), and the substrate-bound (Muller et al., 2011; Wang et al., 2010) structures
have all been solved (Figure 1.3) and will be described in the following sections
to infer from the absence of key pieces of electron density that loop
rearrangement in caspases are key to achieving a catalytically competent state
of the enzyme. In the procaspase-6 zymogen structure, L3 is pinned down by the
linker, which sits atop the active site cavity. L4 is disordered indicating a highly
flexible loop that is possibly not engaged in interaction with other loops. The L2
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that includes the catalytic Cys–163 is buried and stabilized across the dimer
interface, a configuration far from a substrate-binding competent state. Cleavage
in the intersubunit linker generates a mature and active caspase-6 wherein all
loops deviate from the loop orientation of procaspase-6 zymogen. Also, with the
intersubunit cleaved, L3 orients closer to L4, together with the reoriented L2,
forms the catalytically active substrate-binding cavity. The conformations of the
60’s and the 130’s region in the mature unliganded caspase-6 are extended,
which represent a noncanonical conformation of caspase-6. In particular, the
observed conformation in the 130’s region is not present in any other caspases.
All other caspases are constitutively found in the canonical (strand) conformation,
regardless of the activation state of the enzyme. Upon binding to an active site
peptide-based inhibitor, L2 engages with L2’ of the other half of the dimer and the
rest of the loops are oriented to form the active site poised to bind and cleave
substrates.

The structural details of the activation of caspase-6 provide the

platform to ascertain how mechanistically a caspase can be specifically targeted.
Several inhibitors designed to target the mature caspase-6 have been shown to
revert to its zymogen-like conformation particularly L2 being buried deep in the
dimer interface cavity and thus suggests that the mobility of these loops is critical
for the proper assembly of the substrate-binding groove for efficient binding and
catalysis of substrates. Despite the abundance of crystal structures of the various
forms of caspases, the information on the conformational dynamics of regions
not visible in the crystal structures possibly due to their high flexibility are still
missing specially the regions of the prodomain, linker, and in
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Figure 1.3 Structures of Caspase-6 Maturation Variants
The structures of procaspase-6 zymogen (PBD code 3NR2), the mature
unliganded (PBD code 2WDP), and the substrate-bound (PDB code 3OD5)
caspase-6.

some parts of L2 and L4. Thus, to provide a complete picture of the underlying
mechanism of caspase activation, the missing information on the conformational
dynamics in these disordered regions must be satisfied. This dissertation is
geared to address this information gap with emphasis on the impact of the
prodomain and linker on the conformational dynamics of caspase-6 along its
route to proteolytic activation.

1.4 Distinguishing Features of Caspase-6
The discovery of unique and exploitable features in a caspase is an
impeccable contribution towards efforts on targeted regulation of caspases. The

8

fact that caspases, in addition to having the same overall protein fold, share the
same active site chemistry making targeted regulation of caspases very
challenging. Structural studies have uncovered several key features in caspase-6
that are distinguishing from the rest of the member of the caspase family. Mature,
unliganded caspase-6 displays an extended helical conformation in its 60’s and
130’s regions (Baumgartner et al., 2009; Vaidya et al., 2011) as well as having a
longer L2, atypical for caspases. When locked in the extended helical
conformation, mature caspase-6 is incompetent to bind substrates. This inability
to bind and catalyze substrate turnover can be attributed to the Cys–His catalytic
dyad, whose reactive centers should be within 1.8 to 3.5 Å (Štrajbl et al., 2000),
are pushed way from each other by 9 Å (Vaidya et al., 2011) while a longer L2
was shown to regulate the autoactivation process of a procaspase-6 zymogen
(Wang et al., 2010). In addition, sequence alignment analysis revealed that the
regions of lowest amino acid conservation are in the regions of the prodomain
and L4 across all caspases. Thus, despite some unique structural features of
unknown functions, these points to an opportunity for strategic design of targeted
regulation of caspases through enhanced understanding of these regions.
Biochemical and cellular studies of caspases have been important in
underscoring unique functions and regulatory mechanisms of caspases.
Particularly, the cellular studies in caspase-6 that revealed a unique selfactivation mechanism (Klaiman et al., 2009), which could possibly be associated
with caspase-6 being only weakly apoptotic, with its major roles outside the
apoptotic pathways. The mechanism of self-activation of procaspase-6 was
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further elucidated using structural studies through protein X-ray crystallography
(Wang et al., 2010). Caspase-6 has been shown to often be activated by
caspase-3, which is not typical for an executioner caspase that are usually
activated by initiator caspases. Caspase-6 assumes roles that overlap to the
roles of other caspases including as an inflammatory caspase being activated by
caspase-1 (Guo et al., 2006) and as an initiator caspase directly cleaving
caspase-8 (Cowling and Downward, 2002). In addition, although caspase-6
shares 41% and 37% sequence identity with executioner caspase-3 and
caspase-7, respectively, its substrate specificity differs from that of executioners
and matches closely to that of the initiator caspases (Julien et al., 2016;
Thornberry et al., 1997). Lastly, IAPs (inhibitor of apoptosis proteins), known
inhibitors of caspae-3 and caspase-7, which binds in the active site, cannot bind
and inhibit caspase-6 (Suzuki et al., 2001). This suggests the possible existence
of a unique conformational ensemble of caspase-6 in cellular conditions.
Together, these data on the unique structural, biochemical, and cellular functions
of caspase-6 suggest the potential for targeted regulation in caspase-6 that are
open to exploration. This dissertation stages the exploitation of a unique cysteine
in the most diversified loop (L4) in caspases, which has enabled targeted
regulation of caspase-6.
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1.5 Regulatory Mechanisms of Caspase-6
Several regulatory mechanisms have been demonstrated in caspase-6,
which emphasizes the importance of its functions in the various cellular
processes. One of the regulatory mechanisms in caspase-6 is through its
prodomain. The prodomain in caspase-6 is not as clearly associated with
particular cellular functions as in other caspases where the prodomain has been
shown to participate, for example, in protein-protein interactions, which impact
protein folding (Feeney and Clark, 2005) and proteasomal degradation (Choi et
al., 2009). Recently, the prodomain has been found to inhibit the self-activation of
procaspase-6 in HEK293T cells (Klaiman et al., 2009) and in vitro at low protein
concentrations (Cao et al., 2014). In addition, zinc binding to caspase-6 has been
reported to inhibit the enzyme activity of caspase-6. The regulatory mechanism
was further explored using crystallography and found that zinc allosterically binds
to caspase-6 in a region with low amino acid sequence conservation and thus is
proposed to be an exosite unique to caspase-6 (Velazquez-Delgado and Hardy,
2012b).
One of the most highly interrogated mechanisms of enzyme regulation is
through posttranslational modification and casapse-6 is not an exception. It has
been shown that caspase-6 is phosphorylated at Ser–257 in vivo and in vitro
(Suzuki et al., 2004). As a phosphomimetic to interrogate the mechanism of
inhibition, the S257D substitution was introduced into mature caspase-6 and its
crystal structure was solved, revealing the inhibitory action of phosphorylation,
which stems from a steric clash that causes misalignment of substrate binding
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groove resulting to a substrate-binding incompetent conformation (VelazquezDelgado and Hardy, 2012a). Meanwhile, this same position was interrogated and
a phosphomimetic S257E was introduced into the procaspase-6 zymogen and
was found, in addition to the steric hindrance regulatory mechanism, to affect the
self-activation of procaspase-6 by “locking” the enzyme in the TEVD-bound
inhibited state (Cao et al., 2012). Quite recently, palmitoylation of caspase-6 by
palmitoyl acytransferase HIP4 was found to exert inhibitory mechanism to
caspase-6 (Skotte et al., 2016). Predominant palmitoylation was found to be at
the unique Cys–264 within L4 of caspase-6, which results in steric blockage of
the substrate-binding groove as well as possibly through inhibition of caspase-6
dimerization.
Taken together, the fact that caspase-6 is tightly regulated at several
levels indicate the sensitivity of the cellular homeostatic machineries to the
presence of caspase-6. To add to this already complex regulatory mechanism of
caspase-6, this dissertation explores cellular nucleotides as regulatory natural
ligands specific for procaspase-6 zymogen form, of which cellular consequences
remain to be uncovered.

1.6 Cancer-Associated Functions of Caspase-6
One of the hallmarks of cancer is the failure of apoptosis (Hanahan and
Weinberg, 2011). Caspase-6 is broadly classified as one of the executioner
caspases in the apoptotic cascade; however, the association of caspase-6 in
cancer has been largely unexplored. Recent MS-based proteomics approach
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revealed several unique caspase-6 substrates (Julien et al., 2016) that were
identified to be tumor-associated based on its inclusion in the census of human
cancer genes (Futreal et al., 2004). Notable substrates, among many others,
include the subcellular tumor antigen p53, TP53 and the breast cancer type 1
susceptibility protein, BRCA1. Thus, the association of caspase-6 with these
known tumor-associated substrates suggests the potential involvement of
caspase-6 in the development of cancer.
In addition, a study on inflammation-induced tumorigenesis in a mouse
model of colon cancer was shown to be independent of caspase-6.(Foveau et al.,
2014). Mice overexpressing caspase-6 showed changes in the colonic tumor
multiplicity, burden or distribution to be like that of the caspase-6 deficient mouse
model of colon cancer. Thus, suggesting that caspase-6 is unlikely to contribute
to coilitis-associated tumors. However, in a separate study, it was shown that
survivin-3B promotes chemoresistance and immune system surveillance escape
by inhibiting caspase-8 and -6 in cancer cells (Vegran and Boidot, 2013).
Survivin-3B increases the resistance of neoplastic cells to chemotherapeutics by
inhibiting caspase-6 and caspase-8 activation (Vegran and Boidot, 2013).
Moreover, survivin-3B overexpression also mediated resistance to cancer
chemotherapy, in this case, through interactions with procaspase-6. Also,
survivin-3B binding to procaspase-6 inhibited its activation despite mitochondrial
depolarization and caspase-3 activation. Thus, suggesting the potential role of
caspase-6 inhibition in promoting chemoresistance in cancer cells.
It has also been shown that select routes of chemotherapeutic intervention
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depend on caspase-6 for cancer apoptotic cell death. One example where
apoptotic execution was found to be solely dependent on caspase-6 rather than
caspase-3 or caspase-7 in cancer apoptosis is aloe emodin (AE), a natural
anthraquinone, is reported to have anti-proliferative activity in various cancer cell
lines and induces apoptosis specifically through the activation of caspase-6
(Suboj et al., 2012). Thus, caspase-6-dependent apoptosis in these cancer cells
lines indicates the unexplored impact of caspase-6 functions in cancer
prevention.
Uncontrolled cell growth and reduced susceptibility to apoptosis are other
hallmarks of cancer, and caspase inhibition can reduce the tendency of cells to
undergo apoptosis, thus promoting tumorigenesis (Hanahan and Weinberg,
2011). Likewise, the development of inhibitory somatic mutations could
potentially diminish cancer cell apoptosis. The Catalogue of Somatic Mutations in
Cancer (COSMIC) database (Forbes et al., 2011), a comprehensive resource of
occurring somatic mutations in human cancer, identified several CASP6 gene
somatic mutations. In addition, a mutational analysis study (Lee et al., 2006)
found several missense and nonsense mutations in CASP6 gene in gastric and
colorectal tumor tissues. The identified tumor mutations have no reports on the
functional characterization of the proteins resulting from mutant CASP6 gene.
This dissertation attempts to determine the effect of these mutations in caspase6 function as a step to contribute to uncovering the roles of caspase-6 in cancer.
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1.7 Neurodegenerative Attributes of Caspase-6
Unlike other executioner caspases, which require processing by initiator
caspases for activation (Chai et al., 2001), caspase-6 can undergo self-cleavage
and activation (Klaiman et al., 2009; Wang et al., 2010). Although self-cleavage
does not lead to apoptosis, caspase-6 self-cleavage may account for some
nonapoptotic roles of caspase-6 including axonal pruning in development
(Harrington et al., 2010; Nikolaev et al., 2009; Schoenmann et al., 2010; Simon
et al., 2012) and in the context of neurodegeneration. Caspase-6 cleaves a
compelling set of neuronal substrates including microtubule-associated protein
Tau (Horowitz et al., 2004). In that study, caspase-6 cleaved tau at Asp-13 in the
N-terminal region implicates caspase-6 in the neurofibrillary tangle formation as
well as in the evolution and progression of Alzheimer’s disease (AD).
Caspase-6 also cleaves the AD-associated substrates amyloid precursor
protein (APP) and presenilin I (PSENI) and II (PSENII) (Albrecht et al., 2009). In
the Albrecht et al. (2009) study, caspase-6 activity was observed in APP Swedish
and PSENI hippocampus and correlated with increased levels of beta amyloid
peptide levels in these samples. The study suggested that the presence of
caspase-6 activity in the AD APP, PSENI, and PSENII mutants implicates
caspase-6 in the pathophysiology of AD.
In addition, caspase-6 also cleaves the Huntington’s disease (HD)associated polyglutamine-expanded and native huntingtin (htt) protein (Graham
et al., 2010; Graham et al., 2006). Those prior studies showed that caspase-6
activity is observed before the onset of motor abnormalities in humans and in
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murine models of HD and further showed that caspase-6 levels were directly
proportional with CAG size and inversely correlated with age of onset. Moreover,
in the YAC mice expressing caspase-6 resistant (C6R) mutant htt, where Asp586 caspase-6 cleavage site in htt was mutated, showed decreases in both
caspase-6 activity and apoptotic cell death. These data suggest that C6R mhtt is
neuroprotective by influencing neuronal and excitotoxic pathways in HD. In a
recent report, the genetic knockout of caspase-6 in the YAC128 mouse model of
HD showed a decrease in mhtt-586 fragment that resulted in a partial rescue of
body weight and reversal of depression-like phenotype, thus implicates caspase6 as a key contributor to some features of HD (Wong et al., 2015).
Finally, caspase-6 cleaves Parkinson disease protein 7 (PARK7), also
known as protein deglycase DJ-1 (Giaime et al., 2010). In that study, cleavage of
DJ-1 by caspase-6 fully accounts for the p-53-dependent cell death and
suggested to be neuroprotective. An early-onset PD-associated mutation in
caspase-6 cleavage (D149A) in DJ-1 showed resistance to caspase-6 proteolysis
and diminished its neuroprotective phenotype in PD.
Caspase-6 has now been embraced as a promising molecular target for
neurodegenerative treatments because cleavage of these neuronal substrates
plays key roles in the pathophysiological outcome in Alzheimer’s (Albrecht et al.,
2007; Galvan et al., 2002; Galvan et al., 2006; Gervais et al., 1999; Guo et al.,
2004; Klaiman et al., 2008; LeBlanc, 2013; Lu et al., 2000; Nguyen et al., 2008;
Saganich et al., 2006; Zhao et al., 2003), Huntington’s (Aharony et al., 2015;
Graham et al., 2010; Graham et al., 2006; Hermel et al., 2004; Milnerwood et al.,
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2010; Riechers et al., 2016; Warby et al., 2008; Wong et al., 2015), and
Parkinson’s diseases (Giaime et al., 2010). Thus, understanding of caspase-6
structure and its relation to function is central to achieving targeted caspase-6
regulation in neurodegeneration.

1.8 Targeted Regulation of Caspase-6 using Natural and Synthetic
Inhibitors
Because of the association of caspase-6 with neurodegeneration, the
need to search for specific inhibitors of caspase-6 invokes a heightened interest.
Unfortunately, caspases have overlapping substrate specificities (McStay et al.,
2008), thus inhibitors directed at the active site will not be selective for only one
caspase. This was demonstrated by the promiscuity of several competitive
peptide-based inhibitor including ED11 (Wong et al., 2015), z-VEID-fmk
(Eichhold et al., 1997) and aza-peptide epoxide and Michael acceptors class of
inhibitors (Ekici et al., 2006; James et al., 2004) and the peptide-based inhibitor
that was designed based on the caspase-6 cleavage site in the transcription
factor AP-2 alpha (Nyormoi et al., 2003). The same promiscuity of caspase-6
active-site directed small molecule inhibitors was also observed including
methylene blue (Pakavathkumar et al., 2015), the class of pancaspase
irreversible inhibitors identified through substrate-based fragment approach
(Leyva et al., 2010) and several other series of sulfonamide Isatin Michael
acceptors (Chu et al., 2009). Taken together, due to the similarity of the binding
interfaces and chemistry of caspases in their active sites, the aim of targeted
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caspase-6 regulation using active site directed inhibitors is nearly impossible.
Several attempts to synthesize uncompetitive small molecule inhibitors
have also been reported. A seemingly potent (11 nM) and selective (10-fold)
caspase-6-specific inhibitors were uncompetitive inhibitors (Heise et al., 2012).
Its inability to inhibiting cleavage of lamin A by caspase-6 in vitro, led the authors
to realize that this inhibitor only works with fluorogenic substrate but not with
other fluorogenic substrate nor any native substrates. Thus, this class of
inhibitors has no potential whatsoever as a drug lead. This finding underscores
the need for new classes of caspase-6 inhibitors.
So far, any attempts to inhibit caspase-6 exploiting the active site have not
been successful, thus allosteric inhibition to enable capase-6 specific inhibition is
promising. An example of an allosteric peptide inhibitor is Pep419 (Stanger et al.,
2012), a low micromolar inhibitor that binds and promotes procaspase-6
zymogen tetramerization, thus preventing proteolytic activation of procaspase-6.
Pep419 was identified through phage display. It has been shown to be selective
for caspase-6 in neuronal cells but exhibited poor cell penetration properties, as it
required electroporation for delivery to neuronal cells. This suggests a clear
limitation for applications in cellular studies and as a future therapeutic lead.
Lastly, an allosteric small molecular inhibitor from a fragment-merging strategy
identified nanomolar-affinity ligands that bind in the dimer interface and stabilize
procaspase-6 and prevent it from activation. These compounds have been
shown to lock L2 in the inactive conformation, thus preventing its rearrangement
as part of the loop assembly to form the substrate-binding competent active site
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cavity (Murray et al., 2014). However, these compounds have unknown
selectivity profile, thus making it less promising to become therapeutic leads.
Moreover, active caspase-6 accumulates before the onset of AD symptoms
(Albrecht et al., 2007), thus stabilizing procaspase-6 zymogen conformation may
be less impactful in the treatment of AD.
Finally, the only known caspase-6-specifc natural inhibitor is the
alternatively spliced isoform of casapse-6 known as procaspase-6b (Lee et al.,
2010). This natural inhibitor binds procaspase-6 and inhibits its proteolytic
activation in vitro and in vivo. However, although the procaspase-6b active site
Cys–163 is intact, it shows no activity nor it can inhibit already activated caspase6. The potential of this natural inhibitor as a scaffold for the design of a peptidebased caspase-6-specific inhibitors is encouraging. The fact that it shows cellbased activity against procaspase-6 proteolytic activation suggests favorable
binding characteristics that can potentially be exploited for therapeutic purposes.
In summary, caspases impact a spectrum of diseases from cancer to
neurodegeneration. Thus, understanding their structure, dynamics, function,
activation, and regulation is critical to providing means to control its cellular
functions for therapeutic purposes. The findings of caspase-6 to be highly
associated in neurodegeneration and cancer provide the necessary inspiration to
search for strategies to specifically target its activity and its associated
debilitating functions. In this dissertation, we use multi-level approach to probe
the domain architecture and structural dynamics of caspase-6 for its targeted
regulation.
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CHAPTER 2
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2.1 Abstract
Caspases are cysteine aspartate proteases that are major players in key
cellular processes, including apoptosis and inflammation. Specifically, caspase-6
has

also

been

implicated

in

playing

a

unique

and

critical

role

in

neurodegeneration; however structural similarities between caspase-6 and other
caspases have hampered precise targeting of caspase-6. All caspases can exist
in a canonical conformation, in which the substrate binds atop a beta-strand
platform in the 130’s region. This caspase-6 region can also adopt a helical
conformation that has not been seen in any other caspases. Understanding the
dynamics and interconversion between the helical and strand conformations in
caspase-6 is critical to fully assess its function and regulation. Here,
hydrogen/deuterium exchange mass spectrometry indicated that caspase-6 is
inherently and dramatically more conformationally dynamic than closely related
caspase-7. In contrast to caspase-7, which rests constitutively in the strand
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conformation before and after substrate binding, the hydrogen/deuterium
exchange data in the L2’ and 130’s regions suggested that prior to substrate
binding, caspase-6 exists in a dynamic equilibrium between the helix and strand
conformations. Caspase-6 transitions exclusively to the canonical strand
conformation only upon substrate binding. Glu-135, which showed a noticeably
different calculated pKas in the helix and strand conformations, appears to play a
key role in the interconversion between the helix and strand conformations.
Because caspase-6 has roles in several neurodegenerative diseases, exploiting
the unique structural features and conformational changes identified here may
provide new avenues for regulating specific caspase-6 functions for therapeutic
purposes.

2.2 Introduction
Caspases are cysteine proteases that recognize aspartate-containing
substrates, and are major players in key cellular processes, including apoptosis
and inflammation. Caspase active sites contain a Cys–His dyad required for
cleavage of peptide bonds adjacent to aspartate residues in select protein
substrates. There are two main classes of caspases, initiator and executioner
caspases, classified based on their cellular function and domain organization.
Initiator caspases (caspase-2, -8, and -9) function upstream in the apoptotic
pathway and activate the downstream executioner caspases (caspase-3, -6, and
-7) by proteolytic cleavage at an intersubunit linker between large and small
subunits. Executioner caspases then cleave a select group of protein targets to
promote apoptosis. Initiator caspases generally exist as monomers and are
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subsequently activated by dimerization mediated by formation of molecular
platform, e.g. apoptosome (Boatright et al., 2003). In contrast, executioner
caspases exist as dimeric inactive zymogens and upon activation by limited
proteolysis become functional dimers (Pop and Salvesen, 2009). Significantly,
classification of caspase-6 as an executioner has not been unequivocal.
Caspase-6 is weakly apoptotic, although overexpression of caspase-6 in
mammalian cells does result in apoptosis (Suzuki et al., 2004). As an
executioner, caspase-6 has been identified as the only caspase that cleaves the
nuclear lamellar protein, lamin A/C during apoptosis (Orth et al., 1996;
Srinivasula et al., 1996; Takahashi et al., 1996). Caspase-6 has been shown to
cleave caspase-8 (Cowling and Downward, 2002) and be activated by caspase-3
(Srinivasula et al., 1998) and caspase-1 (Guo et al., 2006), suggesting that
caspase-6 assumes simultaneous roles as an executioner, initiator, and
inflammatory caspase.
Unlike other executioner caspases, which necessitate processing by
initiator caspases for activation (Chai et al., 2001), caspase-6 is capable of selfcleavage and activation (Klaiman et al., 2009; Wang et al., 2010). Although selfcleavage does not lead to apoptosis, this caspase-6 self-cleavage may account
for some nonapoptotic roles of caspase-6 including axonal pruning in
development (Harrington et al., 2010; Nikolaev et al., 2009; Schoenmann et al.,
2010; Simon et al., 2012) and in adult brains (Park et al., 2010) as well as in B
cell activation and differentiation (Watanabe et al., 2008). In the context of
neurodegeneration, caspase-6 cleaves a compelling set of neuronal substrates
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including microtubule-associated protein tau (Horowitz et al., 2004), amyloid
precursor protein (Albrecht et al., 2009), presenilin I and II (Albrecht et al., 2009),
polyglutamine-expanded and native huntingtin protein (Graham et al., 2006), and
Parkinson disease protein 7 (PARK7), also known as protein deglycase DJ-1
(Giaime et al., 2010). Caspase-6 is considered a promising molecular target for
neurodegeneration treatments because cleavage of these neuronal substrates
plays key roles in the pathophysiological outcome in Alzheimer’s (Albrecht et al.,
2007; Galvan et al., 2002; Galvan et al., 2006; Gervais et al., 1999; Guo et al.,
2004; Klaiman et al., 2008; LeBlanc, 2013; Lu et al., 2000; Nguyen et al., 2008;
Saganich et al., 2006; Zhao et al., 2003), Hungtington’s (Aharony et al., 2015;
Graham et al., 2010; Graham et al., 2006; Hermel et al., 2004; Milnerwood et al.,
2010; Riechers et al., 2016; Warby et al., 2008; Wong et al., 2015), and
Parkinson’s diseases (Giaime et al., 2010). Thus, a full understanding of
caspase-6 structure and its relation to function is central to achieving caspase-6specific regulation in neurodegeneration.
Perhaps the most unique feature of caspase-6 is that it is the only
caspase that can adopt two very different structural conformations. These two
conformations stem from structural changes in the 130’s region, which generates
the platform upon which substrate binds (Figure 2.1). Structures of the
procaspase-6 zymogen, in which the intersubunit linker occupies and orients the
active site loops (Cao et al., 2014; Wang et al., 2010), and mature caspase-6
bound to a substrate-like inhibitor (Liu et al., 2011; Muller et al., 2011a; Wang et
al., 2010) are similar to other caspases and show the canonical strand
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conformation. These structures underscore the observation that caspase-6 is
fully capable of adopting the canonical caspase active site conformation. The
mature unliganded caspase-6 is also capable of adopting a distinctive and
noncanonical conformation, with extended helices in the 60’s region (residues
57-70) and 130’s region (residues 125-142) (Baumgartner et al., 2009; Vaidya et
al., 2011). These conformational changes are also accompanied by a 21°
outward rotation of the 90’s helix (Figure 2.1). This helical conformation of
unliganded caspase-6 is not seen in crystal structures of other caspases. In fact,
the helical form is disallowed in all other caspases by the presence of helixbreaking residues in this region (Vaidya and Hardy, 2011; Vaidya et al., 2011). In
caspase-6, when the 130’s region is in the extended helical conformation, the
Cys–His catalytic dyad, whose reactive centers must be within 1.8 to 3.5
angstroms of one another to achieve catalysis (Štrajbl et al., 2001), are pushed
away from each other by 9Å. In addition, the top of the 130’s helix prevents
substrate binding. As a consequence, caspase-6 is catalytically inactive when
locked in this conformation. In order for caspase-6 to accommodate a substrate
in the active site, a conformational rearrangement has to occur in the 60’s, 90’s,
and 130’s helices and loops 1 to 4. This transition is thought to occur through a
low stability/high energy intermediate strand-containing state in the 130’s region
(Vaidya and Hardy, 2011). Unliganded caspase-6 has also been crystallized in
the canonical strand conformation with a more properly
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Figure 2.1 Caspase-6 Undergoes Helix-Strand Transition Upon Substrate
Binding
The overall fold of canonical caspases before and after substrate binding is
represented by the superimposition of the unliganded (orange, PDB code 1K86)
and the peptide-based substrate mimic DEVD-bound (green, PDB code 1F1J)
structures of caspase-7 (middle). Highlighted regions are the active-site cysteine
(blue), the dimer interface, and the substrate binding loops 1 to 4 (L1, L2, L3, L4).
Caspase-7, like all other caspases, adopts a canonical strand conformation in its
130’s region in both the unliganded state (orange, PDB code 1K86) and the
peptide-based substrate mimic DEVD-bound (green, PDB code 1F1J) states
(right). In contrast, caspase-6 can adopt a noncanonical extended helical
conformation in its 130’s region in the unliganded state (orange, PDB code
2WDP) but recovers the canonical strand conformation upon binding to a
peptide-based substrate mimic VEID-aldehyde (green, PDB code 3OD5) (left).
positioned Cys–His dyad (separated only by 3.6Å) capable of binding substrate
(Muller et al., 2011b). This structure of the mature unliganded form of caspase-6
is similar to all other caspases. Thus, it is clear that caspase-6 is capable of
adopting both helical and strand conformation of the 130’s region in the absence
of substrate. These structures underscore the remaining question: what is the
physiologically relevant structural ensemble for unliganded caspase-6? The goal
of this work is to understand the relative populations of the helical and strand
conformations of mature caspase-6 prior to substrate binding.
The crystal structures of caspase-6 are static molecular snapshots. A
complimentary study to depict temporal dynamic changes is needed to define the
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conformational

ensemble

of

caspase-6

prior

to

substrate

binding.

Hydrogen/deuterium exchange mass spectrometry (H/DX-MS) is a powerful
technique to study protein conformation and dynamics (for review (Pirrone et al.,
2015)) and has been applied to several systems including protein/ligand
complexes (Landgraf et al.), chaperones (Kirschke et al., 2014), amyloid fibrils
(Hodkinson et al., 2012), viral proteins (Snijder et al., 2014), antibody-drug
conjugates (Pan et al., 2014), and even peripheral (Burke et al., 2012) and
transmembrane (Mehmood et al., 2012) proteins. H/DX-MS reports the extent of
hydrogen bonding and relative solvent exposure of the backbone amide
hydrogens, and is well suited for extrapolating different protein conformations
(Wales and Engen, 2006).
In this study, H/DX-MS combined with molecular dynamics (MD)
simulations, was used to probe the distinct conformational dynamics in caspase6 relative to caspase-7 upon peptide-based substrate binding. Caspase-7 serves
as an ideal control, possessing the same overall fold, but maintaining
constitutively the strand-form before and after substrate binding. Our results
show that caspase-6 displays a unique backbone dynamics in the 130’s region
compared to caspase-7, consistent with the helix-strand interconversion upon
substrate binding. Moreover, the protonation of Glu-135 in this region was found
to be an important contributor to the stability of the helical state of unliganded
caspase-6. Exploiting these unique structural features may provide new avenues
for regulating specific caspase-6 functions.
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2.3 Results
2.3.1 Overall H/DX-MS Profiles of Caspase-6 and Caspase-7

To explore the differences in the backbone dynamics and conformational
flexibility of caspases, caspase-6 and caspase-7 were profiled using H/DX-MS in
the mature unliganded and bound to a substrate-like inhibitor states. The
substrate-bound states were achieved by binding inhibitors built from the
tetrapeptide recognition substrates, VEID-aldehyde for caspase-6 and DEVDaldehyde for caspase-7. The H/D exchange rate of the backbone amide
hydrogen with deuterium in the solvent is interpreted as reporting the local
fluctuations of the conformational states of proteins (Englander and Kallenbach,
1983). Thus, fast rates of H/D exchange indicate higher solvent accessibility and
flexibility of associated protein region, whereas those regions that show slow
rates of H/D exchange are characterized as being buried and rigid (Wales and
Engen, 2006). Peptide heat maps show the extent of the relative deuterium
uptake of the peptic peptides of caspase-6 and caspase-7 in both the unliganded
and inhibitor-bound forms after being subjected to between 10 seconds and 2
hours of H/D exchange (Figure 2.2). The corresponding relative deuterium
uptake profiles were mapped onto the crystal structures of caspase-6 (PBD code
2WDP) and caspase-7 (PDB code IK86) (Figure 2.3). The percent difference in
the relative deuterium uptake of the unliganded and inhibitor-bound states of
caspase-6 and caspase-7 were also mapped onto the linear amino acid
sequences (Figure 2.4) and onto the corresponding crystal structures (Figure
2.5). All deuterium uptake plots for both unliganded and bound states of
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caspase-7 and caspase-6 were also prepared (Figure 2.6 and Figure 2.7).
Overall, peptides covering 91% and 93% of the linear sequences of caspase-6
and caspase-7, respectively, were observed (Figure 2.8). Approximately 70% of
the backbone amide hydrogens in both caspase-6 and caspase-7 underwent less
than 30% H/D exchange within 10 seconds, suggesting well-folded and
dynamically stable proteins overall. In contrast, the other 30% of the backbone
amide hydrogens were rapidly deuterated. These rapidly deuterated regions are
predominantly observed in the highly flexible regions, including the loop bundles
(L2, L2’, L3, L4), which form the substrate-binding groove of caspases (Fig. 1).
The reproducibility of the H/DX-MS experiment was extremely high across the
majority of the sequence, and even small differences in the susceptibility to H/D
exchange between the unliganded and liganded states of caspases could be
accurately quantified, facilitating identification of regions in which H/D exchange
was altered in the presence of a peptide-based substrate-mimic (Figure 2.6 and
Figure 2.7).
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Figure 2.2 H/D Exchange Heat Map of the Relative Deuterium Incorporation
For each peptic peptide of the unliganded and the peptide-based substrate
mimic-bound states of caspase-7 (A) and caspase-6 (B), the percent relative
deuterium level for each H/D exchange incubation time (minutes: 0.17, 1, 10, 60,
and 120) is mapped onto its corresponding linear sequence. The percent relative
deuterium incorporation is calculated by dividing the observed deuterium uptake
by the theoretical maximum deuterium uptake for each peptide. The H/DX MS
experiments followed 64 peptides common to both unliganded and DEVD-bound
caspase-7 that covers 93% of the linear sequence. Likewise, H/DX MS
experiments followed 70 peptides common to both unliganded and VEID-bound
caspase-6 that covers 91% of the linear sequence. Peptic peptides with no H/D
exchange data at any given incubation time are colored white. All caspase-6 and
caspase-7 variants used in the H/DX-MS experiments were cleaved and active
forms lacking both the prodomain (residues 1-23 in both caspase-6 and caspase7) and linker (residues 180-193 in caspase-6; residues 199-206 in caspase-7).
The secondary structural elements are also shown on top of the caspase-6 and
caspase-7 sequences. The percent relative deuterium level of each peptic
peptide represents the average values of duplicate experiments performed on
two separate days.
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Figure 2.3 Relative Deuterium Incorporation of Caspase-6 and Caspase-7
Mapped onto its Corresponding Structures
The percent relative deuterium incorporation of caspase-7 (A) and caspase-6 (B)
before and after binding to peptide-based substrate mimic as a function of H/D
exchange incubation period are shown mapped onto its corresponding crystal
structures. The percent relative deuterium incorporation is calculated by dividing
the observed deuterium uptake by the theoretical maximum deuterium uptake for
each peptide. Caspase-7 percent deuterium uptake is mapped onto its
unliganded (PBD code 1K86) and DEVD-bound (PBD code 1F1J) crystal
structures. Caspase-6 percent deuterium uptake is mapped onto its unliganded
(PBD code 2WDP) and DEVD-bound (PBD code 3OD5) crystal structures.
Regions of the protein without H/D exchange data are shown in gray.
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Figure 2.4 Heat Maps of the Percent Difference in Deuterium Level Between
Caspase-6 and Caspase-7
Heat maps of the percent difference in the deuterium uptake level between the
unliganded and the peptide-based substrate mimic-bound states of caspase-7
(A) and caspase-6 (B) are shown mapped onto its corresponding linear
sequence. The H/D exchange incubation period (minutes: 0.17, 1, 10, 60, and
120) are shown from top to bottom. The percent relative deuterium incorporation
is calculated by dividing the observed deuterium uptake by the theoretical
maximum deuterium uptake for each peptide. Red regions undergo more H/D
exchange (less protected, more flexible) in the unliganded state compared to the
peptide-based substrate-bound state. Blue regions undergo less H/D exchange
(more protected, less flexible) in the unliganded state compared to the peptidebased substrate-bound state. Peptic peptides with no H/D exchange data are
colored white.
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Figure 2.5 Heat Maps of the Percent Difference in Deuterium Level Between
Caspase-6 and Caspase-7 Mapped onto its Corresponding Structures
Heat maps of the percent difference in the deuterium uptake level between the
unliganded and the peptide-based substrate mimic-bound states of caspase-7
(A) and caspase-6 (B) are shown mapped onto its corresponding crystal
structures (PBD code 1K86 for caspase-7; PBD code 2WDP for caspase-7).
Regions of the protein without H/D exchange data are shown in gray.
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Figure 2.6 Deuterium Uptake Plots of Caspase-7 in the Unliganded and
DEVD-bound States
Relative deuterium uptake plots comparing the unliganded (black line) and the
DEVD-bound (blue line) states of caspase-7 as a function of H/D exchange
incubation period. The amino acid sequence and number are shown for each
peptic peptide of caspase-7. The standard deviations of two independent H/DXMS experiments performed in two separate days are indicated.
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Figure 2.6 Deuterium Uptake Plots of Caspase-7 in the Unliganded and
DEVD-bound States (continue…)
Relative deuterium uptake plots comparing the unliganded (black line) and the
DEVD-bound (blue line) states of caspase-7 as a function of H/D exchange
incubation period. The amino acid sequence and number are shown for each
peptic peptide of caspase-7. The standard deviations of two independent H/DXMS experiments performed in two separate days are indicated.
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Figure 2.7 Deuterium Uptake Plots of Caspase-6 in the Unliganded and
VEID-bound States
Relative deuterium uptake plots comparing the unliganded (black line) and the
VEID-bound (blue line) states of caspase-6 as a function of H/D exchange
incubation period. The amino acid sequence and number are shown for each
peptic peptide of caspase-6. The standard deviations of two independent H/DXMS experiments performed in two separate days are indicated.
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Figure 2.7 Deuterium Uptake Plots of Caspase-6 in the Unliganded and
VEID-bound States (continue…)
Relative deuterium uptake plots comparing the unliganded (black line) and the
VEID-bound (blue line) states of caspase-6 as a function of H/D exchange
incubation period. The amino acid sequence and number are shown for each
peptic peptide of caspase-6. The standard deviations of two independent H/DXMS experiments performed in two separate days are indicated.
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Figure 2.7 Deuterium Uptake Plots of Caspase-6 in the Unliganded and
VEID-bound States (continue…)
Relative deuterium uptake plots comparing the unliganded (black line) and the
VEID-bound (blue line) states of caspase-6 as a function of H/D exchange
incubation period. The amino acid sequence and number are shown for each
peptic peptide of caspase-6. The standard deviations of two independent H/DXMS experiments performed in two separate days are indicated.
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Figure 2.8 H/DX-MS Peptide Coverage Map for Caspase-6 and Caspase-7
Coverage Map of the peptic peptides identified from H/DX-MS experiments for
caspase-7 (A) and caspase-6 (B) in both unliganded and peptide-based
substrate mimic-bound states. In both caspase-6 and caspase-7, the protein
constructs used were designed to exclude the prodomain and linker, which
represents the fully cleaved and active form of the enzyme.
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2.3.2 Caspase-7 Adopts the Canonical Strand Conformation Before and After
Substrate Binding

Caspase-7 serves as an ideal control for observing conformational
changes and dynamics in a canonical caspase before and after binding of a
substrate-like inhibitor. All crystal structures of caspase-7 to date show the
canonical (130’s strand) structure before and after binding of a substrate-like
peptide-based inhibitor, DEVD (Figure 2.1). During H/DX-MS on caspase-7, only
slight changes in the overall H/D exchange occurred upon binding of a substratelike inhibitor (DEVD) (Fig. 2.2–A). The percent relative deuterium incorporation is
calculated by dividing the observed deuterium uptake by the theoretical
maximum deuterium uptake for each peptide. As expected, the most significant
differences in the deuterium uptake in the unliganded versus the DEVD-bound
states mapped onto peptides from within the active site loop 2 (L2, peptides 181191 and 182-192). There were no significant changes in the deuterium uptake
between the unliganded and the DEVD-bound states in the 60’s and 90’s helices
of caspase-7, which were covered by peptides 85-97 and 117-136, respectively
(Figure 2.9A, C, and D). The 130’s is the region that undergoes a helix-strand
interconversion in caspase-6. The 130’s region comprises residues 125-142 for
caspase-6 and 148-165 for caspase-7. In caspase-7, the corresponding 130’s
region was covered by five peptides: 148-161, 148-166, 150-166, 151-166, and
152-166. In particular, peptide 150-166 within the 130’s region of caspase-7
(Figure 3A, C, and Figure 2.10) showed changes in deuterium incorporation that
are observable from the earliest time point and persisted throughout the
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deuterium labeling time with almost the same difference between the unliganded
and the DEVD-bound states. The shape of this deuterium incorporation curve
indicates (Morgan and Engen, 2009) that one rapidly exchanging amide
hydrogen at Ile-150 and one at other residue between 152-166 are deuterated
prior to the earliest time point of the H/D exchange experiment (Figure 2.9C).
Nevertheless, these data showed only very slight difference (2-6%) in the
deuterium uptake in the unliganded versus the DEVD-bound state (Figure 2.4A)
suggesting that the 130’s region of caspase-7 is partially protected and
moderately dynamic but that binding of DEVD does not impact the overall
structure. The minor changes in conformational dynamics in the 60’s and 130’s
regions with virtually no changes in the 90’s helix of caspase-7 in the unliganded
versus the DEVD-bound states are consistent with the reported invariantly
canonical strand structures of caspase-7 (Chai et al., 2001; Wei et al., 2000)
(Figure 2.1). Importantly, this demonstrates that the magnitude of change in the
theoretical maximum deuterium uptake expected to occur directly from substratelike inhibitor binding to a caspase active site should be on the range of 2-6%, if
not accompanied by changes in protein conformational states or their dynamics.
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Figure 2.9 Caspase-6 Shows Distinct Conformational Dynamics in its 130’s
Region
Difference in deuterium uptake (Da) of the corresponding peptic peptides in the
unliganded and the peptide-based substrate mimic-bound states of caspase-7
(A) and caspase-6 (B) at the indicated time points of exposure to deuterium in
solution. The residue numbers for each peptic peptide are listed with
corresponding secondary structural elements. For these data, a deuterium
uptake difference greater than 0.6 Da is considered significant at 98% confidence
interval. The intensity of the blue color represents the peptides that undergo
significant decrease in H/D exchange (less solvent exposed, less flexible) upon
peptide-based substrate mimic binding. The intensity of the red color represents
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the peptides that undergo significant increase in H/D exchange (more solvent
exposed, more flexible) upon peptide-based substrate mimic binding. (C)
Representative deuterium incorporation plots for peptic peptides covering the
60’s, 90’s, and the 130’s region of caspase-7 (upper panel) and caspase-6 (lower
panel) in both unliganded (black lines) and peptide-based substrate mimic-bound
(blue lines) states. The representative MS spectra of the highlighted peptic
peptides are shown in Figure 2.10 and Figure 2.11. Error bars represent the
standard deviation (SD) of duplicate H/DX-MS measurements done on two
separate days. The residue numbering is listed for the homologous regions in
caspase-7 and caspase-6, which have different numbering for the structurally
homologous regions due to differences in the lengths of their respective subunits.
(D) Difference in deuterium uptake between the unliganded and the DEVD-bound
states of caspase-7 after 2-hr incubation mapped onto the structure of caspase-7
(PDB code 1K86) shown in both ribbon and surface representations. (E)
Difference in deuterium uptake between the unliganded and the VEID-bound
states of caspase-6 after 2-hr incubation mapped onto the structure of caspase-6
(PDB code 2WDP) shown in both ribbon and surface representations.
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Figure 2.10 Representative MS Spectra of Key Peptides in Caspase-7
Representative MS spectra of the peptic peptides following H/D exchange
experiments of the unliganded and peptide-based substrate mimic-bound states
of caspase-7. The relative location of the highlighted regions (60’s, green; 90’s,
cyan; 130’s, orange; L1, magenta; L2, red; L3, yellow; L4, pink) and its
representative peptic peptides are shown mapped onto the corresponding crystal
structure of casapse-7 (PBD code 1K86). The amino acid sequence, the charge
state and the residue number covered by the representative peptic peptide are
also indicated.
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Figure 2.11 Representative MS Spectra of Key Peptides in Caspase-6
Representative MS spectra of the peptic peptides following H/D exchange
experiments of the unliganded and peptide-based substrate mimic-bound states
of caspase-6. The relative location of the highlighted regions (60’s, green; 90’s,
cyan; 130’s, orange; L1, magenta; L2, red; L3, yellow; L4, pink) and its
representative peptic peptides are shown mapped onto the corresponding crystal
structure of capase-6 (PDB code 2WDP). The amino acid sequence, the charge
state and the residue number covered by the representative peptic peptide are
also indicated.
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2.3.3 Caspase-6 Shows Different H/D Exchange Dynamics in the 130’s
Region Compared to Caspase-7
In terms of conformational flexibility, caspase-6 might be expected to differ
from all other caspases. Caspase-6 has been observed to exist in both the
canonical strand and helical conformations in the 130’s region (Figure 2.1)
suggesting that interchange between two conformations could be involved in its
function. We anticipated that H/DX-MS would allow identification of regions of
caspase-6 that undergo significant conformational interchange, particularly in the
native state, and are therefore more highly susceptible to H/D exchange. H/DXMS on caspase-6 in the unliganded state or bound to an inhibitor built from the
cognate caspase-6 tetrapeptide substrate (VEID-aldehyde) revealed dramatic
changes in the deuterium uptake levels in several regions of the protein (Figure
2.9–B and –E). H/D exchange in the substrate-binding loops (L2, L2’, L3, and
L4), which are engaged in accommodating the tetrapeptide in the active site,
significantly decreased by 12 to 30% upon VEID binding (Figure 3B and Figure
2.4–B). In particular, the L2’ region of caspase-6 is the most exchangeable
region of the protein before VEID binding, but becomes much less susceptible to
exchange after binding. This is in contrast to caspase-7. In the canonical
conformation of both caspase-6 and -7, L2’ is engaged in interactions with L2. In
caspase-7, L2’ does not show nearly the magnitude in changes in H/D exchange
that L2’ shows in caspase-6. In the helical form of caspase-6, L2’ is not engaged
in any stabilizing interactions (Figure 2.11). Thus, H/D exchange is consistent
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with the model of L2’ being exposed in caspase-6 prior to VEID binding, as is
observed in the helical conformation.
In addition to significant changes in L2’, H/D exchange in the 130’s region
(peptide 119-130) significantly decreased 12-16% upon VEID binding (Figure
2.9B and C; Figure 2.4B), which suggests that this region also becomes
substantially more ordered when substrate binds. The deuterium uptake profile of
caspase-6 peptide 119-130 (Figure 2.9C) showed that in the absence of VEID
binding, there is a significant protection at earlier H/D exchange time points but
uptakes deuterium as a function of time. The shape of this deuterium uptake
curve indicates (Morgan and Engen, 2009) that this region of unliganded
caspase-6 visits the H/D exchange-competent state much more frequently than
after VEID-binding. This suggests that upon substrate binding, this region
becomes less dynamic. VEID- or DEVD-bound caspase-6 (Hill et al., 2016; Wang
et al., 2010) is in the same canonical conformation as DEVD-bound casp-7 (Wei
et al., 2000). The dispersed and significant differences in H/D exchange that are
observed for caspase-6 (Figure 2.9B and E; Figure 2.4B) indicate that there are
conformational differences that cannot be explained just by the protection from
substrate binding changes. If unliganded caspase-6 rested in the canonical
strand conformation, we would expect to see changes in the H/D exchange for
unliganded vs. peptide-based substrate mimic-bound similar to those for
caspase-7 (Figure 2.9). If caspase-6 rested exclusively in the helical form, we
would also expect to see relatively small changes in deuterium uptake because
residues in a stable helix should be resistant to H/D exchange. Only during the
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transient unfolding of either the strand or helix conformations during
interconversion of the 130’s region, would we expect increased susceptibility to
H/D exchange. Moreover, the total percentage of H/D exchange was the same
between caspase-6 and caspase-7 (Table 2.1), making it possible to conclude
that observed local differences in H/D exchange behavior reflects bona fide
conformational differences between caspase-6 and -7. The much more
significant changes in susceptibility to H/D exchange that we observed for
caspase-6 in both the L2’ and the 130’s regions are consistent with the model
that in the unliganded form caspase-6 is in a dynamic ensemble with states
intermediate between the helical and strand conformations.

Table 2.1 Percent of Total Amide Hydrogen Exchanged with Deuterium
unliganded
ligand-bound
caspase-6
22.4%
18.0%
caspase-7
23.3%
21.6%
The number of amide hydrogen exchanged in 2
hours, relative to the total number of exchangeable
amide hydrogen in each peptide and corrected for %
of sequence coverage achieved in each analysis is
listed.
2.3.4 Local pKas of Key Amino Acid Residues Within the 130’s Region Vary
Between the Unliganded (Helical) and the VEID-bound (Strand) States of Caspase-6

The H/D exchange data suggest that caspase-6 exists in a dynamic
equilibrium

that

transitions

between

the

helical

and

canonical

strand

conformations, but the molecular basis of this interconversion was not defined.
Inspection of the 130’s region in both unliganded and VEID-bound states of
caspase-6 revealed an altered set of interactions among key residues in this
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region (Figure 2.12A). In particular, residues His-52, Glu-63, Glu-135, and Glu221 have distinct molecular contacts in the unliganded (helical) compared to the
VEID-bound (strand) conformations. For example, His-52 makes H-bonding
contacts with Asp-90, Tyr-128, and Glu-135 in the helical state but loses these
contacts upon its transition to strand state upon substrate binding. The change in
the microenvironment of these residues is reflected in the changes in their
calculated microenvironment pKas between the helical and strand conformations
(Figure 2.12B). The difference in the pKas ranges from 0.9 to 6.6 pH units and
generally transitions from a basic to a more acidic microenvironment following
helix-strand interconversion. In fact, the helical structures of caspase-6 were all
trapped during low-pH crystallization (Baumgartner et al., 2009; Vaidya et al.,
2011) whereas the strand conformation of unliganded caspase-6 was trapped
during neutral pH crystallization (Muller et al., 2011b). The H/D exchange
reported here was performed at neutral pH, but strongly suggests that caspase-6
is constantly undergoing an interconversion between the helical and strand
states even at neutral pH. On the basis of the local pKa changes between the
two-state conformations of caspase-6, we proposed that the protonation of key
residues within the 130’s region would impact the dynamics of this region.
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Figure 2.12 Protonation State of Glu-135 is Critical to the Dynamics of the
130’s Region
(A) The unliganded (orange) and VEID-bound (green) states of caspase-6
present different local charge states of four identified residues in close proximity
and within the 130’s region, which are deprotonated upon substrate binding
(shown in black). (B) Calculated local pKas of the four amino acid residues that
undergo differential protonation states between the unliganded (helical) and the
VEID-bound (strand) states of caspase-6. (C) Plot of root-mean-square
fluctuation (RMSF, Å) against the backbone atoms of each amino acid in
caspase-6. A 1.2 ns-long simulated annealing-based MD simulation was
performed in all capase-6 protonation variants. The unliganded helical
protonation variant represents the control ensemble of the triply protonated state
(HisH-52, GluH-135, GluH-221) of caspase-6. The VEID-bound (strand)
protonation variant represents the control ensemble of the triply deprotonated
state (His-52, Glu-135, Glu-221) of caspase-6. The unliganded with deprotonated
E135 represents the protonation variant of caspase-6 with deprotonated Glu-135
but remains protonated at the other two residues (HisH-52 and GluH-221).
Residue-by-residue fluctuations are shown for caspase-6 in the unliganded
(helical) state (black), VEID-bound (strand) state (red), and the unliganded
caspase-6 with deprotonated Glu-135 (blue). The RMSF profile of unliganded
caspase-6 with deprotonated Glu-135 behaves similarly to VEID-bound (strand)
state in the 130’s region (inset view). (D) Variation of the RMSF (Å) along key
regions of caspase-6 mapped onto the structure of unliganded caspase-6 (PDB
code 2WDP) highlighting only the 60’s, 90’s and 130’s regions.
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2.3.5 Protonation State of Glu-135 is Key to Conformational Changes in the
Caspase-6 130’s Region

We performed 1.2 ns-long simulated annealing-based molecular dynamics
simulations on the unliganded (PDB code 2WDP) and VEID-bound (PBD code
3OD5) caspase-6 to determine the key factors that contribute to the helix-strand
transition. In these studies, protonation states of His-52, Glu-135, and Glu-221
were varied from fully protonated (optimal for the unliganded structure) to fully
deprotonated (optimal for the VEID-bound structure). A simulation plot of the
annealing studies (Figure 2.12C) shows pronounced difference in the root-meansquare fluctuation (RMSF) profile between the control ensembles of the triply
protonated and triply deprotonated states, particularly in the amino acid residues
within the 130’s region (inset view). Altering the protonation states of His-52 and
Glu-221 did not result in significant changes in the RMSF profile compared to the
control ensembles of caspase-6. Significantly, the protonation state of a single
residue, Glu-135, appeared to control the conformational dynamics of the 130’s
region, with Glu-135 and GluH-135 reproducing to a large extent the RMSF
profiles of triply deprotonated and triply protonated states, respectively. This
observation suggests that the protonation state of Glu-135 is critical to the
transition between the unliganded helical and the canonical strand conformations
of caspase-6. Mapping the displacement observed during the molecular
dynamics simulations onto the structure of caspase-6 underscores the propensity
of the 130’s helix to undergo a structural transition (Figure 2.12D). This transition
could be significantly facilitated by the deprotonation of a single residue, Glu-135,
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in the helical state. On the other hand, when caspase-6 in the canonical strand
conformation with deprotonated Glu-135 transitions to the helical state, the
dramatic change in the microenvironment should strongly favor protonation,
which would be easier to achieve at a lower pH. Once protonated, the helical
conformation is stabilized. Thus, the protonation state of Glu-135 is likely one of
the major contributing factors in stabilizing the helical form of caspase-6.

2.3.6 E135Q, a Mimic of Protonated E135, Stabilizes Caspase-6

Because protonation of Glu-135 appears to be a critical factor for
stabilizing the helical state of caspase-6, we generated a variant, E135Q, which
maintains the size of Glu, but mimics the protonated (GluH) state. The kinetic
parameters of E135Q are similar to wild type (WT), suggesting that the E135Q
substitution does not negatively impact caspase-6 in processing of a peptidebased substrate, VEID-AMC (Fig. 2.13–A). We expected that the E135Q
mutation would have a more significant impact on basal caspase-6 function, if
there were as large energy barrier to the interconversion between the helical and
strand states. The activity profile of E135Q as a function of pH is also similar to
that of WT caspase-6, suggesting that increasing the helical fraction does not
prevent conversion to the strand form in the presence of substrate (Fig. 2.13–B)
suggesting a low energy barrier between the two conformational states in the
presence of substrate. WT and E135Q did not show significant differences in
their CD spectra suggesting that the secondary structures are similar in the
unliganded conformation (Figure 2.14A). In contrast, E135Q showed a pH-
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dependent thermal stability profile distinct from that of WT caspase-6 (Fig. 2.14B
and E), consistent with the calculated fraction of Glu-135 protonated in the helical
state (Figure 2.14C). E135Q is more stable than WT caspase-6, particularly at
pH 7.5 and 8.5 (Figure 2.14E). Although this is a small stabilization, it is of the
same magnitude as the stability increase when WT caspase-6 binds an activesite ligand (Vaidya et al., 2011), suggesting that stabilization is relevant. At a
lower pH, helical WT caspase-6 should be predominantly protonated at the E135
position (Figure 2.14C) and H-bonding interactions with neighboring residues
Arg-54 and Glu-131 will be favored (Figure 2.14D). Meanwhile, at a higher pH,
deprotonation of Glu-135 is expected to occur and a stronger negative charge of
the side chain carboxylate group of Glu-135 will be enhanced, leading to
electrostatic interactions as the dominant interaction with neighboring Arg-54 and
His-52 in the vicinity. In addition, just 3.8 Å above Glu-135 sits the negatively
charged Glu-131 residue, which will likely also be deprotonated at a higher pH
promoting electrostatic repulsion that should destabilize the helical structure in
the 130’s region. Conversely, the GluH-135-mimicking E135Q will likely engage
in H-bonding with neighboring residues Arg-54 and Glu-131 and avoid the helix
destabilizing electrostatic repulsion. At a more basic pH, the stabilizing effect of
the E135Q is more pronounced due to the deprotonation of Glu-135 in the helical
state and the sustained H-bonding interaction with Arg-54 and Glu-131 that
results in higher stability of the E135Q compared to caspase-6 WT. In summary,
using E135Q as a surrogate for GluH-135 suggests that protonation of this
residue leads to overall stabilization of caspase-6. This further suggests that a
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significant fraction of caspase-6 exists in the helical state, since deprotonation,
which should favor conversion to the strand conformation leads to a
destabilization relative to the E135Q variant.

Figure 2.13 E135Q Has Similar Kinetics and pH Profile as WT Caspase-6
(A) The Michaelis-Menten kinetic parameters of caspase-6 WT and the
“constantly protonated” variant, E135Q. The values are reported as mean ± SEM
of three independent trials performed on three separate days. (B) The activity of
caspase-6 WT (black line) and E135Q (blue line) variants as a function of pH.
For normalization, the highest and the lowest relative fluorescence response for
each data set was set to 100% and 0%, respectively and reported as fractions.
Error bars represent the standard deviation (SD) of duplicate measurements on
two separate days. All caspase-6 activity assays used fluorescence-based
measurements following cleavage of a peptide-based substrate mimic VEIDAMC by caspase-6.
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Figure 2.14 The Stabilizing Effect of Constantly Protonated E135Q Variant
is More Pronounced at Higher pH
(A) The CD spectra of caspase-6 WT (black line) and the E135Q (blue line)
variant measured at different pHs. (B) CD thermal denaturation profiles of
caspase-6 WT (black dotted line) and E135Q (blue dotted line) at the indicated
pHs. Normalization of the CD signal was achieved by setting the highest and the
lowest values for each data set as 100% and 0%, respectively. The thermal
denaturation data were then fitted to the Boltzmann sigmoidal equation (black
solid line in WT and blue solid line in E135Q) where the midpoint of the curve
was determined to be the apparent Tm. (C) The expected percent protonation of
Glu-135 at different pH was determined based on the calculated pKas in Figure
2.12B following the Henderson-Hasselbalch equation. (D) Interactions between
Glu-135 and adjacent residues that impact the helix-strand interconversion. (E)
The individual apparent Tms and the differences in the apparent Tm values of
caspase-6 WT and E135Q at different pH are tabulated. The apparent Tm values
are reported as mean ± SD of duplicate measurements on two independently
prepared samples performed on two different days.
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2.4 Discussion
This study reveals that caspase-6 has local backbone dynamics in L2’ and
in the 130’s region consistent with the helix-strand interconversion. These data
showing a helix-strand interconversion are in contrast to previous work on the
unliganded caspase-6 determined at the physiological pH 7.4, which showed a
canonical strand structure in the 130’s region of unliganded caspase-6. The
authors concluded that the earlier two helical structures of unliganded caspase-6
assumed a pH-inactivated form as it was crystallized at pH 4.5 (Muller et al.,
2011b). If that was true, and in solution caspase-6 existed exclusively in the
canonical strand conformation, the H/D exchange for caspase-6 should mirror
caspase-7. The fact that the H/D exchange for caspase-6 with and without a
substrate-mimic is so strikingly different from that of caspase-7 with and without a
substrate-mimic strongly supports the helix-strand interconversion model as
governing caspase-6 structure and dynamics prior to substrate binding.
All caspases have mobile loops critical for substrate binding and catalysis.
Caspase-6 is different because it has additional mobile regions. Two distinct
conformational states have been identified in the 130’s region by crystallography,
and H/DX-MS has identified a unique interconversion likely between those two
states.

Although caspase-6 is the only caspase known to adopt the helical

conformation and can interconvert to the canonical form upon substrate binding,
this type of secondary structural shift is not confined to caspases but has also
been observed in other protein systems. Helix-strand interconversion is exploited
in nature to allow GTP hydrolysis by EF-Tu (Abel et al., 1996; Polekhina et al.,
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1996), susceptibility to conformational diseases (Pan et al., 1993), and
membrane association (Liao et al., 2013; Shepard et al., 1998; Yassine et al.,
2009). For example, the influenza A M2 protein, a proton channel that facilitates
viral assembly and budding, is found to interconvert between alpha-helical and
beta-sheet conformations dependent on the membrane composition (Liao et al.,
2013). The binding of M2 protein to 1,2-dimyristoyl-sn-glycero-3-phosphocholine
(DMPC) promotes the beta-sheet conformation while its binding to cholesterolrich membrane enriched the alpha-helical conformation. Thus, the biological role
of the secondary structure switch in caspase-6 is intriguing. One could imagine
such a change in structure to play roles in other yet unidentified functions such
as substrate recognition and specificity, cellular signaling and transport, or even
binding of natural regulators in the cell.
Our work suggests that the helix-strand interconversion is dependent on
the microenvironment pKas of a specific residue in the 130’s region and,
correspondingly, on the pH. Protonation–conformation coupling is important for
the function of several protein systems including the nitric oxide carrier heme
protein, Nitrophorin 4 (Di Russo et al., 2012), β-lactoglobulin (Qin et al., 1998)
and the E. coli multidrug efflux transporter AcrB (Murakami et al., 2006). Specific
titratable amino acids in a region influence the conformation and function of the
protein. These amino acids are expected to have different protonation states in
the helical and strand conformations resulting from two sets of distinct pKa
values. In caspase-6, the Glu-135 within the 130’s region displays two distinct
microenvironment pKa values, which are 4.4 pH units apart between the helical
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and the strand conformations. In our simulations, the change in the protonation
state of the Glu-135 impacts the relative stability of the helical state of caspase-6.
The relevance of this finding may be explained in the context of the pH of the
environment that caspase-6 experiences. The pH may dictate the preference of
one conformation of caspase-6 than the other. It has been suggested that pH
fluctuation happens in the cellular context where oxidative stress results in
cytosolic acidification that can ultimately lead to neurodegeneration (for review
(Majdi et al., 2016)). Oxidative stress, a trigger for apoptosis, induced by addition
of hydrogen peroxide in HEK 293/Tau cells, increases active caspase-6 and
caspase-3 activity (Zhao et al., 2014). An increase in caspase-6 activity has been
also documented in global brain ischemia (Ding et al., 2012) and acute ischemic
stroke (Akpan et al., 2011) where slight intracellular acidification has been
observed to acidify slightly to pH 6.43 (Nedergaard et al., 1991). Although the
precise role of the two-state conformations of caspase-6 is still not known, pH
changes in the context of neurodegeneration could conformationally enrich
caspase-6

in

either

helical

or

strand

conformations.

The

pH-induced

conformational change may explain the propensity of caspase-6 to recognize
different substrates at various cellular processes including apoptosis and
neurodegeneration. Future studies on determining the substrate preference of
caspase-6 in the context of varying intracellular pH condition may shed light into
the importance of the unique two-state conformation of the protein.
In addition to having strikingly different secondary structures, the helical
and the strand states of caspase-6 have different electrostatic surface potentials

64

(supplemental Figure 2.15). Interestingly, the caspase-6 helical conformation
exposes an aromatic-rich hydrophobic patch at the top of the 130’s helix (Figure
2.16). Hydrophobic patches are often involved in substrate recognition
(Schulman et al., 1998). The differences in electrostatics and hydrophobic
exposure might be expected to influence substrate recognition and function.
Critical inspection of the helical and the strand structures of caspase-6 revealed
that the top of the 130’s helix as well as the surrounding residues within loop 1
are flocked with exposed hydrophobic patch that contains Phe-55, Phe-56, Trp57 and Tyr-128. One might imagine that this cluster of aromatic residues could
potentially function as an exosite for initial substrate recruitment by helical
caspase-6. Accommodation of the substrate near the active site might then
facilitate transition of helical caspase-6 to the substrate-binding competent strand
state for efficient catalysis. Upon the eventual release of the substrate, caspase6 may then return to continuous helix-strand interconversion. This potential role
of the hydrophobic patch on caspase-6 is at present unexplored and untapped.
Future studies dissecting potential exosites for cellular and neuronal substrates
of caspase-6, e.g. tau and huntingtin proteins, could shed light on protein–protein
interactions that might fruitfully be exploited for novel therapeutics in the future.
Caspase-6 has been predicted to be the only caspase capable of
undergoing a helix-strand interconversion (Vaidya and Hardy, 2011; Vaidya et
al., 2011), however this assertion has been debated (Muller et al., 2011b). Our
H/D exchange data convincingly confirm that the structural dynamics of caspase6 are fundamentally different than that of other caspases, which are always in the
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Figure 2.15 Electrostatic Potential Map of Caspase-6
Map of the electrostatic potential of caspase-6 in the unliganded (left, PDB code
2WDP) and the VEID-bound (right, PDB code 3OD5) states are shown (red,
acidic regions; blue, basic regions; white, hydrophobic/neutral regions). The
vacuum electrostatic potential maps were generated using Pymol (Schrödinger)
and the arrow indicates electrostatic potential map around the hydrophobic
patch.

Figure 2.16 A Model Showing Caspase-6 Undergoes a Helix-Strand
Transition Upon Substrate Binding
Prior to substrate binding, capase-6 favors the noncanonical (helical)
conformation and transition to canonical strand conformation upon substrate
binding. This transition may be facilitated by the presence of a dynamic
hydrophobic patch (light orange, inset view) that may also function as an exosite
for substrate binding. After substrate cleavage and release, caspase-6 exists in a
dynamic equilibrium between the helical and strand states.
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canonical strand conformation. These data further support strongly a model
where unliganded caspase-6 interconverts between the helical and strand
conformations. Studies on caspase-6 structure and dynamics are particularly
relevant as caspase-6 is implicated in several neurodegenerative disorders
including Alzheimer’s and Huntington’s diseases. Thus, if trapping the helical
conformation is indeed inactivating, then stabilizing the helical conformation may
be a promising mode of achieving caspase-6-specific inhibition. On the other
hand, cleavage of the neuronal substrate DJ-1 (Giaime et al., 2010) appears to
be protective against neurodegeneration in Parkinson’s disease. If the exposed
hydrophobic patch does serve as a substrate-recruiting exosite (Figure 2.16),
promoting the caspase-6 helical conformation might increase interaction with
substrates like DJ-1, for which cleavage is neuroprotective.

2.5 Materials and Methods
2.5.1 Generation of Caspase Variants

The wild-type (WT) caspase-6 used in this study was a constitutive twochain (CT) form of caspase-6 derived from the synthetic, E. coli codon-optimized
(His)6 C-terminally tagged caspase-6 gene (Celtek Bioscience) that was ligated
into the NdeI/BamHI sites of pET11a vector (Vaidya et al., 2011). The wild-type
caspase-7 used was a constitutively two-chain corrected (CTC) version in
pET23b that is designed to independently express the large and small subunits
of caspase-7 with (His)6 tag at the C-terminus (Witkowski and Hardy, 2011). In
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both caspase-6 and caspase-7, the protein constructs were designed to exclude
the prodomain (residues 1-23 in both caspase-6 and caspase-7) and linker
(residues 180-193 in caspase-6; residues 199-206 in caspase-7). Phusion® sitedirected mutagenesis (Thermo ScientificTM) was used to introduce the E135Q
mutation in the caspase-6 CT construct.

2.5.2 Caspase Protein Expression and Purification

The caspase-6 and caspase-7 constructs were transformed into the
BL21(DE3) T7 express strain of E. coli (NEB). Overnight seed cultures were
initially grown in 2×YT media supplemented with 0.1 mg/mL ampicillin (Sigma) at
37 °C. Dense cultures were then diluted 1000-fold with 2×YT containing 0.1
mg/mL ampicillin and shaken at 37 °C until OD600 reached 0.6. Protein
expression was induced by the addition of 1 mM IPTG, and shaken at 20 °C for
18 hours. Cells were centrifuged at 4,700 x g for 10 min at 4 °C and stored at -20
°C until use. Freeze-thawed cells were lysed using a microfluidizer (Microfuidics,
Inc.) in lysis buffer (50 mM Tris, pH 8.5, 300 mM NaCl, 5% glycerol, 50 mM
imidazole) and centrifuged at 30,600 x g for 1 hour at 4 °C. The supernatant was
loaded into a 5-mL HiTrap nickel-affinity column (GE Healthcare) and washed
with lysis buffer until the absorbance returned to baseline. The protein was eluted
with elution buffer (50 mM Tris, pH 8.5, 300 mM NaCl, 5% glycerol, 250 mM
imidazole) and diluted 5-fold with buffer A (20 mM Tris, pH 8.5, 2 mM DTT) to
reduce the salt concentration. This protein sample was then loaded into a 5-mL
HiTrap Q HP column (GE Healthcare). The column was developed with a linear
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NaCl gradient and the protein was eluted in 20 mM Tris, pH 8.5, 200 mM NaCl, 2
mM DTT. This eluted protein was stored at -80 °C until use. The purified
caspases were analyzed by SDS-PAGE to confirm identity and purity.

2.5.3 Caspase Activity Assays

To measure caspase activity, 100 nM purified caspase was assayed over
7 min at 37 °C in casp-6 activity assay buffer (100 mM HEPES, 120 mM NaCl,
0.1% CHAPS, 10% sucrose, 5 mM DTT) or in caspase-7 activity assay buffer
(100 mM HEPES pH 7.5, 5 mM CaCl2, 10% PEG 400, 0.1% CHAPS, 5 mM
DTT). For substrate titration, a range of 0-500 μM fluorogenic substrate VEIDAMC [N-acetyl-Val-Glu-Ile-Asp-(7-amino-4-methyl-coumarin), Enzo Life Sciences
Inc.] was used for caspase-6 and a range of 0-200 μM fluorogenic substrate
DEVD-AMC [N-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin, Enzo Life
Sciences Inc.] was used for caspase-7. Fluorescence kinetic measurements
(λex/λem: 365nm/495nm) were performed in three independent trials on three
different days in 100-μL reactions in a 96-well format using a microplate reader
(SpectraMax M5, Molecular Devices). Initial velocities versus substrate
concentration were fit to a rectangular hyperbola using GraphPad Prism
(GraphPad Software, San Diego, USA) to determine the kinetic parameters Km
and kcat. Enzyme concentrations were determined by active-site titration with the
quantitative covalent inhibitor VEID-CHO (N-Acetyl-Val-Glu-Ile-Asp-aldehyde;
Enzo Life Sciences Inc.) for caspase-6 or DEVD-CHO (N-Acetyl-Asp-Glu-ValAsp-aldehyde; Enzo Life Sciences Inc.) for caspase-7. Protein was added to

69

inhibitor solvated in DMSO in 96-wells V-bottom plates at room temperature for
1.5 hours in caspase activity assay buffer. Aliquots (90 μL) were transferred in
duplicate to black-well plates and assayed with 50-fold molar excess of
substrate. The protein concentration was determined to be the lowest
concentration at which full inhibition was observed and was thus used to
calculate kcat.

2.5.4 Hydrogen/Deuterium Exchange Mass Spectrometry

H/D exchange experiments were performed using an initial stock of 15 μM
caspase-6 or caspase-7 in 20 mM Tris pH 8.5, 200 mM NaCl and 2 mM DTT in
H2O. For samples without substrate-like inhibitor, 1μL of DMSO was added to a
final volume of 200 μL; and for substrate-like inhibitor-bound protein samples, 1
μL of 30 μM peptide substrate-like inhibitor was added (VEID-CHO for caspase6; DEVD-CHO for caspase-7) to a final volume of 200 μL. The protein samples
were incubated at room temperature for 1 hour and then introduced into the
nanoACQUITY system equipped with H/D exchange technology for UPLC
separation (Wales et al., 2008) (Waters Corp., Milford, MA), which performed all
subsequent manipulations for the H/D exchange. H/D exchange was initiated by
dilution of each sample 15-fold with D2O exchange buffer (10 mM phosphate pD
7.5, 200 mM NaCl) and the mixture was incubated at predetermined H/D
exchange time points (mins: 0.17, 1, 10, 60, 120) at 25 °C. At the indicated H/D
exchange time point, an aliquot from the exchange reaction was removed and
deuterium labeling was quenched by adding equal volume of quench buffer (100
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mM phosphate pH 2.5, 200 mM NaCl) at 3 °C. For the non-deuterated samples,
the same procedure was performed in H2O buffers. Quenched samples were
introduced into a 5 μm BEH 2.1 x 30 mm EnzymateTM immobilized pepsin column
(Waters Corp., Milford, MA) at 100 μL/min in 0.1% formic acid at 10 °C then
incubated for 4.5 min to allow on-column digestion. Peptide fragments were
collected at 0 °C on a C18 VanGuard trap column (1.7 μm x 30 mm) (Waters
Corp., Milford, MA) for desalting with 0.1% formic acid in H2O and were then
separated using 1.8 μm HSS T3 C18 2.1 x 30 mm nanoACQUITY UPLC®
column (Waters Corp., Milford, MA) for 10-min gradient from 0.1% formic acid to
acetonitrile (7 min: 5-35%, 1 min: 35-85%, 2 min hold: 85% acetonitrile) at 40
μL/min at 0 °C. Fragments were subsequently mass-analyzed using Synapt G2Si
ESI-Q-Tof mass spectrometer (Waters Corp., Milford, MA). In between sample
injections, a wash step was performed to minimize peptide carry-over. Accurate
mass and collision-induced dissociation in data-independent acquisition mode
(MSE) (Geromanos et al., 2009) and ProteinLynx Global Server (PLGS) 3.0
software (Waters Corp., Milford, MA) were used to determine the peptic peptides
in the undeuterated protein samples analyzed on the same UPLC-ESI-Q-ToF
system used for H/DX-MS experiments. Peptic peptides generated from PLGS
were imported into DynamX 3.0 (Waters Corp., Milford, MA) with peptide quality
thresholds of MS1 signal intensity ≥5000, maximum sequence length of 25 amino
acids, maximum mass error of 1 ppm, and minimum products per amino acid of
≥0.3. Automated results were manually inspected to ensure the corresponding
m/z and isotopic distributions at various charge states were properly assigned to
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the appropriate peptic peptide. DynamX 3.0 was then used to generate the
relative deuterium incorporation plot and H/DX heat map for each peptic peptide.
The relative deuterium incorporation of each peptide was determined by
subtracting the weight-averaged centroid mass of the isotopic distribution of
undeuterated control sample from that of the weight-averaged centroid mass of
the isotopic distribution of deuterium-labeled samples at each labeling time point.
All comparisons were performed under identical experimental conditions, thus
negating the need for back exchange correction in the determination of the
deuterium incorporation. Thus, H/D exchange levels are reported as relative
(Wales and Engen, 2006). The fractional relative deuterium uptake was
calculated by dividing the relative deuterium uptake of each peptic peptide by its
theoretical maximum uptake. All H/DX-MS experiments were performed in
duplicate on two separate days and a 98% confidence limit for the uncertainty of
the mean relative deuterium uptake of ±0.6 Da was calculated as described
(Houde et al., 2011). Differences in deuterium uptake between two states that
exceed 0.6 Da were considered significant.

2.5.5 Circular Dichroism Spectroscopy

Thermal stability of caspase-6 variants at various pHs was monitored by
loss of circular dichroism signal at 222 nm over a range of 20-90 °C. CD spectra
(250-190 nm) were measured on a J-1500 CD spectrometer (Jasco) with Peltier
temperature controller. An appropriate buffer for effective buffering capacity was
used at a particular pH (20 mM MES pH 6.2, 120 mM NaCl; 20 mM phosphate
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buffer pH 7.5, 120 mM NaCl; or 20 mM Tris pH 8.5, 120 mM NaCl). Sample
proteins were buffer exchanged three times into each appropriate buffer using an
Amicon Ultra-0.5 mL centrifugal filter (MWCO 10K) (Millipore) and the protein
concentration (5 μM) was determined by absorbance at 280 nm (Nanodrop
2000C spectrophotometer). All data were collected at least in duplicate on
different days. The melting curves were plotted using GraphPad Prism
(GraphPad software) and fitted to a Boltzmann-Sigmoidal plot to determine the
apparent melting temperature, Tm, apparent.

2.5.6 Caspase Activity versus pH

The activity of caspase-6 variants were assessed as a function of pH
using 20 nM protein and 60 μM of VEID-AMC as a substrate in appropriate buffer
at various pH (4.5-9.0). The common components for all buffer at different pHs
contained 120 mM NaCl, 0.1% CHAPS, 10% sucrose, 5% glycerol and 5 mM
DTT. The following buffers were used at 100 mM concentration with its
corresponding pH range: acetate (pH 4.5-5.0), MES (pH 5.5-6.5), HEPES (pH
7.0-7.5), and Tris base (pH 8.0-9.0). Fluorescence kinetic measurements
(λex/λem: 365nm/495nm) were performed in duplicate in 100-μL reactions in a 96well format using a SpectraMax M5 microplate reader (Molecular Devices).

2.5.7 In Silico Model Preparation

The initial model for the mature dimeric human Caspase-6 was generated
by producing an all-atom structure of the truncated enzyme by using the
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coordinates of C (residues 31–165 & 201–293) and D (residues 31–165 & 199–
293) chains in the ligand-free structure (PDB code: 2WDP) and Maestro’s Protein
Preparation Wizard (Schrödinger, LLC). Next, the C-terminus of the cleaved
intersubunit linker in each protomer was rebuilt by i) grafting the residues 166–
175 from procaspase-6 structure (PDB code: 4N5D, chain A) using the Prime’s
Protein Splicing tool (version 3.8, Schrödinger, LLC), and ii) attaching the
pentapeptide terminus (residues 175–179) in its extended conformation to the
resulting chimeric structures. The N-terminal residues of the linker (194–201),
missing in the 2WDP chains was reconstructed using the coordinates from a
Zn(II)-bound caspase-6 structure (PDB code: 4FXO). The resulting chimeric
dimer was subjected to a protonation state assignment algorithm (Epik,
Schrödinger, LLC) and restrained minimization (force field: OPLS3) sequence
within Maestro’s Protein Preparation Wizard. The model was further refined via a
simulated annealing sequence within Desmond (version 4.0, D. E. Shaw
Research & Schrödinger, LLC). Thus, an NVT ensemble was built with
neutralized (by 8 Cl– ions) system and further Na+ and Cl– ions to simulate 150
mM concentration in an explicit SPC solvent model (16,783 water molecules),
using an orthorhombic simulation box (10Å buffer) with periodic boundary
conditions. The ensemble was then subjected to the following 7-stage schedule:
i) incubation at 10K for 30 ps, ii) heating to 100K for 70ps, iii) heating to 300K for
100ps, iv) heating to 400K for 100ps, v) incubation at 400K for 200ps, vi) cool
down to 300K for 500ps, vii) incubation at 300K for 200ps. The structure from the
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final frame of the 1.2-ns simulation was re-minimized (Prime, OPLS3) and
selected as the starting point for all subsequent simulations.

2.5.8 Simulated Annealing Studies of Protonation Variants

Protonation states of the residues in the two forms of caspase-6 were
obtained using Epik algorithm (Schrödinger, LLC) and the all-atom models
derived from unliganded (PDB code 2WDP) and VEID-bound (PDB code 3OD5)
forms. Using the refined model obtained above, several protonation state
variants at Glu and His residues (HisH–protonated His; GluH–protonated Glu)
were produced: i) ‘2WDP-like’ or the triply protonated helical caspase-6 variant
(HisH-52, GluH-135, and GluH-221), ii) ‘3OD5-like’ or the triply deprotonated
strand caspase-6 variant (His-52, Glu-135, and Glu-221), iii) ‘His-52’ (His-52,
GluH-135, and GluH-221), iv) ‘Glu-135’ (HisH-52, Glu-135, and GluH-221) and v)
‘Glu-221’ (HisH-52, GluH-135, and Glu-221). The resulting models were
neutralized with the corresponding number of Cl– ions and treated as described
above to produce starting NVT ensembles for simulated annealing experiments.
The 1.2-ns-long 7-stage schedule was re-applied on the protonation variants,
and the root-mean-square fluctuation (RMSF) analysis was performed using the
Simulation Event Analysis tool within Desmond.
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CHAPTER 3
THE MULTIPLE PROTEOLYTIC EVENTS THAT LEAD TO CASPASE-6
ACTIVATION EACH IMPACT THE CONFORMATION OF DISCRETE
STRUCTURAL REGIONS
This chapter is being prepared for submission as: Dagbay, K. B. and J. A. Hardy.
2017. The Multiple Proteolytic Events that Lead to Caspase-6 Activation Each
Impact the Conformation of Discrete Structural Regions.

3.1 Abstract
Caspase-6 is critical to the neurodegenerative pathways of Alzheimer’s,
Huntington’s and Parkinson’s disease and has been identified as a potential
molecular target for treatment of neurodegeneration. Thus, understanding the
fine structural details underlying the mechanism of caspase-6 activation is
important to precisely control its function.

In this work, hydrogen/deuterium

exchange mass spectrometry (H/DX–MS) was used to map the local changes in
the conformational flexibility of procaspase-6 as it undergoes the series of
cleavage events that ultimately lead to the fully active, substrate-bound state.
Intramolecular self-cleavage at Asp-193 evoked higher solvent exposure in the
regions of the substrate binding loops L1, L3, L4 and in the 130’s, the
intersubunit linker region, and the 26–32 region, as well as stabilization of loop 2.
Further removal of the linker allowed caspase-6 to gain more flexibility in the
130’s region and in the L2 region converting caspase-6 into a competent
substrate-binding state. The prodomain region is found to be intrinsically
disordered independent of the activation step of caspase-6; however, its
complete removal resulted in the protection of the adjacent 26–32 region,
suggesting that this region may play a regulatory role. The molecular details of
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caspase-6 dynamics in solution provide a comprehensive scaffold for strategic
design of therapeutic approaches for neurodegenerative disorders.

3.2 Introduction
Caspases are a family of cysteine-aspartate proteases that are central
players in apoptosis and inflammation. Caspases are expressed as dimeric yet
inactive zymogens (procaspases) and activated via proteolytic cleavage at
conserved aspartate residues to generate the large and small subunits. Based on
their cellular function and domain organization, caspases are classified as
initiator (caspase-2, -8, and -9) or executioner (caspase-3, -6, and -7). In the
canonical caspase activation route, initiator caspases activate executioner
caspases through proteolytic processing which promotes apoptosis in cells.
Caspase-6 is unique among caspases for its role in neurological disorders
including Alzheimer’s (Albrecht et al., 2007; Guo et al., 2004; LeBlanc, 2013),
Huntington’s (Aharony et al., 2015; Graham et al., 2010; Graham et al., 2006;
Wong et al., 2015) , and Parkinson’s (Giaime et al., 2010) diseases. Neuronal
proteins that are known substrates of caspases-6 include microtubule-associated
protein Tau (Horowitz et al., 2004), amyloid precursor protein (Albrecht et al.,
2009), presenilin I and II (Albrecht et al., 2009), polyglutamine-expanded and
native huntingtin protein (Graham et al., 2006) and Parkinson disease protein 7
(PARK7), also known as protein deglycase DJ-1 (Giaime et al., 2010). Cleavage
of these neuronal substrates by caspase-6 is recognized to impact the
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physiological outcomes in these neurological disorders. Thus, making caspase-6
an attractive molecular target for treatment of neurodegeneration.
Although it is categorized as an executioner caspase, caspase-6
sometimes plays roles as an initiator or even as an inflammatory caspase,
making its classification complex. Even though caspase-6 is a weak executioner
of apoptosis, its overexpression in mammalian cells results in apoptosis (Suzuki
et al., 2004) where it is the only known caspase to cleave the nuclear lamellar
protein, lamin A/C (Orth et al., 1996; Srinivasula et al., 1996; Takahashi et al.,
1996). As an initiator, caspase-6 activates caspase-8 (Cowling and Downward,
2002). Caspase-6 is also associated with the inflammatory pathway by being
activated by caspase-1 (Guo et al., 2006). Moreover, a noncanonical route for
activation has been reported in caspase-6. Caspase-6 is often activated by
caspase-3 rather than by initiator caspases (Simon et al., 2012; Slee et al.,
1999); however, it can also be activated in the absence of caspase-3 (Allsopp et
al., 2000; Doostzadeh-Cizeron et al., 2000; LeBlanc et al., 1999) and is reported
to self-activate in vitro and in vivo (Klaiman et al., 2009; Wang et al., 2010b).
Caspase-6 cleavage sites are located at the prodomain (Asp-23) and at
both sides of the intersubunit linker (Asp-179 and Asp-193) (Figure 3.1). The
intersubunit linker joins the large and the small subunits of procaspase-6 with the
active site Cys-163 located within the large subunit. The active site cavity of
caspase-6 is composed of four flexible loops (L1, L2, L3, L4) that undergo
structural rearrangement to accommodate the substrate in the substrate binding
pockets (S1, S2, S3, S4). Current evidence of caspase-6 activation pathway
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(Figure 3.1B) proposed that the initial intramolecular self-cleavage at Asp-193 in
the intersubunit linker is required for procaspase-6 self-activation (Klaiman et al.,
2009; Wang et al., 2010b), whereas caspase-3 activates caspase-6 by cleavage
at Asp-179. Subsequent proteolytic cleavage by caspase-3, caspase-1, or by
caspase-6 itself (intermolecularly) at Asp-23 in the prodomain and at Asp-179 in
the intersubunit linker (Guo et al., 2006; Klaiman et al., 2009; Srinivasula et al.,
1998; Wang et al., 2010b) leads to full maturation of caspase-6. All substratebinding loops are then available to accommodate the substrate in the substratebinding groove to enable proteolysis.
The prodomain is the most distinctive region of caspases in terms of its
sequence conservation (Clark, 2016; Vaidya et al., 2011), and is therefore
perhaps the most promising region for achieving selective regulation. As a result,
the function of the prodomain varies among caspases. The prodomain of initiator
caspases comprise caspase recruitment domain (CARD) or death effector
domains (DED), which are typically longer than executioner caspase
prodomains. The long prodomain facilitates recruitment to the activating scaffold,
which is important for initiator caspase activation (Muzio et al., 1998; Qin et al.,
1999). In executioner caspases, the short prodomain has a variety of functions.
In caspase-3, it facilitates folding by acting as a chaperone (Feeney and Clark,
2005), suppresses zymogen activation in vivo (Meergans et al., 2000) and binds
Hsp27 for inhibition of its proteolytic activation (Voss et al., 2007). In caspase-7,
the prodomain-adjacent region acts as an exosite for substrate recognition
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Figure 3.1. Caspase-6 Maturation State Variants
(A) Linear cartoon of procaspase-6 illustrating the prodomain (green), large
subunit (light gray), intersubunit linker (magenta) and small subunit (dark gray).
The active site C163 is denoted by a dot. Triangles indicate proteolytic cleavage
sites. (B) Model of full-length procaspase-6 zymogen colored as in (A) was
generated based on zymogen structures 4IYR and 3NR2 with missing regions
modeled de novo. The inset view shows details of binding interactions of the
intersubunit linker residues (magenta) binding into the S1–S4 subsites. (C)
Cartoon of expected conformational changes in caspase-6 constructs
representing various points along the zymogen maturation (cleavage) pathway
colored as in (A) with substrate as an ellipsoid (red). FL indicates full-length
uncleaved procaspase-6 zymogen. The C163S catalytic site substitution renders
caspase-6 inactive and incapable of self-activation. ΔN indicates removal of the
N-terminal prodomain (1–23). D23A substitution renders caspase-6 uncleavable
after the prodomain. D179A prevents cleavage of the intersubunit linker. D179CT
constructs have a stop codon inserted after residue 179 to allow expression of a
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constitutively two-chain caspase-6, mimicking native cleavage at D179. (D)
Maturation-state caspase-6 variants purified from overexpression in E. coli. (E)
Catalytic properties of caspase-6 maturation state variants. (F) Cleavage of Tau383 protein (3 μM) is not impacted by the maturation state of caspase-6, tested
at increasing concentrations (0–3 μM).
(Boucher et al., 2012) and protects a nuclear localization signal (Yaoita, 2002). In
caspase-6, the prodomain inhibits its self-activation in vivo but not in vitro
(Klaiman et al., 2009) and silences all modes of zymogen activation in vivo
(Cowling and Downward, 2002). Taken together, these findings clearly
demonstrate that the prodomain is an integral part of caspase function and
regulation.
In spite of its importance, in caspases, structural and functional details of
the prodomain as well as the intersubunit linker are inadequately understood
because the electron density in these regions has been missing in all caspase
crystal structures to date. In particular, these regions in procaspase-6 (Cao et al.,
2014) or in cleaved caspase-6 (Vaidya et al., 2011) have never been visualized.
In addition to the properties of the prodomain and intersubunit linker being
ethereal, the impact of the prodomain and linker on the conformational flexibility
and dynamics in other regions of caspase-6 also remains elusive. Thus, probing
the fine details of the influence of cleavage state and the presence or absence of
the prodomain and linker on the individual conformational flexibility in all regions
caspase-6 is expected to provide a complete picture detailing the underlying
mechanism of caspase-6 proteolytic activation. Furthermore, insight into the
functional and structural consequences of caspase-6 activation is likely to add to
our understanding of other caspases as well.
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Since the prodomain and the intact linker have eluded crystallization and
our NMR structure determination has also not been successful, solution phase
techniques,

including

the

use

of

hydrogen/deuterium

exchange

mass

spectrometry (H/DX-MS), are anticipated to be valuable to study the structural
behavior over the entirety of the caspase-6 structure. H/DX-MS has emerged as
a powerful tool to study changes in protein structure and dynamics resulting from
protein-protein or protein-ligand interaction in solution (Chalmers et al., 2006;
Englander, 2006; Konermann et al., 2011). Previously in the realm of caspases,
H/DX-MS has been used to probe the unique helix-strand interconversion in
caspase-6 (Dagbay et al., 2017) and the conformational changes associated with
the activation of Pak2 following caspase-3 cleavage and autophosphorylation
(Hsu et al., 2008). Nevertheless, a detailed understanding of the dynamic
changes of a caspase as it progresses through the stages of proteolytic
activation has not been undertaken. In this work, we report the use of H/DX-MS
to trace the discrete conformational flexibility profile along the proteolytic
activation of procaspase-6 as it matures upon initial intramolecular self-cleavage
and subsequent intermolecular cleavage of the prodomain and intersubunit
linker.

3.3 Results
3.3.1 H/DX-MS Profile of Caspase-6 Maturation State Variants
To map the changes in the conformational dynamics accompanied by
caspase-6 proteolytic activation, a panel of caspase-6 variants that represents
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each maturation state of caspase-6 (Figure 3.1 B and C) were prepared. The fulllength (FL) procaspase-6 C163S, the catalytic-site inactivated variant represents
the zymogen form of procaspase-6. Caspase-6 D23A D179A represents the form
of caspase-6 following initial activation by intramolecular self-cleavage at Asp193. This variant maintains the prodomain, but is self-cleaved at Asp-193 in the
intersubunit linker. Caspase-6 D23A D179CT has the prodomain intact but lacks
the entire intersubunit linker (residues 180–193). Caspase-6 ΔN D179CT
represents the fully cleaved, mature form of caspase-6, lacking both the
prodomain and intersubunit linker. All caspase-6 variants used in this study
(except FL caspase-6 C163S) were active for cleaving both tetrapeptide
substrate VEID-AMC (Figure 3.1D) and protein substrate Tau protein (Figure
3.1E).
H/DX-MS of the panel of caspase-6 maturation state variants was
performed using identical protocol previously reported (Dagbay et al., 2017).
Following incubation of proteins in deuterium for between 10s and 2h to allow
H/D exchange on intact caspase-6, samples were subjected to on-column pepsin
digestion followed by mass spectrometry for peptide mass analysis. A heat map
of the relative differential deuteration profiles of regions in caspase-6 over the
course of H/D exchange incubation time are depicted for each of the maturation
state variants, from self-activation to full maturation and eventual binding to a
substrate (Figure 3.2).

The corresponding relative deuterium uptake profiles

were also mapped onto a model of full-length procaspase-6 zymogen (Figure
3.3), where the crystal structures of the zymogen (PDB codes 4IYR and 3NR2)
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were used as templates and the missing residues were modeled using
Chimera/Modeller (Pettersen et al., 2004; Webb and Sali, 2014). The use of this
hybrid model structure, which has complete sequence coverage of caspase-6,
ensures all observed peptides could be represented during visualization of the
results of the H/DX-MS. As anticipated, the ordered and buried regions in the
core of caspase-6 had lower H/D exchange level than flexible or exposed regions
of caspase-6. These most highly exchangeable regions comprised mainly the
substrate binding loops, the intersubunit linker, and the prodomain. Notably, the
H/D exchange at the proteolytic cleavage sites (TETD23, DVVD179, and TEVD193)
are among the highest in caspase-6, including in the zymogen form, suggesting
that the higher conformational flexibility of this region is required for greater
access to proteolytic cleavage by caspase-6 and other proteases. Approximately
75% of the backbone amide hydrogens underwent less than 30% of H/D
exchange within 10 s, suggesting that caspase-6 is a properly folded and
dynamically stable protein overall. The peptic peptide coverage ranges from
90.8–92.1% across the linear amino acid sequences of the caspase-6 maturation
variants with an average redundancy of 2.46 (Figure 3.4). Together, these results
suggest that all caspase-6 variants used were amenable to H/DX-MS
experiments, which enable precise detection of the diverse conformational
flexibility of caspase-6 upon proteolytic activation.
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Figure 3.2. H/D Exchange Heat Map of the Relative Deuterium Incorporation
for Caspase-6 Maturation-State Variants
For each peptic peptide from the caspase-6 maturation-state variants, the
percent relative deuterium level for each H/D exchange incubation time (minutes:
0.17, 1, 10, 60, and 120) is mapped onto the corresponding linear sequence of
caspase-6. The percent relative deuterium incorporation is calculated by dividing
the observed deuterium uptake by the theoretical maximum deuterium uptake for
each peptide. The H/DX MS experiments followed all observed peptides and
covers 90.8–92.1% of the combined linear sequences. Peptic peptides with no
H/D exchange data at a given incubation time or regions absent in various
constructs are colored white. Secondary structural elements are depicted above
the primary sequence. The percent relative deuterium level of each peptic
peptide represents the average values of duplicate experiments performed on
two separate days. §H/DX-MS data set have been reported in (Dagbay et al.,
2017). See also Figure 3.3 for the percent deuterium uptake mapped onto the
structure,
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Figure 3.3. The Percent Relative Deuterium Incorporations of Caspase-6
Mutation Variants over the Course of the H/D Exchange Incubation Period
are Mapped onto the Model Structure of Caspase-6
The percent relative deuterium incorporation is calculated by dividing the
observed deuterium uptake by the theoretical maximum deuterium uptake for
each peptide. The intensities of the red and blue colors indicate increase and
decrease in H/D exchange, respectively. The regions of the protein for which not
H/D exchange data are available are shown in gray.
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Figure 3.4. Coverage Map of the Peptic Peptides of Caspase-6 Maturation
Variants Identified from H/DX-MS.
The teal color represents the set of peptic peptides found in all caspase-6
maturation variants covering the core regions of caspase-6. Peptic peptides
highlighted in green were found in FL C163S, D23A D179A, and D23A D179CT
covering the prodomain region. Peptic peptides highlighted in gray represent the
linker region found only in FL C163S and D23A D179A. Peptic Peptides
highlighted in black and blue colors were found in FL C163S and D23A D179A,
respectively. Peptic peptides exclusively found in one or more caspase-6
maturation variants were the result from the variation in the caspase-6
constructs, including the presence of the prodomain or linker and mutations in
the active-site cysteine and proteolytic cleavage sites of caspase-6. The peptic
peptide coverage ranges from 90.8–92.1% across the linear amino acid
sequences of the caspase-6 maturation variants with an average redundancy of
2.46.

3.3.2

Intramolecular

Self-Cleavage

at

Asp-193

Influences

Local

Conformation and Dynamics
In the crystal structure of the procaspase-6 zymogen (Figure 3.1B), the
active site pocket is occupied with the

190

TEVDA194—region of the intersubunit

linker—which forms an antiparallel β-sheet with
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217

YSHRE221 residues in the L3

through six main-chain hydrogen bonds (Wang et al., 2010b). Consequently, the
scissile peptide bond between the Asp-193 and Ala-194 sits atop the active site
Cys-163, which is primed for hydrolysis by intramolecular self-cleavage, a unique
self-activation mechanism of caspase-6 (Klaiman et al., 2009; Wang et al.,
2010b) that has not been directly observed in any other caspases, likely due to
the fact that caspase-6 had a longer intersubunit linker than most other
caspases. The H/D exchange of peptide 186–193, which derives from the
190

TEVDA194 region, significantly increased upon self-cleavage at Asp-193

(Figure 3.5A, and I). This increase in H/D exchanges suggests that the
190

TEVDA194 site is more exposed in the Asp-193-cleaved form (D23A D179A)

compared with the zymogen (FL C163S).
Our data show that initial cleavage at Asp-193 impacts the overall
conformational flexibility of caspase-6 substrate binding loops (L1, L2, L4), the
regions of the 130’s, and 26–32 (Figure 3.5A). In the crystal structure of
procaspase-6 zymogen, the side chains of

190

TEVDA194 occupy the substrate

binding pockets S1 to S4 (Figure 3.1A). It is therefore not surprising to observe
higher H/D exchange in the L1 region (peptide 56–74) where Arg-64 is engaged
as part of the S1 pocket for substrate binding. Likewise, the part of 130’s region
(peptide 130–142) that sits below the activity site cavity also has higher H/D
exchange in the Asp-193-cleaved form compared with the zymogen. The
increase in the
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Figure 3.5. Caspase-6 Displays Variable Conformational Flexibility Across
States of its Proteolytic Activation.
Differences in deuterium uptake (Da) of the corresponding peptic peptides
identified in caspase-6 maturation variants [(A) D23A D179A, (B) D23A D179CT,
(C) ΔN D179CT, and (D) ΔN D179CT + VEID)] comparison to the zymogen (FL
C163S) at the indicated time points of exposure to deuterated solvent. The
residue numbers for each peptic peptide are listed with the corresponding
secondary structural elements. These statistically significant differences in the
H/D exchange between the caspase-6 maturation variants [(E) D23A D179A, (F)
D23A D179CT, (G) ΔN D179CT, and (H) ΔN D179CT + VEID)] and the zymogen
(FL C163S) after 2 h incubation were mapped onto the model structure of
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caspase-6 shown in both ribbon and surface representations. For these data, a
deuterium uptake difference greater than 0.6 Da is considered significant at the
98% confidence interval. The intensities of the blue and red colors indicate
peptides that undergo either a statistically significant decrease (less
exchangeable/flexible, blue) or increase (more exchangeable/flexible, red),
respectively, during H/D exchange along the path of caspase-6 proteolytic
activation. (I) Representative deuterium incorporation plots of key peptic peptides
identified in caspase-6 maturation variants covering the regions of 26–32, 90’s,
130’s, the linker and the substrate-binding loops L1 to L4. The representative MS
spectra of the highlighted peptic peptides are shown in supplemental Fig. S3.
Error, S.D. of duplicate H/DX-MS measurements done on two separate days
(see Figures 3.12 and 3.13 for the deuterium uptake plots of all peptides
identified).

H/D exchange levels in the L1 and 130’s region suggests that these regions are
relatively protected in the zymogen state and are being more exposed after initial
cleavage at Asp-193 due to an overall increase in the mobility of this region.
L2 in caspase-6 is relatively long compared to L2 in caspase-3 and
caspase-7. Substitution of residues in L2 of caspase-6 with L2 residues from
caspase-3 and caspase-7 as well as truncation of at least three amino acid
residues (170–173) from the N-terminus of L2 prevented self-activation of
procaspase-6 (Wang et al., 2010b), suggesting that a long L2 is required for
binding the sequence

190

TEVDA194 of the intersubunit linker into the substrate

binding groove. This suggests a critical role of L2 in regulating the intramolecular
self-cleavage at Asp-193. In terms of conformational dynamics, the L2 region
(peptide 159–176) was found to have a significant decrease in H/D exchange
upon cleavage at Asp-193 (Figure 3.5A and I). Interestingly, in the crystal
structure of the procaspase-6 zymogen, part of L4 (residues 261–271) is flexible
and not engaged in binding with

190

TEVDA194. This same region of L4 is covered
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by peptide 264–278 where the H/D exchange profile was slightly perturbed
(protected at early time points but exposed after 2 h) upon Asp-193 cleavage.
The L4 and the L2—which are located on the same face of the protein—were the
only regions of casapse-6 that experienced significant protection upon Asp-193
cleavage. The L2 peptide 159–176 and the L4 peptide 264–278 show charge
complementarity: part of L2 is negatively charged and part of L4 is positively
charged (Fig S3). The result that both L2 and L4 regions

Figure 3.6. Map of the Electrostatic Potential of the Model Structure of
Procaspase-6 Built from the Zymogen Crystal Structures (PBD code 4iyr
and PDB code 3NR2)
The missing residues of each PDB template structures were built by de novo
modeling using Chimera/Modeller platform. The electrostatic potential map (red,
acidic regions; blue, basic regions; white, hydrophobic/neutral regions) was
generated using PyMOL Molecular Graphics System (Schrödinger, LLC).
Highlighted are key regions of in caspase-6 that undergoes statically significant
changes in the H/D exchange along caspase-6 proteolytic activation.
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complementarity to each other suggests that L2 and L4 are interacting after selfactivation of caspase-6 at Asp-193, potentially initiating loop reorganization for
proper substrate binding.
Finally, it is interesting that self-activation at Asp-193 resulted in a
statistically significant increase in H/D exchange of the 26–32 region after
subtractive analysis of overlapping peptides 26–48 and 33–48 (Figure 3.5A, E
and I). This suggests that the 26–32 region is relatively protected in the zymogen
and is exposed after initial self-cleavage at Asp-193. This region immediately
follows the prodomain in sequence. Intriguingly, the 26–32 region is situated in
the same loop as one of the residues (K36) in the allosteric and regulatory site
for zinc binding in caspase-6 (Velazquez-Delgado and Hardy, 2012) and the
identified exosite in capase-7 (38KKKK41) that promotes efficient cleavage of
poly(ADP ribose) polymerase 1 substrate (Boucher et al., 2012). These data
collectively suggest that the initial intramolecular cleavage at Asp-193 impacts
the overall flexibility of caspase-6 in the context of the proper assembly of
structural elements that enables caspase-6 activation and regulation.

3.3.3 Complete Removal of the Linker is Important to Attain the Fully
Exposed Substrate-Binding Cavity
The linker region contains two proteolytic cleavage sites within the
regulatory L2 in caspase-6. In the zymogen structure of procaspase-6, part of
this region (residues 186–193) is ordered and accommodated in the substrate-
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binding groove and the rest of the linker residues are disordered (Wang et al.,
2010b). After initial intramolecular self-cleavage at Asp-193 (D23A D179A),
caspase-6 can exist in a state where the linker is still attached to the large
subunit with the intact

176

DVVD179 site. This Asp-179 is not a good substrate for

intramolecular cleavage by caspase-6 because the ISL is not long enough to
position Asp-179 for self cleavage (Wang et al., 2010b). However, Asp-179 is the
first site to be intermolecularly cleaved by caspase-3 (Srinivasula et al., 1998;
Wang et al., 2010b) and other caspases intermolecularly. A crystal structure of
cleaved caspase-6 with intact linker was solved but the electron density of the
entire linker region (180–193) was missing. Thus, the structural behavior of the
linker and its impact on the dynamics during caspase-6 activation are still
unexplored. In this H/DX-MS study, 100% of the linker region was covered by
peptides 178–185 and 186–193 (Figure 3.5A, B, and I). The significant increase
in the H/D exchange of the C-terminal part of the linker region (186–193)
between the zymogen and the Asp-cleaved form suggests that prior to cleavage
at Asp-193 in the zymogen form, the region of the 186–193 is bound to the
substrate binding groove—consistent with the crystal structure of procaspase-6
zymogen. However, the exchange profile of the 178–185 region between the
zymogen and Asp-cleaved form was unaffected, suggesting that this region, a
contiguous part of L2, has the same conformational flexibility in both the
zymogen and Asp-193 cleaved form. The shape of the curve for deuterium
incorporation over the time course of H/D exchange often reveals interesting
structural features for particular regions of the protein, and provides meaningful
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interpretation of the H/D exchange data as has been described elsewhere
(Morgan and Engen, 2009). The H/D exchange profile of peptide 178–185 in both
the zymogen and the Asp-193-cleaved form showed a nearly maximal uptake of
deuterium even at the earliest time point (10s) and remained at that same high
level throughout the H/D exchange experiment (Figure 3.5I). This deuterium
uptake profile suggests that the 178-185 region has high solvent exposure and
the absence of H-bond interactions, as is characteristic for unstructured regions.
Conversely, peptide 185–193 exchange parameters suggest a partially
protected, moderately dynamic region.

Peptide 185–193 showed a one-

deuterium difference between the zymogen and Asp-193 self-cleaved forms at
the earliest time point (10s), suggesting that this region is more exposed after
Asp-193 cleavage. This one-deuterium difference persisted throughout the H/D
exchange time course (Figure 3.5I). In the crystal structure of the zymogen, the
190

TEVDA194 cleavage site is folded as a β-strand, which rests in the substrate-

binding groove and is expected to be highly protected from H/D exchange. The
fact that the 185-193 peptide in the Asp-193 cleaved form of caspase-6 shows
less protection than in the zymogen suggests that only prior to zymogen
activation does the intersubunit linker remains stably bound to the active site.
Further along the activation pathway of caspase-6, the complete removal
of the intersubunit linker occurs when Asp-179 is cleaved (D23A D179CT or
ΔND179CT). Removal of the linker resulted to a global H/D exchange profile that
is significantly altered compared with the zymogen (Figure 3.5B, C, F, G).
Removal of the intersubunit linker resulted in a significant exposure—relative to
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the zymogen—of the regions in the substrate binding loops: L1 (peptide 56–74),
L2 (peptide 159–176), L3 (peptides 210–216 and 217–227) and L4 (peptides
264–278 and 269–278) and the 130’s region (peptides 119–130, 130–142, and
133–142). Moreover, the differences in the H/D exchange between cleaved
forms of capase-6 in the absence or presence of the linker showed a similar
trend where removal of the linker resulted in a statistically significant increase in
the H/D exchange in the substrate binding loops and the top of the 130’s region
(Figure 3.7A and B). Collectively, these data suggest that the removal of the
linker renders the substrate-binding groove fully exposed and competent to bind
substrate.
Once the substrate-binding groove is exposed, substrate can bind to the
fully cleaved, mature caspe-6 (ΔND179CT + VEID). The H/D exchange profiles
of the loop bundles (L1–L4) and the top of the 130’s region (peptide 119–130)
were significantly decreased relative to the zymogen upon substrate binding
(Figure 3.5D, H and I). This suggests that these regions undergo significant
structural reorganization and protection upon engaging substrate, resulting to a
lower conformational flexibility of these regions.

3.3.4 Substrate-binding Groove is Accessible in Cleaved Caspase-6,
Independent of the Presence of the Prodomain or Linker
The H/DX data show that the overall accessibility of the substrate-binding
groove increases even further as caspase-6 matures into its substrate-binding
competent state. To further explore this observation, we sought a complementary
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technique to interrogate the conformation of the substrate-binding groove before
and after substrate binding. Caspase-6 has only two tryptophan residues, which
are found in L1 (Trp-57) and L3 (Trp-227) (Figure 3.8A). Trp-57 is completely
exposed in crystal structures of both the zymogen and mature forms of caspase6. However, in the zymogen, Trp-227 sits immediately adjacent to the substratebinding groove as part of the S4 specificity pocket within L3 (Figure 3.1B), which
forms an antiparallel β-strand with the linker in the zymogen state Intrinsic
tryptophan fluorescence is influenced by the polarity of the environment, where
shifts in the emission maxima towards longer wavelengths (red shift) indicate
higher solvent exposure. All maturation variants of caspase-6—from its zymogen
to self-cleavage at Asp-193 and subsequent removal of the prodomain and
linker—were subjected to intrinsic fluorescence measurements (Figure 3.8B and
Fig S5). Notably, all caspase-6 cleavage variants clustered in two classes of
emission spectra where all linker-cleaved (singly cleaved or complete removal of
the linker) forms of caspase-6 showed a 9nm red shift towards a more solvent
exposed state relative to the zymogen, irrespective of the presence of the
prodomain (Figure 3.8B). This suggests that initial Asp-193 cleavage in the linker
leads to the relative exposure of the bound intersubunit linker. Thus, Asp-193
cleavage activates caspase-6 by generating an open and more dynamic,
substrate-binding competent active site.
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Figure 3.7 Intersubunit Linker Cleavage Increases Conformational
Flexibility of All Substrate-Binding Loops
Comparative differences in the H/D exchange profiles among cleaved caspase-6
maturation variants [(A) D23A D179A versus D23A D179CT, (B) D23A D179A
versus ΔN D179CT, and (C) D23A D179CT versus ΔN D179CT] at the indicated
time points of exposure to deuterated solvent. These statistically significant
differences in the H/D exchange among cleaved casapse-6 maturation variants
[(E) D23A D179A versus D23A D179CT, (F) D23A D179A versus ΔN D179CT,
and (G) D23A D179CT versus ΔN D179CT] after 2 h incubation were mapped
onto the model structure of caspase-6 shown in both ribbon and surface
representations. For these data, a deuterium uptake difference greater than 0.6
Da is considered significant at the 98% confidence interval. The intensities of the
blue and red colors represent the peptides that undergo either a statistically
significant decrease (less exchangeable/flexible, blue) or increase (more
exchangeable/flexible, red), respectively, in the H/D exchange along the path of
caspase-6 proteolytic activation.
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Figure 3.8 Intersubunit Linker Cleavage Leads to Increased Exposure of the
Substrate-Binding Groove
(A) Comparison of the crystal structures of procaspase-6 zymogen (PDB code
3NR2) (left) and mature, unliganded casapse-6 (PDB 2WDP) (right) highlighting
the only two tryptophan residues, Trp-57 and Trp-227, as well as the relative
location of the intersubunit linker (magenta) and the active-site Cys-163. (B) The
intrinsic tryptophan fluorescence profiles of caspase-6 mutation variants.
Fluorescence emission scan of 305–400 nm were collected after excitation at
295 nm of 3-μM proteins in 10 mM phosphate buffer, pH 7.5, 120 mM NaCl and 2
mM DTT. Data presented here are a representative from three independent
experiments (see Figure 3.13 for the λex 280nm).
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3.3.5 The Prodomain is Intrinsically Disordered
An attempt to solve the crystal structure of procaspase-6 zymogen with intact
prodomain has been reported (Cao et al., 2014) but no electron density for the
prodomain was visible, suggesting that the prodomain may be a mobile region.
Although both biological (Klaiman et al., 2009) and biochemical studies (Cao et
al., 2014; Cowling and Downward, 2002) revealed that the prodomain impacts
caspase-6 function, the existing structural data on the prodomain are extremely
limited. In this work, the structural properties of the prodomain were explored
using H/DX-MS, as well as its impact on the dynamics of caspase-6 during
proteolytic activation. The electrostatic potential map of the 23-amino acid
prodomain of caspase-6 showed an obvious charged-polarized region (Figure
3.9A). The N- and C- termini are packed with positively and negatively charged
residues, respectively. H/DX-MS studies covered 22 of the 23 amino acids of the
prodomain represented by five overlapping peptic peptides (2-19, 3–19, 5-19, 819 and 18–24) (Figure 3.2, Figure 3, Figure 3.7, Figure 3.15, and Figure 3.16).
The H/D exchange profile of the prodomain region showed no statistically
significant changes between the zymogen and the cleaved forms of caspase-6
irrespective of the presence or absence of the linker (Figure 3A, 3B, and 6B).
Likewise, the H/D exchange profile of the prodomain region showed no
statistically significant changes between cleaved forms of caspase-6 with or
without the linker (Figure 3.7A and 6B). The H/D exchange profiles of peptides in
both the zymogen and cleaved forms of caspase-6 with intact prodomain (Figure
3.9B) showed nearly maximal uptake of deuterium by the earliest time point,
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which persisted at that same level over the course of the H/D exchange
experiment. The corresponding MS spectra of prodomain peptides in all forms of
caspase-6 with intact prodomain of caspase-6 with intact prodomain showed a
well-defined isotopic distribution (Figure 3.9C). Collectively, these data suggest
that independent of the activation state of caspase-6, the prodomain is highly
solvent exposed, consistent with this region being unstructured or intrinsically
disordered. Subtractive analysis of the H/D exchange profiles of the cleaved
casapse-6 variants (with intact prodomain but with or without the linker) and the
fully cleaved, mature caspase-6

(Figure 3.7B and C) revealed statistically

significant decrease in the deuterium uptake at positions 26–32 after cleavage at
Asp-23. This suggests that the removal of the prodomain results in protection of
the 26–32 region from H/D exchange in solution. Similar to the prodomain, the
26–32 region is polarized in terms of its electrostatic potential (Figure 3.6). The
negatively charged C-terminal end of the prodomain is likely to repel the
negatively charged N-terminal portion of the 26–32 region. Once the prodomain
is removed, the 26–32 region folds upon itself as evidenced by the decrease in
the H/D exchange upon removal of the prodomain in the absence of any
significant changes in the H/D exchange to the rest of the region of caspase-6
(Figure 3.7C). The full sequence of caspase-6 was analyzed for protein disorder
using DISOPRED (Webb and Sali, 2014) (Figure 3.9D). Regions of the
prodomain and the linker were predicted to be in highly disordered state and
further categorized these regions as being involved in protein binding. In addition,
CD spectra of caspase-6 with or without the prodomain (Figure 3.9E) showed no
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Figure 3.9. The Prodomain is Intrinsically Disordered
(A) An electrostatic potential map of the procaspase-6 prodomain with its
corresponding amino acid sequence. The blue and red regions represent the
relative localization of the positive and negative potentials, respectively. (B) The
deuterium uptake profile of a representative peptic peptide (2–19) in the
prodomain identified in the prodomain-containing caspase-6 maturation variants.
Error, S.D. of duplicate H/DX-MS measurements done on two separate days. (C)
The corresponding MS spectra of peptide 2–19 presented in (B). (D) Prediction
of the disordered (blue) and protein binding (orange) regions of caspase-6 using
DISOPRED server. (E) CD spectra of cleaved caspase-6 with (D23A D179CT)
and without (ΔN D179CT) the prodomain.
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dramatic changes in the secondary structures of caspase-6, consistent with the
prodomain being in a disordered state. In addition, the intrinsic tryptophan
fluorescence profile of both procaspase-6 zymogen and cleaved forms with or
without the prodomain (Figure 3.8B) were superimposable, suggesting that the
prodomain does not impact the Trp-227 environment near the active site.
Altogether, the H/DX-MS and the biophysical measurements imply that the
prodomain is an unstructured region of caspase-6, which does not form any
stable contacts with neither the active site nor the caspase-6 core at any point
during the course of caspase-6 proteolytic maturation.

3.4 Discussion
The H/DX reported here has allowed us to follow the diverse
conformational changes that occur in caspase-6 as it progresses through the
zymogen maturation pathway (Figure 3.10). These data are the first to provide
insight on the prodomain and intersubunit linker of caspase-6 as these regions
have been absent in all crystal structures of the enzyme. The initial
intramolecular cleavage of the zymogen at Asp-193 in the linker resulted in
changes in the conformational dynamics of the substrate binding loops L1 to L4,
the 130’s and the 26–32 regions. Moreover, the cleavage at Asp-193 also
allowed region of L2 to engage with L4. Further along the proteolytic activation
pathway, removal of the linker increases the conformational flexibility of all
substrate binding loops, and the 130’s region. Upon substrate binding, all
substrate-binding loops are engaged to accommodate the substrate, including
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the top of the 130’s region. Importantly, the prodomain is found to be intrinsically
disordered independent of the activation state of caspase-6, i.e. zymogen or Asp193 self-cleaved form. However, the prodomain impacts the conformational
flexibility of the 26–32 region dependent on the proteolytic activation state of
caspase-6.
The changes in the dynamics of caspase-6 reported here reflect with previously
reported changes in the thermal stability profile of maturation variants of
caspase-6 (Vaidya et al., 2011). The zymogen was found to be the least stable
form of caspase-6 with at least 8°C lower in the apparent melting temperature
compared to its cleaved forms. The Asp-193 self-cleaved form (with intact
prodomain and linker) is the most stable form of caspase-6 while the fully
cleaved and mature form has intermediate stability between the zymogen and
the Asp-193 self-cleaved caspase-6. The dramatic gain in the apparent thermal
stability of the zymogen after the initial intramolecular self-cleavage at Asp-193
could likely be accounted as the outcome of the changes in the conformational
dynamics of caspase-6. In particular, we observed a stabilizing interaction of L2
and L4 promoted by the presence of the prodomain and Asp-193-cleaved linker.
Previous work on a proteome-wide thermal stability studies across various cell
types from E. coli to mammalian cells showed a direct association between
protein stability and intracellular abundance and an inverse relationship between
protein stability and aggregation (Leuenberger et al., 2017). Thus, the gain of
stability as a consequence of altered conformational dynamics during proteolytic
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Figure 3.10. A Schematic Model Highlighting the Changes in the
Conformational Flexibility of Caspase-6 Along its Path to Proteolytic
Maturation
Initial intramolecular self-cleavage of the procaspase-6 zymogen at Asp-193 in
the intersubunit linker results to significant exposure of the linker, the 130’s, the
26–32 region, and the substrate binding loop 1 (L1) whereas L2 and L4 are
engaged in a stabilizing interaction. The subsequent intermolecular cleavage of
the prodomain at Asp-23 results in the protection of the 26–32 region. The
complete removal of the linker upon intermolecular cleavage at the Asp-179 site
results to more exposure of regions in the 130’s and all the substrate binding
loops 1 to 4. And upon substrate binding (red ellipsoid), the 130’s and the
substrate-binding loops 1 to 4 become protected to engage the substrate in the
active site cavity. The intensities of the red and blue colors represent the
exposure or protection, respectively, relative to the conformational flexibility of
the procaspase-6 zymogen.
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activation in caspase-6 may be relevant to the lifetime of the protein in the cell
and its interaction with the proteasome for degradation. Crystal structures of the
mature unliganded caspase-6 showed that prior to substrate binding, the 130’s
region can exist in either the canonical (strand) (Muller et al., 2011) or
noncanonical (helical) (Baumgartner et al., 2009; Vaidya et al., 2011)
conformations. Mature caspase-6 exists exclusively in the canonical (strand)
conformation in all substrate-bound structures—a unique structural feature not
observed in any other caspases. We have recently reported H/DX-MS coupled
with molecular dynamics simulations which shows that the 130’s region of the
mature unliganded caspase-6 is in constant interconversion between the helical
and strand conformations prior to substrate binding and converts completely to
the strand conformation after substrate binding (Dagbay et al., 2017). H/DX-MS
results presented here show that the presence of the linker affects slow H/D
exchange in the 130’s region in caspase-6 (Figure 3I). At long time points, the
H/D exchange profile of the Asp-193 cleaved caspase-6 with intact linker was
similar to the canonical (strand) caspase-6 forms: the zymogen and substratebound caspase-6; however, it is distinct from the H/D exchange profile of the
mature unliganded caspase-6 irrespective of the presence of the prodomain.
Thus, these data suggest that the presence of the linker promotes a higher
fractional residence in the canonical (strand) conformation of caspase-6. This
dynamic conformational state of caspase-6 may represent one of the
conformational ensembles that enable fine-tuning of pathways in the cell leading
to caspase-6 activation.
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Although the biological consequences of the dynamic nature of the 130’s
region are still unknown, there have been previous cell-based studies that
reported the relative activity of the maturation state variants of caspase-6. Each
maturation state variant showed unique in vivo activity in HEK293T cells
(Klaiman et al., 2009) suggesting that each cleavage state of caspase-6 may
play unique functional roles in cells. These differences in cellular activity are
certainly related to the dynamics changes observed in this study. In addition, the
caspase-6 intersubunit linker is long relative to the other executioners, caspase-3
and -7, and is the only linker computationally classified to contain a protein
binding motif (Figure 3.9D and Figure 14). This insinuates the linker as potentially
playing a role in substrate selection and specificity as well as in the several
protein-protein interactions in which caspase-6 has been identified to participate
(Jung et al., 2014; Riechers et al., 2016).
In this work, we present several lines of evidence that the prodomain in
caspase-6 is intrinsically disordered in all activation states. In addition, the crystal
structure of procaspase-6 zymogen with an intact prodomain showed no visible
electron density for the prodomain region (Cao et al., 2014). In this work, the
prodomain of caspase-6 was computationally predicted to be both disordered
and a protein-binding region. Consistent with these observations, H/DX-MS
covered the region of the prodomain with H/D exchange profile suggested that
the prodomain is an unstructured or intrinsically disordered region. In general,
disordered regions of proteins are often involved in molecular recognition (for a
review see (Mittag et al., 2010)). It is thought that several metastable
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conformations of proteins with disordered binding sites enable recognition of
molecular targets with remarkable specificity and low affinity. Intriguingly, the
presence of the prodomain in cleaved capase-6 is dispensable for caspase-6
activity in vitro against peptide substrates, but has been reported to impact
caspase-6 activity intracellularly (Klaiman et al., 2009). This may indicate that
the prodomain binds proteins, potentially substrates or regulatory partners. The
caspase-6 prodomain has also been implicated in limiting self-activation through
intermolecular cleavage at Asp-193 at low protein concentrations in vitro (Cao et
al., 2014). Despite growing evidence of the roles of the prodomain in regulating
caspase-6 activity, its biological role remains poorly understood, however our
characterization as an intrinsically disordered protein might provide the insight
needed to further the elucidation of prodomain roles.
The prodomains of caspase-3 and -7 are also predicted to be intrinsically
disordered (Figure 14) and the prodomains of several caspases have been
reported to participate in protein-protein interactions (Boucher et al., 2012; Choi
et al., 2009; Voss et al., 2007; Yaoita, 2002), impacting enzyme activity and
apoptotic signal transduction, as well as mediating binding to molecular
chaperones, cellular localization and substrate selection. Caspase prodomains
also appear to be “hot spots” for regulatory post-translational modifications (Eron
et al., 2017; Martin et al., 2008; Nutt et al., 2005) modulating enzyme activity and
binding to initiator caspases resulting in decreased apoptosis, as well as
impacting proteasomal degradation. The prodomain also mediates folding of
procaspase-3 (Feeney and Clark, 2005). The prodomain is one of the least
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conserved regions of the caspase family (Clark, 2016; Vaidya et al., 2011) so it is
possible or even likely that each prodomain plays unique roles that have yet to
be fully uncovered.
The exchangeability of the 26–32 region, which is immediately adjacent to
the prodomain, changes in unforeseen ways as caspase-6 progresses along the
proteolytic activation pathway. Initial self-cleavage at Asp-193 of the zymogen
results in increased exposure of the 26–32 region, suggesting that an interaction
of the 26-32 region, which is present in the zymogen, is lost upon initial cleavage.
However, once caspase-6 fully matures by proteolytic cleavage of the prodomain
and linker, the 26–32 region exhibits a less flexible conformation similar to the
zymogen state. This finding may be relevant to fine-tuning caspase-6 activity that
stems from diverse conformational flexibility profile of caspase-6 along its
pathway to full maturation. Notably, the 26–32 region is located in close proximity
to Lys-36, one of the ligands in the allosteric site for zinc binding identified in
caspase-6 (Velazquez-Delgado and Hardy, 2012). Moreover, this region is also
positioned in the same loop as two regulatory sites in caspase-7. PAK2 mediated
phosphorylation of Ser–30 in this region prevents caspase-7 activation by
caspase-9 (Eron et al., 2017)The

38

KKKK site within the caspase-7 N-terminal

domain is an exosite used for substrate selection and is the only identified
exosite in any caspase. The differential conformational flexibility of the 26–32
region could potentially expose or protect key regulatory sites in caspases. For
example, the differential exposure or protection of the 26–32 region in various
activation states may explain differential substrate recruitment that has been
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observed intracellularly (Klaiman et al., 2009). While it is exciting to observe
enzymatic differences in the cellular context, we recognize that insights into the
molecular mechanisms can only be accomplished by in vitro investigation such
as those included in this work.
In summary, H/DX-MS revealed the distinct conformational dynamics in
critical regions of the caspase-6 structure, including regions like the prodomain
and intersubunit linker, which have not been observable by any other techniques.
At each stage along the proteolytic activation pathway, changes in distinct
regions of caspase-6 have been observed. These changes are confined in all
substrate-binding loops, the 130’s and 26–32 region. We anticipate that many of
these changes would also be relevant in the activation pathways of other
caspases. In addition, we have observed that the prodomain is intrinsically
disordered. The structural dynamic changes provided in this study afforded new
insights into the underlying molecular mechanism of caspase-6 activation and
regulation.

Caspase-6

is

implicated

in

neurological

disorders

including

Alzheimer’s, Huntington’s and Parkinson’s diseases. The structural features and
conformational changes described here may inspire new approaches for
manipulating caspase-6 in the context of neurodegeneration.
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Figure 3.11. Representative MS Spectra of Key Peptic Peptides Following
H/D Exchange Experiments of Caspase-6 Maturation Variants
The relative location of the highlighted peptic peptides for the following regions
are mapped onto the hybrid model of procaspase-6: peptide including the 26–32
region, purple blue; top of 130’s region, green; 130’s region, orange; part of L1,
cyan; L2, red. The amino acid sequence, the MS charge state distribution and
the residue numbers covered by the representative peptic peptide are also
indicated. (B) The relative location and charge state distribution of peptides from
additional highlighted regions: L3, yellow; L4, light pink; N-terminal part of linker,
blue; C-terminal part of linker, magenta).
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Figure 3.12. Additional Representative MS spectra of Key Peptic Peptides
Following H/D Exchange Experiments of Caspase-6 Maturation Variants
The relative location of the highlighted peptic peptides for the following regions
are mapped onto the hybrid model of procaspase-6: peptide including the 26–32
region, purple blue; top of 130’s region, green; 130’s region, orange; part of L1,
cyan; L2, red. The amino acid sequence, the MS charge state distribution and
the residue numbers covered by the representative peptic peptide are also
indicated. (B) The relative location and charge state distribution of peptides from
additional highlighted regions: L3, yellow; L4, light pink; N-terminal part of linker,
blue; C-terminal part of linker, magenta).
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Figure 3.13 Intrinsic Fluorescence Profile of Caspase-6 Maturation Variants
Excited at 280 nm
Fluorescence emission scan from 305–400 nm were collected after excitation at
280 nm of proteins (3 μM) in 10 mM phosphate buffer, pH 7.5, 120 mM NaCl and
2 mM DTT. Data presented here are representative of three independent
experiments.

Figure 3.14 Prediction of Disorder
and Protein Binding in Caspases
Amino sequence of caspases-3 (A)
and caspase-7 (B) were submitted to
the DISOPRED server for the
prediction of regions of the protein
that are disordered (blue line) as well
as possible motifs for protein binding
(orange lines).
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Figure 3.15. Relative Deuterium Uptake Plots of Caspase-6 Maturation
Variants Over the Course of the H/D Exchange Experiment
The different colors represent the deuterium uptake profile of caspase-6 mutation
variants FL C163S (black), D23A D179A (blue), D23A D179CT (green), ΔN
D179CT (orange), and ΔN D179CT + VEID (red). The covered residues for each
peptic peptide of caspase-6 mutation variants are indicated. Error bars, S.D. of
duplicate H/DX-MS measurements done on two separate days.
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Figure 3.16. Additional Relative Deuterium Uptake Plots of Caspase-6
Maturation Variants Over the Course of the H/D Exchange Experiment
The different colors represent the deuterium uptake profile of caspase-6 mutation
variants FL C163S (black), D23A D179A (blue), D23A D179CT (green), ΔN
D179CT (orange), and ΔN D179CT + VEID (red). The covered residues for each
peptic peptide of caspase-6 mutation variants are indicated. Error bars, S.D. of
duplicate H/DX-MS measurements done on two separate days.
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3.5 Materials and Methods
3.5.1 Generation of Caspase Variants
The caspase-6 variants FL C163S, D23A D179A, D23A D179CT, ΔN
D179A, and ΔN D179CT were derived from the synthetic, E. coli codonoptimized (His)6 C-terminally tagged caspase-6 gene (Celtek Bioscience) that
were ligated into the NdeI/BamHI sites of pET11a vector (Vaidya et al., 2011).
The ΔN C163S with C-terminal (His)6-tag was generated using FL C136S as
template through Phusion® site-directed mutagenesis (Thermo ScientificTM).

3.5.2 Caspase Protein Expression and Purification
Caspase-6 constructs were transformed into the BL21(DE3) T7 express
strain of E. coli (New England Biolabs). Overnight seed cultures were initially
grown in 2xYT medium supplemented with 0.1 mg/ml ampicillin (Sigma) at 37
°C. Dense cultures were then diluted 1,000-fold with 2xYT containing 0.1 mg/ml
ampicillin and shaken at 37 °C until A600 reached 0.6. Protein expression was
induced by the addition of 1mM isopropyl 1-thio-β-D-galactopyranoside and
cultures were shaken at 20 °C for 18 h. Cells were centrifuged at 4,700 x g for
10 min at 4 °C and stored at −20 °C until use. Freeze-thawed cells were lysed
using a microfluidizer (Microfuidics, Inc.) in lysis buffer (50 mM Tris, pH 8.5, 300
mM NaCl, 5% glycerol, 50 mM imidazole) and centrifuged at 30,600 x g for 1 h at
4 °C. The supernatant was loaded into a 5-ml HiTrap nickel affinity column (GE
Healthcare) and washed with lysis buffer until the absorbance returned to
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baseline. The protein was eluted with elution buffer (50 mM Tris, pH 8.5, 300 mM
NaCl, 5% glycerol, 250 mM imidazole) and diluted 5-fold with buffer A (20 mM
Tris, pH 8.5, 2 mM DTT) to reduce the salt concentration. This protein sample
was then loaded into a 5-ml HiTrap Q HP column (GE Healthcare). The column
was developed with a linear NaCl gradient, and the protein was eluted in 20mM
Tris, pH 8.5, 200mM NaCl, 2mM DTT. This eluted protein was stored at −80 °C
until use. The purified caspases were analyzed by SDS-PAGE to confirm identity
and purity.

3.5.3 Caspase Activity Assays
To measure caspase activity, 100 nM purified caspase was assayed over
7 min at 37 °C in caspase-6 activity assay buffer (100 mM HEPES, 120 mM
NaCl, 0.1% CHAPS, 10% sucrose, 5 mM DTT). For substrate titration, a range of
0-500 μM fluorogenic substrate VEID-AMC [N-acetyl-Val-Glu-Ile-Asp-(7-amino-4methyl-coumarin), Enzo Life Sciences Inc.] was used. Fluorescence kinetic
measurements (λex/λem: 365nm/495nm) were performed in three independent
trials on three different days in 100-μL reactions in a 96-well format using a
microplate reader (SpectraMax M5, Molecular Devices). Initial velocities versus
substrate concentration were fit to a rectangular hyperbola using GraphPad
Prism (GraphPad Software, San Diego, USA) to determine the kinetic
parameters KM and kcat. Enzyme concentrations were determined by active-site
titration with the quantitative covalent inhibitor VEID-CHO (N-Acetyl-Val-Glu-IleAsp-aldehyde; Enzo Life Sciences Inc.). Caspase-6 was added to inhibitor
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solvated in DMSO in 96-wells V-bottom plates at room temperature for 1.5 hours
in caspase activity assay buffer. Aliquots (90 μL) were transferred in duplicate to
black-well plates and assayed with 50-fold molar excess of substrate. The protein
concentration was determined to be the lowest concentration at which full
inhibition was observed and was thus used to calculate kcat.

3.5.4 Tau Protein Expression and Purification
The human Tau-383 (0N4R) variant in pMXB10 vector (a generous gift
from Bing Zhou) was expressed in BL21(DE3) T7 express E. coli strain (New
England Biolabs) and purified using chitin beads (New England Biolabs) as
described (Venter et al., 2011; Wang et al., 2010a). Briefly, Tau-BL21(DE3) T7 E.
coli cells were grown in 2x YT media until A600 reached 0.6. Cells were
harvested, lysed and centrifuged at 30,600 xg for 1 h at 4 °C. Supernatant was
loaded into the column composed of chitin beads and washed with binding buffer
(20 mM Tris, pH 8.5, 500 mM NaCl, 1 mM EDTA, 0.1% Tween-20) until
absorbance reached baseline levels. The column was flushed with 3-column
volumes of binding buffer with 50 mM DTT and incubated for 16 h at 4°C. After
incubation, the protein was eluted with binding buffer. The eluted protein was
loaded into HiLoad 26/600 Superdex 200 Column and eluted using 200 mM
HEPES, pH 7.5, 150 mM NaCl. The purified protein was analyzed by SDS-PAGE
to confirm identity and purity.

124

3.5.5 Proteolysis of Tau Protein by Caspase-6 Variants
Human Tau protein (3 μM) was incubated with varying concentrations of
active caspase-6 activation state variants (0–3 μM, 2-fold dilution) in caspase-6
assay buffer (100 mM HEPES pH 7.5, 10% sucrose, 0.1% CHAPS, 120 mM
NaCl, and 5 mM DTT) at 37 °C for 6 h. SDS loading buffer was added to the
samples and boiled for 10 mins prior to analysis by 16% SDS-PAGE. The gels
were imaged using ChemiDocTM MP imaging system (Bio-Rad).

3.5.6 Hydrogen/Deuterium Exchange Mass Spectrometry
H/D exchange experiments on caspase-6 were performed as described
previously (Dagbay et al., 2017). Briefly, an initial stock of 15-μM proteins in 20
mM Tris pH 8.5, 200 mM NaCl and 2 mM DTT in H2O was prepared. The protein
samples were then introduced into the nanoACQUITY system equipped with H/D
exchange technology for UPLC separation (Wales et al., 2008) (Waters Corp.,
Milford, MA), which performed all subsequent manipulations for the H/D
exchange. Accurate mass and collision-induced dissociation in data-independent
acquisition mode (MSE) (Geromanos et al., 2009) and ProteinLynx Global Server
(PLGS) 3.0 software (Waters Corp., Milford, MA) were used to determine the
peptic peptides in the undeuterated protein samples analyzed on the same
UPLC-ESI-Q-ToF system used for H/DX-MS experiments. Data from peptic
peptides generated from PLGS were imported into DynamX 3.0 (Waters Corp.,
Milford, MA) with peptide quality thresholds of MS1 signal intensity ≥5000,
maximum sequence length of 25 amino acids, maximum mass error of 1 ppm,
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and minimum products per amino acid of ≥0.3. Automated results were manually
inspected to ensure the corresponding m/z and isotopic distributions at various
charge states were properly assigned to the appropriate peptic peptide. DynamX
3.0 was then used to generate the relative deuterium incorporation plot and H/DX
heat map for each peptic peptide. The relative deuterium incorporation of each
peptide was determined by subtracting the weight-averaged centroid mass of the
isotopic distribution of undeuterated control sample from that of the weightaveraged centroid mass of the isotopic distribution of deuterium-labeled samples
at each labeling time point. All comparisons were performed under identical
experimental conditions, negating the need for back exchange correction in the
determination of the deuterium incorporation. Thus, H/D exchange levels are
reported as relative (Wales and Engen, 2006). The fractional relative deuterium
uptake was calculated by dividing the relative deuterium uptake of each peptic
peptide by its theoretical maximum uptake. All H/DX-MS experiments were
performed in duplicate on two separate days and a 98% confidence limit for the
uncertainty of the mean relative deuterium uptake of ±0.6 Da was calculated as
described (Houde et al., 2011). Differences in deuterium uptake between two
states that exceed 0.6 Da were considered significant.

3.5.7 Circular Dichroism Spectroscopy
Caspase-6 activation state variants (8 μM) were concentrated and diluted
three times in 10 mM phosphate buffer, pH 7.5 with 120 mM NaCl an in an
Amicon Ultra-0.5 mL centrifugal filter (MWCO 10K) (Millipore). Following buffer
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exchange, caspase-6 concentrations were determined by 280-nm absorbance.
CD spectra (250-190 nm) were measured on a J-1500 CD spectrometer (Jasco)
with Peltier temperature controller. All data were collected at triplicate on different
days.

3.5.8 Intrinsic Fluorescence Spectroscopy
Caspase-6 activation state variants (3 μM) in 20 mM phosphate buffer, pH
7.5, 120 mM NaCl, and 2 mM DTT were prepared. Fluorescence emission scans
(305–400 nm) were collected after excitation at 280 nm or 295 nm using J-1500
spectrometer (Jasco) equipped with fluorescence emission monochromator
(FMO-522) and detector (FDT-538). Signal was acquired by setting the emission
detector at high-tension voltage value of 700 V, the data integration time (D.I.T)
to 1 s and data pitch to 1 nm. The bandwidth used for excitation and emission
was 2 nm and 10 nm, respectively.

3.5.9 Caspase-6 Model Building and Disorder Prediction
The full-length caspase-6 zymogen model (residues 1–293) was built from
crystal structures of caspase-6 zymogen. In this model, chain A was derived from
PBD code 4iyr (chain A); chain B of this model was derived from PDB code
3NR2 (chain A) as templates. The missing residues ([1–30, 174–186, and 292–
293] in PBD code 4iyr (chain A); [1–30, 167–186, 261–271, and 292–293] in PBD
code 3NR2 (chain A)) were built by de novo modeling using Chimera/Modeller
platforms (Pettersen et al., 2004; Webb and Sali, 2014). All illustrations with
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molecular visualization were generated using the PyMOL Molecular Graphics
System (Schrödinger, LLC). Amino acid sequences of caspase-3, -6, and -7 were
submitted to the DISOPRED (Ward et al., 2004) server for the prediction of
protein disorder.
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CHAPTER 4
TUMOR-ASSOCIATED MUTATIONS IN CASPASE-6 NEGATIVELY
IMPACT ITS CATALYTIC EFFICIENCY
This chapter is being prepared for submission as: Dagbay, K. B., Barrett, and J.
A. Hardy. 2017.The Tumor-Associated Mutations in Caspase-6 Negatively
Impact Catalytic Efficiency.
4.1 Abstract
Unregulated, particularly suppressed programmed cell death is one of the
distinguishing features of many cancer cells. The cysteine protease caspase-6,
one of the executioners of apoptotic cell death, plays a crucial role in regulation
of apoptosis. Several CASP6 gene somatic mutations in tumor tissues have been
reported. This work explores the effect of CASP6 tumor-associated mutations on
the catalytic efficiency and structure of caspase-6. In general, these mutations
showed decreased overall catalytic turnover. Mutations within 8-Å of the
substrate-binding pocket of caspase-6 were found to be the most catalytically
deactivating. In particular, the R259H substitution was found to be the most
inactivating among caspase-6 tumor-associated variants. This substitution
disrupts the cation–π stacking interaction between Arg–259 and Trp–227, which
is indispensable for proper assembly of substrate-binding loops in caspase-6.
Sequence conservation analysis at the homologous position across the caspase
family suggests a role of this cation–π stacking in the catalytic function of
caspases generally. These data suggest that caspase-6 deactivating mutations
contribute to the multifactorial carcinogenic transformation.
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4.2 Introduction
Caspases are a family of cysteine-aspartic proteases that are critical to
mediating programmed cell death and maintaining homeostasis within the cell.
Caspases are synthesized as inactive procaspase zymogens consisting of a
connected prodomain, large subunit, intersubunit linker region, and small subunit
(Figure. 4.1A).

Depending on their functions within the apoptotic cascade,

caspases are classified as initiators (caspase-2, -8, -9) or executioners (caspase3, -6, -7) (Pop and Salvesen, 2009; Yan and Shi, 2005). When the cell receives a
death signal, either from cellular stress (intrinsic pathway) or an extracellular
death ligand (extrinsic pathway), initiator caspases are recruited to the
apoptosome (caspase-9) or DISC complex (caspase-8) to begin the signal
cascade (Fuentes-Prior and Salvesen, 2004). The constitutively dimeric
executioner caspases are activated when cleaved at the intersubunit linker by the
initiator caspases. Active executioner caspases proteolytically cleave substrates,
which are both structural and repair proteins, at critical aspartic acid residues,
which can activate or deactivate the substrates. Both the extrinsic and intrinsic
apoptotic pathways eventually lead to the destruction of the cell (Earnshaw et al.,
1999; Grutter, 2000; Inoue et al., 2009; McIlwain et al., 2013).
Caspase-6 is expressed as an inactive zymogen that is activated by
proteolytic processing at a conserved aspartate residue in the intersubunit linker
(Asp–193) between the large and small subunits (Srinivasula et al., 1996).
Caspase-6 is further processed in the prodomain (Asp-23) and for removal of the
linker (Asp-179). Caspase-6 is often activated by caspase-3 rather than by
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initiator caspases (Slee et al., 1999) and has been shown to undergo selfactivation both in vitro and in vivo (Klaiman et al., 2009; Wang et al., 2010).
Caspase-6 is less apoptotic than either caspase-3 and -7, which are directly
processed by initiators caspase-8 and -9 (Boatright and Salvesen, 2003).
However, the overexpression of caspase-6 alone has been shown to promote
cell death (Suzuki et al., 2004). Structurally, caspase-6 has the closest homology
with caspase-3 and caspase-7, but has a preference for cleaving VEID motifs
rather than the DEVD consensus sequence favored by caspase-3 and -7
(Talanian et al., 1997). Furthermore, caspase-6 has a distinct set of substrates
compared to other caspases, such as lamin A/C (Ruchaud et al., 2002). An
extensive analysis of caspase-2 and caspase-6 native substrates using MSbased proteomics revealed 204 unique caspase-6 substrates (Julien et al.,
2016). Many caspase-6 specific substrates that were identified are known to be
tumor-associated based on its inclusion in the census of human cancer genes
(Futreal et al., 2004). Representative cancer-associated caspase-6 substrates
include the double-strand-break repair protein, RAD21; the cellular tumor antigen
p53, TP53; the breast cancer type 1 susceptibility protein, BRCA1; the DNA
repair protein complementing XP-G cells, ERCC5; the DNA mismatch repair
protein, MLH1; and the ras-related protein Rab-10, RB10. Thus, the crosstalk of
caspase-6 with these known tumor-associated substrates suggests the potential
involvement of caspase-6 in development of cancer.
As mediators of apoptotic cell death, caspases natively play an essential
role in preventing the development of cancer. Unregulated cell proliferation and
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Figure 4.1 Tumor-Associated Mutations are Widely Distributed Across
Caspase-6
(A) Linear cartoon of procaspase-6 illustrating the prodomain (black circle), large
subunit (light gray box), intersubunit linker (black zigzag) and small subunit (dark
gray box). The active site Cys–163 is denoted by a dot. Inverse triangles indicate
proteolytic cleavage sites. (B) Relative abundance of the types of mutations
observed in CASP6 gene. (C) Observed tumor-associated nonsense (green sphere)
and missense (red spheres) mutations in caspase-6 are mapped onto the model
structure of full-length procaspase-6 with the active-site cysteine drawn as yellow sticks.
The attachment point for the prodomain is visible only for one of the monomers in this
orientation. The model procaspase-6 structure was generated based on zymogen
structures 4IYR and 3NR2 with missing regions modeled de novo. Substrate-binding
loops (L1, L2, L3, L4) along with key regions in caspase-6 (90’s, 130’s and the active
site) are also indicated. Highlighted bold are the tumor-associated mutations
interrogated in this study. An asterisk (*) indicates a premature appearance of stop
codon characteristic of a nonsense mutation.
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reduced apoptotic index are hallmarks of cancer, and caspase inhibition can lead
to a reduced apoptotic index, thereby promoting tumorigenesis (Hanahan and
Weinberg, 2011). Inhibited expression of proapoptotic molecules and the
development of inhibitory somatic mutations could downregulate cancer cell
apoptosis. Somatic mutations in caspases have been identified in tumorassociated tissues (Frejlich et al., 2013; Hosomi et al., 2003; Kim et al., 2009;
Lee et al., 2006; Liu et al., 2002; Soung et al., 2008; Soung et al., 2003; Soung et
al., 2004; Yoo et al., 2004). For example, CASP8 somatic mutations were found
in advanced gastric cancer carcinoma that significantly decreased caspase-8
apoptotic activity (Soung et al., 2005a). The well-known MCF-7 breast cancer cell
line lacks caspase-3 expression due to a functional deletion mutation in the
CASP3 gene (Devarajan et al., 2002). Importantly, these somatic mutations
evidence a decrease in caspase activity when compared to wild type and
suggest caspase inhibition contributes to cancer pathogenesis.
Perhaps due to its diminished apoptotic role, caspase-6 has not been as
highly scrutinized for its role in cancer pathogenesis as other caspases. Initial
work to compile a list of CASP6 somatic mutations in tumor-associated tissues
has been reported more than a decade ago (Lee et al., 2006). Three CASP6
somatic mutations were detected in gastric and colorectal cancer tissues that
were classified to be missense and nonsense mutations, but no studies reporting
functional characterization of the proteins resulting from mutant CASP6 have
been reported. To further explore the impact of somatic mutations on the function
of caspase-6, in the present study caspase-6 tumor-associated variants were
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produced and tested. Selected CASP6 somatic mutations identified from the
Catalogue of Somatic Mutations in Cancer (COSMIC) database (Forbes et al.,
2011), a comprehensive resource of occurring somatic mutations in human
cancer, and from the initial CASP6 mutational analysis study (Lee et al., 2006)
were selected. CASP6 mutations from the COSMIC database were chosen
based on their confirmed somatic status, their mutation type, and their varied
structural location within the enzyme (Table 4.1, Figure 4.1C). Based on these
criteria, seven caspase-6 tumor-associated variants were generated with amino
acid changes located in the prodomain, large, and small subunit. This panel
allowed us to explore the trend of somatic CASP6 mutations in cancer
pathogenesis and associated decreased apoptotic activity.

4.3 Results and Discussion
4.3.1 Mutations in CASP6 Gene Have Been Identified in Tumor Tissues
One of the hallmarks of cancer is the failure of apoptosis (Hanahan and
Weinberg, 2011). Caspase-6 is broadly classified as one of the executioner
caspases in the apoptotic cascade; however, the association of caspase-6 in
cancer has been largely unexplored. A search of the COSMIC database and
other somatic mutations in the human CASP6 gene (Forbes et al., 2011; Lee et
al., 2006) revealed that caspase-6 harbored several mutations in tumor tissues.
Of all reported mutations in CASP6, 64% resulted from missense mutations
encoding a different amino acid after a single nucleotide change in the codon of
CASP6 gene (Figure 4.1B). Caspase-6 also harbored functionally deleterious
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mutations including deletions (frameshifts) resulting from a shift in the reading
frame and nonsense mutations resulting to a premature appearance of a stop
codon within the CASP6 gene. A significant fraction (27%) also showed
synonymous substitution (silent) mutations where a codon change leads to
encoding the same amino acid in caspase-6. Interestingly, these tumorassociated mutations, with emphasis on nonsense and missense mutations, are
distributed across the structure of caspase-6, impacting regions both within the
active site cavity and substrate-binding loops (Figure 4.1C) and outside,
suggesting potential of these mutations to modulate caspase-6 function.
In addition, caspase-6 showed a differential gene regulation profiles in
various tumor tissues, which have also been tested and catalogued in the
COSMIC database (Figure 4.2). Both overexpression and underexpression of
caspase-6 have been observed across various tumor and tumor-associated
tissues. For a particular tumor tissue, an aberrant gene regulation profile usually
correlates with the observation of mutant CASP6 genotypes in tumors from those
tissues (Figure 4.2). There were exceptions to this pattern, particularly in the
tumor-associated samples from the adrenal gland, central nervous system
(CNS), hematopoietic/lymphoid, lung, and the soft tissues, in which changes in
gene regulation patterns did not correlate with enhanced mutational frequency in
the CASP6 gene. Although a number of CASP6 mutations detected in tumor
samples, only 0.13% of the total 29,665 tumor tissue samples showed mutations
in CASP6.
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Figure 4.2 Aberrant CASP6 Gene Regulation Correlates with Percent
Mutation in Caspase-6 in Tumor-Associated Tissue Types
CASP6 gene expression level in various tumor-associated tissues as catalogued
from the COSMIC database. In parenthesis is the total number of samples tested
for a given tumor tissue type. Percentage CASP6 gene expression (left) is
presented as either underexpression (green) or overexpression (red).
Percentage of samples with mutated CASP6 gene in tumor tissue type
catalogued from the COSMIC database. In parenthesis is the fraction of the
samples with mutations in the CASP6 gene relative the total number of samples
(right).
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While the identities of these mutations in CASP6 in tumor tissues have been
reported, the effect of each mutation on caspase-6 function is completely
unstudied. Together, these mutations and atypical gene expression profiles may
implicate caspase-6 in tumorigenesis.
Meanwhile, some tumor samples that harbored CASP6 gene mutations
also contain mutations in other caspases (Table 4.1). Particularly interesting is
the co-existence of mutations in the initiator CASP8, a known oncogene
(Stupack, 2013), where 24% of the tumor samples with CASP6 mutations also
harbored CASP8 mutations. Although the functional consequences of these
mutations in other caspases are not known, the co-existence of mutations in
other caspases and other apoptotic proteins may be expected. This may suggest
the existence of altered regulation of the apoptotic cascade or other nonapoptotic
pathways relevant to the evolution of a tumor phenotype.

4.3.2 Caspase-6 Variants from Tumor Tissues Have Decreased Activity
To further investigate the effect of these mutations on caspase-6 function,
seven caspase-6 tumor-associated mutations were selected based on their
distribution across the caspase-6 structure (highlighted in bold in Figure 4.1C).
All selected CASP6 mutations had a confirmed somatic (non-germline) status
and we focused our interrogation on less conservative mutations. Representative
missense mutations were selected from within the region of the prodomain
(M19R), the 90’s (L98F), within the dimer interface (M208T and K285N), at the
base of the helix adjoining L4 (E247K), and within 8-Å radius of the active site
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Table 4.1. Identified Missense and Nonsense Mutations in Caspase-6 from
Various Tumor Tissue Types and its Corresponding Tissue Distribution.
Data were pooled from the COSMIC database (Forbes et al., 2011) and from a
reported CASP6 mutational study (Lee et al., 2006). Highlighted in bold are the
specific caspase-6 tumor-associated variants interrogated in this study.
Mutation
H11Y
G14D
M19R
D23V
R28K
M30I
A34T**

Tissue
Prostate
Skin
Ovary
Bone
Skin
Endometrium
Endometrium,
Stomach

Histology
Carcinoma
Carcinoma
Carcinoma
Ewings sarcoma
Carcinoma
Carcinoma
Carcinoma

R44K

Colon

Carcinoma

C68F
L98F
L98H
K99E**¶
K99T

Kidney
Endometrium
Thyroid
Liver
Cervix

Carcinoma
Carcinoma
Carcinoma
Carcinoma
Carcinoma

H101R**¶
V106I
V115A
D146E
P174S
E183D!

Liver
Cervix
Stomach
Liver
Skin
Endometrium

Carcinoma
Carcinoma
Carcinoma
Carcinoma
Carcinoma
Carcinoma

E191K
M208T

Urinary tract
Large Intestine

Carcinoma
Carcinoma

R220W

Endometrium

Carcinoma

E247K
E247*

Lung
Breast

Carcinoma
Carcinoma

R259C

Endometrium

Carcinoma

R259H
R260*
P276S
A279V!

Colon
Large Intestine
Breast
Endometrium

Carcinoma
Carcinoma
Carcinoma
Carcinoma

K285N

Lung

Carcinoma

Other Caspase Mutations+
none
none
none
none
caspase-8 (S33F, S375F)
caspase-2 (A259A)
caspase-3 (L118I, D192N);
caspase-4 (R55W); caspase-10
(E22D); caspase-14 (E49K)
caspase-3 (F193L);
caspase-8 (R162I)
none
caspase-1 (frameshift)
none
none
caspase-8 (N197T); caspase-14
(Q70K)
none
none
caspase-5 (frameshift)
none
none
caspase-7 (K109N); caspase-8
(R52I, R111I, T461P, T503P)
none
none
caspase-2 (L232R, R417W,
L125F); caspase-3 (R207*);
casp-4 (V252I);
caspase-5 (Y87*, Y116*);
none
caspase-4 (E351A); caspase-8
(D73A, D132A, E399*, E441*)
caspase-1 (G85W); caspse-2
(A412V); caspase-4 (K42Q);
caspase-7 (T18A); caspase-8
(E36*, E95*)
none
none
none
caspase-7 (K109N); caspase-8
(R52I, R111I, T461P, T503P)
none

Reference
(Robinson et al., 2015)
(Pickering et al., 2014)
(CGARN**, 2011)
(Crompton et al., 2014)
(Sharpe et al., 2015)
(Forbes et al., 2011)
(Forbes et al., 2011)
(Lee et al., 2006)
(Durinck et al., 2015)
(Forbes et al., 2011)
(Forbes et al., 2011)
(Forbes et al., 2011)
(Forbes et al., 2011)
(Forbes et al., 2011)
(Forbes et al., 2011)
(Wang et al., 2014)
(Forbes et al., 2011)
(Sharpe et al., 2015)
(Forbes et al., 2011)
(Forbes et al., 2011)
(Forbes et al., 2011)
(Forbes et al., 2011)

(Forbes et al., 2011)
(Forbes et al., 2011)
(Forbes et al., 2011)

(Lee et al., 2006)
(Forbes et al., 2011)
(Forbes et al., 2011)
(Forbes et al., 2011)
(Forbes et al., 2011)

!
*Nonsense
mutations identified in caspase-6. **Mutation found in two separate samples.
+

¶♯

Mutations found in the same sample ID. Other caspase mutations found in the same sample ID.
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Cys–163 (R259H and P276S). These caspase-6 variants were expressed in E.
coli and purified to homogeneity. The activities of the caspase-6 tumorassociated variants were assessed using a fluorogenic peptide-based substrate,
VEID-AMC (Table 4.2). These variants were observed to have 2–457 fold
decreases in catalytic efficiency compared to the wild type (WT) caspase-6.
Mutations within the substrate-binding groove, P276S and R259H, showed the
most negative impact on caspase-6 activity. The decrease in the catalytic
efficiency of all the caspase-6 tumor-associated variants suggests that the
mutations have caused changes in the structure or dynamics that result in less
effective substrate catalysis.
Caspase-6 is the sole caspase for which a mechanism for intramolecular
self-cleavage has been observed (Klaiman et al., 2009; Wang et al., 2010) and
WT caspase-6 is capable of self-maturation upon bacterial expression
(Velazquez-Delgado and Hardy, 2012).
Table 4.2 Kinetic Parameters of Selected Caspase-6 Tumor-Associated
Variants
from COSMIC
Bindal
et al.,from
2011) and
Table 2. Identified
Kinetic parameters
of selectedDatabase
caspase-6 (Forbes,
cancer variants
identified
COSMIC
database
(Forbes,
Bindal
al. 2011) and other sources (Lee, Kim et al. 2006).
Other
Sources
(Lee,
Kim et
al., et
2006).
Caspase-6
KM
kcat
103 x kcat/ KM
Fold decrease in
-1
-1 -1
mutation
(µM)
(s )
(M s )
turnover versus WT
WT
M19R
L98F
M208T
E247K
P276S
R259H
K285N

34 ± 3.6
163 ± 19
46 ± 4.2
170 ± 12.0
84 ± 10
314 ± 26
577 ± 135
50 ± 4.0

1.1 ± 0.03
0.80 ± 0.04
0.68 ± 0.02
1.5 ± 0.04
1.6 ± 0.06
0.57 ± 0.02
0.04 ± 0.01
0.18 ± 0.01

32
5.0
15
8.8
19
1.8
0.07
3.6

1
6.40
2.10
3.60
1.70
18.0
457
8.90

Kinetic parameters of caspase-6 tumor-associated variants were determined using fluorogenic
substrate, VEID-AMC using 100-nM enzyme in capase-6 activity assay buffer. Error, represents
standard error of the mean (S.E.M.) of two independent experiments.
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All of the caspase-6 tumor-associated variants were overexpressed in E. coli for
18 h at 20°C and purified in the same manner (described in the Materials and
Methods). These expression conditions led to full activation of WT caspase-6.
Despite identical conditions of expression and purification, variations in the
cleavage patterns of the caspase-6 tumor-associated variants were observed
(Figure 4.3A). Typically, caspase-6 is proteolytically cleaved at three sites
located in the prodomain and linker regions (Figure 4.1A) that are essential for its
full maturation and activation. When caspase-6 tumor-associated variants were
allowed to undergo self-proteolysis, L98F and K285N showed nearly full
maturation indicated by the presence of only the large and small subunits,
suggesting relatively proteolytically active caspases. The rest of the caspase-6
tumor-associated variants were unable to completely remove the linker
suggesting a decrease in their proteolytic activity compared to L98F and K285N
variants.
The caspase-6 tumor-associated variants were allowed to undergo selfproteolysis in vitro by 24-hr incubation in caspase-6 activity assay buffer at 37 °C
(Figure 4.3B). As expected, the full-length wild type (FL WT) caspase-6 showed
a higher fraction of the fully cleaved large and small subunits, indicating close to
full maturation. The caspase-6 phosphomimetic variant, S257D, is a surrogate of
a phosphorylated caspase-6 at position 257. The S257D substitution is
inactivated due to a misaligned substrate-binding groove of caspase-6
(Velazquez-Delgado and Hardy, 2012) and correspondingly, showed no further
cleavage into its large and small subunits (Figure 4.3B). L98F showed similar
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cleavage pattern as FL WT. R259H and P276S showed higher fractions of large
subunits with attached intersubunit linker, a cleavage pattern different from the
FL WT and L98F, which indicates that these variants slowed self-cleavage
activity. Thus, the accessibility of the intersubunit linker to caspase-6 appears to

Figure 4.3 Selected Caspase-6 Tumor-Associated Variants Showed
Decreased in Proteolytic Activity
(A) Cleavage pattern of caspase-6 tumor-associated variants expressed in E. coli
and purified to homogeneity. All caspase-6 tumor-associated mutations were
introduced into the full-length (FL) caspase-6 wild-type (WT) construct in pET11a
bacterial expression vector. (B) Self-cleavage pattern of recombinant caspase-6
tumor-associated variants (3 μM) before and after 24-h incubation in caspase-6
activity assay buffer at 37 °C. (C) Proteolysis of catalytically inactive procaspase6 C163S (3 μM) by caspase-6 tumor-associated variants (0.3 μM) before and
after 24-h incubation in casapse-6 activity assay buffer at 37 °C. (D) Proteolysis
of catalytically inactive procaspase-6 C163S (3 μM) by caspase-6 tumorassociated variant, R259H CT (0.3 μM) after incubation in caspase-6 activity
assay buffer at 37 °C for the indicated times. Two-chain forms of the mature and
fully cleaved wild type (ΔN D179CT) and R259H CT caspase-6 variants were
generated to allow independent expression of the large and small subunits
without the need for proteolytic cleavage for its activation. FL, full-length; ΔN,
removal of the N-terminal prodomain (residues 1–23); Lg, large subunit; L,
intersubunit linker; Sm, small subunit.
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be different in both P276S and R259H suggesting an altered geometry of the
substrate-binding cleft leaning towards a less proteolytically active enzyme.
The activities of selected caspase-6 tumor-associated variants in cleaving
protein substrate in trans (intermolecular cleavage) were tested using
procaspase-6 FL C163S, a catalytically inactive variant of caspase-6, as
substrate (Figure 4.3C). Consistently, both P276S and R259H showed less
proteolytic activity against this protein substrate compared to L98F and WT
caspase-6 (Figure 4.3C). R259H emerged as the least active variant in cleaving
procaspase-6 FL C163S, underscoring the severity of its impact on the proper
assembly of the substrate-binding cavity for efficient proteolysis. As the most
inactive among caspase-6 tumor-associated variants in cleaving both peptidebased and protein substrates, we sought to assess whether the R259H impacted
function in the fully mature form of caspase-6. To achieve this, the R259H
mutation was then introduced into a constitutively two-chain (CT) caspase-6
expression construct (Vaidya et al., 2011) that allows independent expression of
the large and small subunits, mimicking a fully cleaved and mature caspase-6.
The two-chain R259H CT is dramatically inactivated for cleavage of protein
substrate compared to the mature, two-chain (ΔND179CT) wild-type caspase-6.
This result further suggests that the R259H mutation is capable of negatively
impacting the activity of the mature (cleaved) caspase-6 in cleaving protein
substrates. Together, these data suggest that the majority of inactivating
mutations in caspase-6 found in tumor-associated tissues may have acquired
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misaligned substrate binding cleft or other defect-introducing structural changes
that decrease in caspase-6 catalytic efficiency. Thus, it appears that the
impairment of caspase-6 function need only to prevent caspase-6 activity in
trans, against other substrates, whereas self-cleavage in cis poses no significant
threat to these cancer cells.

4.3.3 Caspase-6 R259H Disrupts Interaction Necessary for Proper
Assembly of Substrate-Binding Groove
R259H is the most inactivating mutation among caspase-6 tumorassociated variants we analyzed. To further understand the impact of the R259H
substitution on proper assembly of the substrate-binding groove, the crystal
structure of active and mature caspase-6 (PDB code 2WDP) was further
inspected. Arg–259, which is located at the base of L4, is part of a network of Hbond and cation–π stacking interactions (Figure 4.4A) that provides a stable
foundation for the proper assembly of substrate binding loops, thus essential for
the establishment of a catalytically competent caspase-6. The usually positivelycharged guanidinium group of arginine exhibits a high propensity to stack against
aromatic residues while also capable of H-bonding to neighboring oxygen atoms
(Nandi et al., 1993). In caspase-6, Arg–259 forms two H-bonds with Asp-231 and
likely interacts with Trp-227 through cation–π stacking. Further, Trp-227 also
holds L3 in place through cation–π stacking interaction with His-219. Both
residues (His–219 and Trp–227) are part of the S4 substrate-binding pocket in
caspase-6. This, cation–π interaction between Arg-259 and Trp–227 is highly
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Figure 4.4 R259H Disrupts Interactions Necessary for Proper Assembly of
the Substrate-Binding Groove
(A) The crystal structure of the mature, fully cleaved and unliganded caspase-6 (PDB
code 2WDP) (left). The location of Arg–259, the active site Cys–163, and the two
tryptophan residues (Trp–57 and Trp–227) in caspase-6 are indicated. Inset view
highlights the cation–π stacking and networks of H-bond interactions in which Arg–259
are involved, as well as the substrate binding loops (L3, L4) and substrate-binding
pocket (S4) (middle). The crystal structure of procaspase-6 zymogen (PDB code 3NR2)
and the location of Arg–259, Trp–51, Trp–227, and the intersubunit linker (cyan) are
indicated (left). (B) The amino acid sequence alignment of key residues within the
network of interactions of Arg–259 across caspase family including both apoptotic and
inflammatory caspases. (C) Intrinsic tryptophan fluorescence profiles of full length
procaspase-6 C163S, caspase-6 ΔN D179CT, and caspase-6 ΔN R259H CT. Excitation
at 295 nm primarily probes the polarity of the tryptophan microenvironment. (D) Intrinsic
fluorescence profiles of caspase-6 variants excited at 280-nm wavelength. Excitation at
280 nm probes the polarity of the microenvironment of all aromatic residues in a protein
including tryptophan, tyrosine and phenylalanine.
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conserved across caspase family (Figure 4.4B), suggesting that this interaction is
widely used among caspases to stabilize the substrate binding groove for
efficient substrate binding and catalysis. On the other hand, the Asp–231 position
is not conserved across the caspase family, thus the two H-bonds between Arg–
259 and Asp-231 is unique to caspase-6. This implies that although common
stabilizing interactions exist in caspases, unique interactions are also present for
each individual caspase that may be relevant for its specific structure and
function. In fact, tumor-associated mutations at this position have not been observed in
other caspases. Caspase-7 has a His at the position homologous to caspase-6 Arg-259,
however, His is not deleterious in the caspase-7 context because caspase-7 has an Ala
at the position homologous to Asp-231. These data suggest that because Arg–259

participates in networks of stabilizing interactions it is a critical residue for
caspase function that enabled caspases to properly orient its substrate-binding
loops for efficient execution of enzyme catalysis.
The intrinsic fluorescence properties of Trp-227 allows this residue to
function as a sensitive probe for the cation–π stacking interaction between Arg–
259 and Trp-227 and the other network of interactions that give rise to the proper
assembly of the substrate-binding groove. Caspase-6 has only two Trp residues,
and they are both located in the substrate binding L1 (Trp-57) and at the base of
L4 (Trp-227), which is directly adjacent to Arg-259. Trp-57 in both the zymogen
and active forms are constantly solvent-exposed while the microenvironment of
the Trp-227 varies between these forms of caspase-6 (Figure 4.4A). Thus,
intrinsic tryptophan fluorescence will likely report the relative microenvironment of
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Trp-227 between the absence and presence of R25H mutation and in turn,
provides structural hints as to the proper assembly of the substrate-binding
groove of caspase-6. Intrinsic tryptophan fluorescence is dependent on the
polarity of the environment, where shifts in the maximum emission towards
longer wavelengths (red shift) indicate higher solvent exposure. Intrinsic
fluorescence spectra were collected from caspase-6 variants including the
catalytically inactive procaspase-6 FL C163S, the mature, fully cleaved caspase6 (ΔND179CT), and the two-chain caspase-6 R259H.
As expected, upon specific tryptophan excitation at 295 nm (Figure 4.4C),
the procaspase-6 zymogen showed a 10-nm shift in maximum emission towards
a shorter wavelength (blue shift) compared to the two-chain mature and cleaved
caspase-6 wild type (ΔND179CT) suggesting a less solvent-exposed Trp-227
microenvironment. In the procaspase-6 zymogen structure (Figure 4.4A), the
intersubunit linker sits on top of the substrate-binding groove of procapase-6
zymogen restricting the solvent accessibility of Trp-227, one of the critical
residues in the substrate-binding pocket of caspase-6. Meanwhile, the R259H CT
variant displayed a significantly extended 12-nm shift in maximum emission
towards longer wavelength (red shift) compared to caspase-6 ΔND179CT
indicating a highly solvent-exposed Trp-227 microenvironment. A similar trend
was observed with 280 nm excitation of all aromatic residues (Trp, Tyr, Phe)
(Figure 4.4D). Thus, the change in the polarity of the Trp-227 microenvironment
in the presence of the R25H mutation in caspase-6 suggests a disruption of the
stabilizing cation–π stacking interaction of Arg–259 with Trp-227 as well as the
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disruption of the networks of H-bonding interactions that results in misaligned
loops in the substrate binding pocket incapable of efficient catalytic turnover of
substrates.

4.4 Conclusions
This study demonstrates that all the selected mutations in caspase-6
found in several tumors resulted to an overall decrease in the catalytically
efficiency of caspase-6. The fact that not one of the selected mutations in any of
the regions of caspase-6 had not impacted or increased activity strongly
suggests that diminishing caspase-6 intrinsic activity via somatic mutation is
helpful in establishing a tumorigenic phenotype. In particular, R259H was found
to be severely deactivating via a mechanism that disrupts the cation–π stacking
and the networks of H-bonding interactions necessary for proper alignment of
loops in the substrate-binding groove of caspase-6.
One would anticipate that mutations in caspases would decrease the
apoptotic potential of the cells containing mutant caspases. One naturally
anticipates that neutralizing/inactivating mutations in caspase-6 should likewise
play a role in tumorigenesis. For example, caspase-6 is a direct activator of the
initiator caspase-8. Transfection of COS-7 cells with catalytically inactive
caspase-6 strongly diminished caspase-8 activation (Cowling and Downward,
2002). Thus, in cellular context, activation through caspase-6 presents one of the
regulatory pathways of caspase-8.

CASP8 is a tumor-associated gene and its

polymorphisms are correlated with increased risk for various types of cancer (Ji
et al., 2014; Mandruzzato et al., 1997; Park et al., 2016; Soung et al., 2005b). In
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addition to its central role in apoptosis, caspase-8 has emerging nonapoptotic
roles in cells such as potentiating NF-κB signaling (Su et al., 2005), regulating
autophagy (Bell et al., 2008), and cellular adhesion and migration (Barbero et al.,
2009; Senft et al., 2007). Thus, regulation of caspase-6 may possibly impact both
the apoptotic and the nonapoptic tumor-associated roles of caspase-8. In
addition, natural substrates of caspase-6 in cells has been reported including
those involved in cell death, RNA splicing, cytoskeletal organization, regulation of
transcription, chromosome organization, and in the cell cycle suggesting the
unparalleled importance of the roles of caspase-6 in and outside of the apoptotic
cascade (Julien et al., 2016). Several caspase-6 substrates identified from the
MS-based approach (Julien et al., 2016) are tumor-associated based on its
inclusion in the census of human cancer genes (Futreal et al., 2004) including the
cellular tumor antigen p53, TP53 and the breast cancer type 1 susceptibility
protein, BRCA1. Thus, the cleavage or miscleavage of these tumor-associated
substrates by caspase-6 suggests the possible mechanism for caspase-6 to play
a role in tumor development.
Together with the aberrant regulation of caspase-6, there were also
mutations in other caspases that have been detected in some tumor-associated
tissue samples with caspase-6 mutations. Thus, the co-occurrences of caspase
mutations and the mutations in other tumor-associated genes underscore the
complexity of each individual event of tumorigenesis. The fact that a number of
different mutations in different regions of caspase-6 were observed in different
tumors suggests the possibility that unique contributions of various aspects of
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caspase-6 function may be at play in different cancers. The roles of each
component in the pathway to tumor development will enable a better
understanding of the controlling factors that allow the misregulation observed in
cancer cells of all varieties. This work demonstrates that in cases when caspase6 is mutated in tumors significant impacts on catalytic function are observed.
What remains to be seen is whether other aspects of caspase-6 regulation, such
as post-translational modifications, dynamics and substrate selection are likewise
impacted by these tumor-associated mutations.

4.5 Materials and Methods
4.5.1 Database Analysis of CASP6 Gene Mutations
CASP6 gene mutations in tumor samples were identified from COSMIC
database (http://cancer.sanger.ac.uk/cosmic) (Forbes et al., 2011) and from a
report of CASP6 gene mutations in colorectal and gastric carcinomas (Lee et al.,
2006). Assessment of a total of 29,815 sample tissues across all tumorassociated tissue types was reported for CASP6 gene mutations. Representative
missense mutations were selected based on the location of these mutations in
the caspase-6 structure which spans within the region of the prodomain (M19R),
the 90’s region (L98F), within the dimer interface (M208T and K285N), at the
base of the helix adjoining L4 (E247K), and within 8Å radius of the active site
Cys–163 (R259H and P276S).
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4.5.2 Generation of Caspase-6 Tumor-Associated Variants
The caspase-6 variants full length wild type (FL WT), FL C163S, and ΔN
D179CT were derived from the synthetic, E. coli codon-optimized (His)6 Cterminally tagged caspase-6 gene (Celtek Bioscience) that were ligated into the
NdeI/BamHI sites of pET11a vector (Vaidya et al., 2011). Selected caspase-6
tumor-associated variants were generated using FL WT as template through
Phusion® site-directed mutagenesis (Thermo ScientificTM). The caspase-6
R259H CT variant was particularly generated using caspase-6 ΔN D179CT as
the template for the site-directed mutagenesis.

4.5.3 Caspase-6 Protein Expression and Purification
Caspase-6 expression constructs were transformed into the BL21(DE3)
T7 express strain of E. coli (New England Biolabs). Overnight seed cultures
were initially grown in 2xYT medium supplemented with 0.1 mg/ml ampicillin
(Sigma) at 37 °C. Dense cultures were then diluted 1,000-fold with 2xYT
containing 0.1 mg/ml ampicillin and shaken at 37 °C until A600 reached 0.6.
Protein expression was induced by the addition of 1mM isopropyl 1-thio-β-Dgalactopyranoside and cultures were shaken at 20 °C for 18 h. Cells were
centrifuged at 4,700 x g for 10 min at 4 °C and stored at −20 °C until use.
Freeze-thawed cells were lysed using a microfluidizer (Microfuidics, Inc.) in lysis
buffer (50 mM Tris, pH 8.5, 300 mM NaCl, 5% glycerol, 50 mM imidazole) and
centrifuged at 30,600 x g for 1 h at 4 °C. The supernatant was loaded into a 5-ml
HiTrap nickel affinity column (GE Healthcare) and washed with lysis buffer until
the absorbance returned to baseline levels. These proteins were eluted with
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elution buffer (50 mM Tris, pH 8.5, 300 mM NaCl, 5% glycerol, 250 mM
imidazole) and diluted 5-fold with buffer A (20 mM Tris, pH 8.5, 2 mM DTT) to
reduce the salt concentration. These protein samples were then loaded into a 5ml HiTrap Q HP column (GE Healthcare). The columns were developed with
linear NaCl gradients, and each protein was eluted in 20mM Tris, pH 8.5, 200mM
NaCl, 2mM DTT. These eluted proteins were stored at −80 °C until use. Purified
caspases were analyzed by SDS-PAGE to confirm identity and purity.

4.5.4 Caspase-6 Activity Assays
To measure caspase-6 activity, the activity of 100 nM purified caspase-6
(WT and tumor-associated variants) was assayed over 7 min at 37 °C in
caspase-6 activity assay buffer (100 mM HEPES, 120 mM NaCl, 0.1% CHAPS,
10% sucrose, 5 mM DTT). For substrate titration, a range of 0-500 μM
fluorogenic substrate VEID-AMC [N-acetyl-Val-Glu-Ile-Asp-(7-amino-4-methylcoumarin), Enzo Life Sciences In was used. Fluorescence kinetic measurements
(λex/λem: 365nm/495nm) were performed in two independent trials in 100-μL
reactions in a 96-well format using a microplate reader (SpectraMax M5,
Molecular Devices). Initial velocities versus substrate concentration were fit to a
rectangular hyperbola using GraphPad Prism (GraphPad Software, San Diego,
USA) to determine the kinetic parameters KM and kcat. Enzyme concentrations
were determined by active-site titration with the quantitative covalent inhibitor
VEID-CHO

(N-Acetyl-Val-Glu-Ile-Asp-aldehyde;

Enzo

Life

Sciences

Inc.).

Caspase-6 was added to inhibitor solvated in DMSO in 96-wells V-bottom plates
at room temperature for 1.5 hours in caspase-6 activity assay buffer. Aliquots (90
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μL) were transferred in duplicate to black-well plates and assayed with 50-fold
molar excess of substrate. The protein concentration was determined to be the
lowest concentration at which full inhibition was observed and was thus used to
calculate kcat.

4.5.5 Self-Proteolysis Assay of Caspase-6 Tumor-Associated Variants
Caspase-6 variants (3 μM) were allowed to self-cleave in caspase-6
activity assay buffer (100 mM HEPES pH 7.5, 10% sucrose, 0.1% CHAPS, 120
mM NaCl, and 5 mM DTT) at 37 °C for 24 h. SDS loading buffer was added to
the samples and boiled for 10 mins prior to analysis by 16% SDS-PAGE. The
gels were imaged using a ChemiDocTM MP imaging system (Bio-Rad).

4.5.6 Proteolysis of Procasapse-6 FL C163S Protein by Caspase-6 TumorAssociated Variants
Catalytically inactive procaspase-6 FL C163S (3 μM) was incubated with
each of caspase-6 tumor-associated variants (0.3 μM) in caspase-6 assay buffer
(100 mM HEPES pH 7.5, 10% sucrose, 0.1% CHAPS, 120 mM NaCl, and 5 mM
DTT) at 37 °C for a predetermined time interval. SDS loading buffer was added
to the samples and boiled for 10 mins prior to analysis by 16% SDS-PAGE. The
gels were imaged using ChemiDocTM MP imaging system (Bio-Rad).

4.5.7 Intrinsic Fluorescence Spectroscopy
Caspase-6 tumor-associated variants (3 μM) in 20 mM phosphate buffer,
pH 7.5, 120 mM NaCl, and 2 mM DTT were prepared. Fluorescence emission
scans (305–400 nm) were collected after excitation at 280 nm or 295 nm using a

157

J-1500

spectrometer

(Jasco)

equipped

with

fluorescence

emission

monochromator (FMO-522) and detector (FDT-538). The signal was acquired by
setting the emission detector at high-tension voltage value of 700 V, the data
integration time (D.I.T) to 1 s and data pitch to 1 nm. The bandwidths used for
excitation and emission was 2 nm and 10 nm, respectively.

4.5.8 Caspase-6 Full-length Structural Model Generation
The full-length caspase-6 zymogen model (residues 1–293) shown in
Figure 4.1B was built from crystal structures of the caspase-6 zymogen. In our
model, chain A was derived from PBD code 4iyr (chain A); chain B of this model
was derived from PDB code 3NR2 (chain A) as templates. The missing residues
([1–30, 174–186, and 292–293] in PBD code 4iyr (chain A); [1–30, 167–186,
261–271, and 292–293] in PBD code 3NR2 (chain A)) were built by de novo
modeling using Chimera/Modeller platforms (Pettersen et al., 2004; Webb and
Sali, 2014). All illustrations with molecular visualization were generated using the
PyMOL Molecular Graphics System (Schrödinger, LLC).
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CHAPTER 5
PROCASPASE-6 IS INHIBITED BY NUCLEOTIDES
AT THE DIMER INTERFACE
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5.1 Introduction
Caspases are cysteine aspartate proteases that are associated with
diverse cellular functions including apoptosis, inflammation and more recently in
neurodegeneration (for reviews see (Friedlander 2003; Wang et al., 2014;
Wellington and Hayden, 2000)). In terms of function and length of the prodomain,
caspases are grouped into initiators (casapse-2, -8, and -9) and executioners
(casapse-3, -6, and -7) of programmed cell death (Nicholson, 1999). Caspases
are expressed as inactive zymogens (procaspases) that comprise prodomain,
large and small subunits connected by an intersubunit linker region. Canonical
procaspase activation requires a series of proteolytic cleavages at conserved
aspartate residues between the prodomain and large subunit and in the
intersubunit linker region. During procaspase-6 activation, cleavage at the
intersubunit linker (Asp-D193) is the critical step in transformation of procaspase6 to active caspase-6. Subsequent cleavages in the prodomain (Asp-23) and at
the Asp-179 site in the linker region generate a fully cleaved and mature
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caspase-6. While procaspase-6 is unable to cleave other cellular targets, it
appears to be able to cleave the prodomain, even in the zymogen state
(Velazquez-Delgado and Hardy, 2012). Procaspase-6 is also the only caspase
for which a mechanism for self-activation, a noncanonical route for caspase
activation, has been elucidated (Klaiman et al., 2009; Wang et al., 2010).
Because procaspase-6 has longer loop 2 (L2) compared with the other
caspases, the scissile peptide bond between the Asp-193 and Ala-194 within the
intersubunit linker—a contiguous part of L2—sits close to the active site Cys-163
and can then be primed for hydrolysis by intramolecular self-cleavage. In fact,
shortening the length of L2 has been shown to abolish the capability of
procaspase-6 to auto activate, underscoring the critical role of the longer L2 in
procaspase-6 self-activation (Wang et al., 2010).
Notable functions of caspase-6 are highlighted in its role in axonal
degeneration in amyloid precursor protein-mediated death receptor 6 signaling
(Nikolaev et al., 2009), disruption of neuronal cytoskeleton (Klaiman et al., 2008),
and its abundance in neuropathological lesions in the brains of patients with
Alzheimer’s disease (AD) (Albrecht et al., 2007; Guo et al., 2004). In addition,
caspase-6 has also been shown to cleave polyglutamine expanded Huntingtin
protein, one of the contributing factors in the onset of Huntington’s disease
(Graham et al., 2010; Riechers et al., 2016; Warby et al., 2008). Thus,
understanding the intricate mechanisms of how caspases are activated and
regulated are essential to unraveling strategies to control its multifaceted
disease-related functions.
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A number of years ago, a cavity was discovered at the dimer interface of
caspase-3 and -7 that can be allosterically inhibited by non-native small
molecules (Figure 5.1) (Hardy et al., 2004; Hardy and Wells, 2009) This cavity is
also present and can be inhibited in caspase-1 (Scheer et al., 2006) and
caspase-6 (Dagbay et al., 2014). While the volume, depth and ratio of
hydrophobic and polar residues suggests that this cavity is a small moleculebinding site; no natural, native ligand(s) for this cavity have previously been
reported. In this work, we identify a class of ligands, specifically, naturally
occurring nucleotides that bind to and inhibit procaspase-6 in this region of the
procaspase-6, at the dimer interface.

5.2 Results
5.2.1 Procaspase-6 is Robustly Labeled by the ActivX ATP Acyl Phosphate
Probe
ActivX Pharmaceuticals has developed a series of nucleotide-based, biotinylated,
acyl phosphate probes that have been used to identify several nucleotide-binding
proteins (Patricelli et al., 2011; Patricelli et al., 2007). These probes function by
binding to nucleotide binding sites and allowing proximity-induced nucleophilic
attack at the highly reactive acyl phosphate group, thus forming a covalent bond
between the protein and the biotinylated portion of the probe, which can then be
enriched using a streptavidin-coated solid support or digested with a protease
and identify the labeled peptides using LC-MS/MS. The ATP-based acyl
phosphate probe (Figure 5.2A) has been particularly useful for identifying kinases
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(Patricelli et al., 2007; Rosenblum et al., 2013). We undertook an unbiased
screen for ATP binding proteins. Procaspase-6 was identified as a robust ATPprobe binder, with levels of isolated procapase-6 being roughly equivalent to
levels of many confirmed ATP-binding proteins, including kinases. Using MS/MS
we identified Lys-133 as the probe-labeled residue (Figure 5.2B). Lys-133 is in
the 130’s region of procaspase-6. To confirm that procaspase-6 was indeed
bound by the ATP acyl phosphate probe, apoptosis was induced in Jurkat cells
with the α-FAS antibody. In lysates from resting cells procaspase-6
predominated, whereas in apoptotic cells, predominantly cleaved (active)
caspase-6 was observed by caspase-6 immunoblotting (Figure 5.2B). These
same lysates were also treated with the biotinylated ATP acyl phosphate probes.
Whereas high levels of procaspase-6 were isolated from resting cells, far less
procaspase-6 was isolated from apoptotic cells (Figure 5.2B), further indicating
that procaspase-6 was the main caspase-6 cleavage state identified by the ATP
probe, and suggesting that ATP may be a bona fide binder of procaspase-6. To
examine the relative preference of procaspase-6 for ATP, relative to other
nucleotides, we undertook a competition strategy. Jurkat cell lysates were treated
with the ATP probe and then challenged with 1 mM of various nucleotides
(Figure 5.2D). The amount of procaspase-6 labeled by the ATP probe was then
quantified using LC-MS/MS. ATP, ADP and NADP+ were most effective
competitors with the ATP probe labeling. CTP and GTP also showed significant
inhibition of probe labeling. Together these data suggest that several nucleotides
may be able to bind procapase-6, and potentially implicating the
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Figure 5.1 An Allosteric Site Exists at the
Dimer Interface of Caspases
The cavity at the dimer interface of caspase3 and -7 can be allosterically inhibited by
non-native small molecules (Hardy et al.,
2004; Hardy and Wells, 2009). The natural
ligand for this cavity has not previously been
reported.

Figure 5.2 The ActivX ATP
Acyl Phosphate Probe
Binds
Lys-133
in
Procaspase-6
(A) The acyl phosphate in
the ActivX desthiobiotin-ATP
probe is reactive toward
nucleophilic attack by lysine.
Using
biotin
labeling,
procaspase-6 was isolated.
By mass-spectrometry Lys133 was identified as being
covalently modified by the
ATP-probe. (B) Apoptosis
was induced in Jurkat cells
by addition of the α-FAS
antibody. Samples were
examined with the αcaspase 6 antibody by
immunoblot. Resting cells
expressed
predominantly
procaspase-6, whereas cells
induced
to
undergo
apoptosis showed pool of
active
caspase-6.
(C)
Resting Jurkat cells, or cells
induced to apoptosis by addition of α-FAS antibody were treated with the ActivX
desthiobiotin ATP probe. Biotinylated proteins were isolated by streptavidin
capture and analyzed by mass spectrometry. The relative signal for procaspase6 was significantly greater in resting cells than in apoptotic cells. (D) A panel of
naturally occurring nucleotides was used to compete with the ActivX ATP probe
for binding and labeling of procaspase-6 in Jurkat cell lysates. Percentage
inhibition refers to the level of inhibition of probe labeling of procaspase-6.
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phosphate or deoxyribose moieties as playing a significant role in procaspase-6
binding.

5.2.2 Procaspase-6 Self-Processing is Inhibited by ATP
Given that ATP-based probes robustly label procaspase-6 it seems
plausible that ATP would impact some step in procaspase-6 function. A main
function of procaspase-6 is self-processing. We routinely use a C-terminal His6
tag for isolating active caspase-6. This construct was not appropriate for isolating
procapase-6 because it repeatedly resulted in predominantly active (cleaved)
caspase-6. Using a new N-terminally His6 construct, we were able to isolate a
nearly homogeneous preparation of procaspase-6 (Figure 5.3A). Procaspase-6
was incubated from 0–8 hours in the presence or absence of 20 mM ATP. At this
concentration of ATP, cleavage of procaspase-6 was significantly impeded.
Similarly, when procaspase-6 was incubated with increasing concentrations of
ATP, it became clear that ATP inhibits procaspase-6 processing in a
concentration-dependent manner (Figure 5.3B) with an IC50 of 19 ± 0.8 mM
(Figure 5.3C). Conversely, the activity of mature caspase-6 is not affected by
increasing concentrations of ATP (Figure 5.3D). From these analyses,
procaspase-6 is sensitive to the presence of ATP, which inhibits self-processing,
but that the activity of mature caspase-6 is not ATP-sensitive.
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Figure 5.3 ATP Attenuates
the Procaspase-6 Activity
But Not Caspase-6 Activity
(A)
Self-proteolysis
of
procaspase-6
analog
(caspase-6 FL N-terminally
(His)6 in the absence and
presence of 20 mM ATP at
37 °C at different time
intervals (hr: 0, 0.25, 1, 2, 4,
6,
and
8).
Increasing
incubation time promotes
self-activation
of
procaspase-6 resulting into
large and small subunits
appearance.
The
abbreviations
(FL:
fulllength, ∆N: without prodomain, Lg+L: large subunit
attached to linker, Lg: large
subunit, and Sm: small
subunit) are shown in the
figure. After 6 hr of
incubation, the pro-domain
is fully cleaved in the
absence of ATP while intact in the presence of ATP. (B) Self-proteolysis of
caspase-6 FL N-terminally (His)6 at 6 hr incubation at 37 °C in the presence of
various ATP concentrations (mM: 0, 2.5, 3.75, 5, 7.5, 10, 15, 20, 25, 30, 35, 40,
60). (C) The percent remaining band intensities of (FL+∆N) with respect to Lg+L,
Lg, and Sm band intensities were plotted against various Log [ATP, M] to
determine the IC50 value. ATP inhibits procaspase-6 activity with an IC50 value of
(19 ± 0.8) mM.

5.2.3 ATP Binds Procaspase-6 at Y198
The cavity at the dimer interface of procaspase-6 (Figure 5.4A) is like that
observed in other caspases (Figure 5.1). In addition to FICA and DICA which
bind to the dimer interfaces of caspase-3, -7 (Hardy et al., 2004; Hardy and
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Wells, 2009) and -6 (Dagbay et al., 2014), compound 3, an amino-substituted
isoquinolinone also binds in this region (Figure 5.5) and is a nanomolar affinity
binder of procaspase-6 (Murray et al., 2014). Compound 3 engages Y198 to bind
to this cavity. Given that both ATP and compound 3 share similarity in the
arrangements of their rings, we reasoned that ATP might bind at the same
location as compound 3 (Figure 5.4B). To test this hypothesis, we prepared the
Y198A version of caspase-6. This substitution had no impact on catalytic activity
of the mature form of the enzyme (Figure 5.4D) suggesting that this mutation
does not negatively impact either the structure or the function of the enzyme. In
contrast, Y198A had dramatic impacts on the ability of the ATP probe to label
procaspase-6. Caspase-6 variants were overexpressed in E. coli and lysates
were exposed to the ATP probe. WT caspase-6 is fully processed and mature
under the expression conditions tested. Mature caspase-6 show very little probe
labeling (0.9%, Figure 5.4C). C163S variant, which allows expression of fulllength but inactive procaspase-6 zymogen, was fully labeled. When Y198A is
introduced in the presence of C163S, full-length zymogen was observed, but this
protein was no longer competent to be labeled by the ATP probe. The Y198A
variant could also not be labeled by the ATP probe, however this it likely because
Y198A is fully processed to the mature form (Figure 5.5). Likewise, for the S257D
variant in which approximately half of the enzyme is in the uncleaved zymogen
state and half is in the mature cleaved state, only 42% of the sample is
competent for
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Figure 5.4 Tyr-198 of Procaspase-6 is a Putative Binding Site for ATP Acyl
Phosphate Probe and ATP
(A) The surface representation of procaspase-6 (PBD code 3NR2) highlights the
cavity (yellow) within the dimer interface, a putative nucleotide-binding site. (B)
The dimer interface of procaspase-6 shows the ATP acyl phosphate probelabeling site (Lys-133) near the active site Cys-163. The two Tyr-198 residues
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from each monomer of procaspase-6 form a pi stack within the dimer interface
that is essential for ATP acyl phosphate probe binding. (C) Percent relative ATP
acyl phosphate probe labeling of cleaved and active caspase-6 (WT and Y198A),
catalytically inactive FL caspase-6 S257D, and FL procaspase-6 variants
(C163S, C163S/Y198A) in bacterial cell lysate. (D) The kinetic parameters of
cleaved and active caspase-6 Y198A is similar to the WT suggest that Tyr-198
site is orthogonal to the active site. The values are reported as mean ± s.e.m of
two independent trials performed on two separate days. (E) FL procaspase-6
C163S and (F) FL procaspase-6 C163S/Y198A were incubated with 10% active
caspase-6 in the presence or absence of 20 mM ATP at 37 °C at different time
intervals (min: 0, 15, 60, 240). The band intensities of FL procaspase-6 C163S
and FL procaspase-6 C163S/Y198A were quantified and set at 100%. The extent
of cleavage with or without ATP was reported as percent procaspase-6
remaining at each time point. Error bars represent mean ± s.e.m of five
independent experiments. Statistical analysis was performed using MannWhitney t-test (two-tailed): ns, not significant (P> 0.05), **P< 0.05.
To date, it has been impossible to express and purify uncleaved Y198A
with the active site cysteine intact. We hypothesize that Y198A is more active for
self-processing because critical π stacking interactions between Y198 and
residues in the intersubunit linker are lost. Loss of these interactions increases
flexibility in the procaspase-6 substrate binding groove and active site loop
bundle easing self-activation. Due to this hyperactivity in Y198A procaspase-6
toward intra bacterial cell processing upon overexpression, even with 10-minute
low temperature inductions, it has been impossible to test the impact of ATP on
self-processing of Y198A procaspase-6. Nevertheless, we have observed that
ATP significantly slows the processing of FL procaspase-6 C163S catalytically
inactive variant by WT caspase-6 (Figure 5.4E). On the other hand, ATP does
not impact caspase-6 mediated cleavage of FL procaspase-6 C163S/Y198A
(Figure 5.5.4F), suggesting that Y198 is a critical residue for mediating ATPbinding and inhibition.
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Figure 5.5 The Crystal Structure of Procaspase-6 Bound to Compound 3
Allosteric caspase-6 binder compound 3 (red) is sandwiched at the dimer
interface between Lys-198 (cyan) from each monomer of a dimeric procaspase-6
(PDB code 4N6G). Fragment 3 was identified from a fragment-merging strategy
that generated nanomolar-affinity ligands of procaspase-6 (Murray et al., 2014).

Figure 5.6 Caspase-6 Variants Showed Variation in Cleavage Patterns
Dependent on its Activation State
Caspase-6 variants were expressed in E. coli and lysed and analyzed by
immunoblotting using anti-α-casapse-6 antibody. WT and Y198A are active
capase-6 variants while C163S and C163S/Y198A are catalytically inactive
variants of procaspase-6. S257D is an inactivating mutation that mimics a
phosphorylated form of caspase-6 at position 257.
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5.2.4 Multiple Nucleotides Inhibit Procaspase-6
While it is clear that ATP inhibits procaspase-6 self-processing by a
mechanism that involves Y198, it is not clear that a priori that ATP is the most
significant nucleotide regulator of procaspase-6 activity intracellularly. We
reasoned that the nucleotides that exhibit the strongest IC50 relative to their
intracellular concentration are likely to serve as the most important small
molecule regulators of procaspase-6. Based on their ability to prevent ATP probe
binding (Figure 5.4C), we assessed the ability of ATP, dATP, GTP and the
dinucleotide, Ap4A. Ap4A is synthesized in cells in response to various cellular
stresses including DNA damage (Marriott et al., 2015) and apoptosis (Vartanian
et al., 1999; Vartanian et al., 2003) and is recognized as a pleiotropically-acting
alarmone in cells (Bochner et al., 1984; Varshavsky, 1983). These nucleotides
inhibit procaspase-6 (Figure 5.7) at levels approximately two–fold (for ATP and
GTP), 50-fold (for dATP), and 10-fold (for Ap4A) above the reported intracellular
concentrations (Chandra et al., 2006; Mesner et al., 1999; Rapaport and
Zamecnik, 1976). Although it is clear that ATP binds at the procaspase-6 dimer
interface and impacts function, it is not yet clear which nucleotides are most
critical for regulating caspase-6 function at what intracellular location and at what
stage(s) of the caspase-6 lifecycle.
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Figure 5.7 Structures of Small-Molecule Metabolites.
The structures of small-molecule metabolites (ATP, dATP, GTP, and Ap4A) are
given along with their IC50 values with respect to the self-proteolysis of
procaspase-6 in vitro.
ATP probe labeling.

5.3 Discussion
Caspases are important mediators of key cellular process including
apoptosis, inflammation and in several disease-related pathways. Thus,
dissecting the molecular details of each caspase function and regulation is
crucial to the understanding of caspase-associated signaling that is relevant in
maintaining cellular homeostasis as well as in the molecular evolution of a
disease phenotype. Here we show that a set of nucleotides can bind and inhibit
procaspase-6 self-activation. Specifically, the dimer interface residue Lys-198 is
found to be critical in ATP binding in procaspase-6. The binding of cellular

174

nucleotide ligands to procaspase-6 represents one direct regulatory route of
caspase-6 activation of which cellular consequences are yet to be determined.
Nanomolar-affinity binders of procaspase-6 identified from fragmentmerging strategy have recently been reported (Murray et al., 2014). The crystal
structures of procaspase-6 with several nanomolar binders, including compound
3, revealed the same binding site as the identified ATP binding site in
procaspase-6 reported in this work. Moreover, small molecule thiol-containing
inhibitors of caspase-3 and caspase-7 discovered through tethering approach
(Hardy et al., 2004; Hardy and Wells, 2009) bind to the homologous dimer
interface region in procaspase-6. Thus, the propensity of the dimer interface of
caspases to bind to native and non-native small molecules and negatively
impacts its activity indicates that this site is regulatory and possibly utilized by
caspases in cells.
The Tyr–198 nucleotide-binding site in procaspase-6 is moderately
conserved; only caspase-4 and caspase-7 to have tyrosine in the homologous
position. Together with the possible electrostatic interactions due to the presence
of the phosphate groups, the proposed interaction of nucleotides to Tyr–198 sites
in procaspase-6 is predominantly through pi-pi stacking as adenine in ATP
showed molecular resemblance to compound 3 (Figure 5.5). In the absence of
co-crystal structures of procaspase-6/nucleotide complex, we can only propose a
possible regulatory mechanism. Nucleotide binders, like compound 3, may
regulate procasaspe-6 activity by locking L2 in the inactive helical conformation,
thus stabilizing the less active procaspase-6 conformation (Murray et al., 2014).
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Although the dimer interface may be utilized by some caspases as a regulatory
allosteric site, the type of interaction networks may significantly be divergent. The
binding of FICA and DICA to caspase-7 (Hardy et al., 2004) showed a different
type of interaction networks where two FICA molecules fill the central cavity in a
planar, edge-to-edge network with Tyr-223. On the other hand, DICA interacts
with Ty–223 in cis-type network packing its aromatic ring against the wall of the
dimer cavity. Both regulatory interaction networks in FICA and DICA trapped
mature caspase-6 in the zymogen-like conformation. Together, the accessibility
of the caspase dimer interface by small molecules along with its unique
regulatory network of interactions suggest that various types of cellular activators
or inhibitors could bind to this region and may associate caspases to its diverse
and some are yet unknown apoptotic and nonapoptic functions.
The Tyr-198 pi-pi stacking interaction is only found in the procaspase-6
form. While the Tyr-198 is buried in the dimer interface of procaspase-6 (Wang et
al., 2010), this same Tyr–198 residue is exposed to the solvent upon proteolytic
activation of caspase-6(Baumgartner et al., 2009; Vaidya et al., 2011). Evidently,
ATP binds procaspase-6 but not mature caspase-6 suggesting that nucleotide
binding to procaspase-6 is conformation-specific. Thus, the impact of nucleotide
binding is less pronounced for already activated caspase-6 and may insinuate
that the regulatory roles of nucleotides are less effective in the signaling cascade
where the proteolytic activity of caspase-6 is already in effect.
Several

open

questions

about

nucleotide-mediated

inhibition

of

procaspase-6 beg to be addressed: First, under what cellular conditions
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procaspase-6 binding to nucleotides is occurring. Second, what concentrations of
which specific nucleotides modulate which specific cellular responses. Generally,
an increase in the concentration of endogenous nucleotides is thought to be a
prosurvival mechanism in cells (Chandra et al., 2006). This idea is supported by
other cellular systems where an increased in the endogenous nucleotide levels
up to 17-fold above normal promotes survival in response to DNA damage in
yeast (Chabes et al., 2003) as well as it promotes proliferation and survival in T
lymphocytes (Quemeneur et al., 2003). Likewise, increasing the pool of
nucleotides by overexpression of thymidine kinases involved in the de novo
synthesis of nucleotides (Grusch et al., 2001; Oliver et al., 1997) or exogenous
addition of nucleotide precursors (Kelly et al., 2001), promotes resistance to
apoptosis. This prosurvival mechanism stems from the direct interference of the
cytochrome c binding to Apaf-1 at high nucleotide concentrations, thus prevents
apoptosome formation (Chandra et al., 2006), an upstream event in the apoptotic
cascade. Moreover, at an ATP concentration greater than 1 mM, caspase-9
function is negatively regulated via direct binding (Chereau et al., 2005). Thus,
the high nucleotide concentrations exceeding that of the normal levels during
specific cellular response presents a recurring cellular condition that results in the
shutdown of the general apoptotic machineries, including caspases. In this work,
the inhibition of procaspase-6 at 2-fold higher than normal concentration of
nucleotides (GTP and ATP) may suggests an inhibitory effect of these
nucleotides in the apoptotic function of caspase-6. While it is clear that
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metabolism and apoptosis are highly interconnected, this an example of a class
of small-molecule metabolites directly impacting the function of a procaspase.

5.4 Materials and Methods
5.4.1 Generation of Caspase Variants
The full-length wild-type (FL WT) caspase-6 used in this study was
derived from a synthetic, E. coli codon-optimized (His)6 C-terminally tagged
caspase-6 gene (Celtek Bioscience) that was ligated into the NdeI/BamHI sites of
pET11a vector. Caspase-6 variants (C163S, S257D, Y198A, C163S/Y198A) as
well as the N-terminally (His)6

tagged FL casp-6 were generated using

Phusion® site-directed mutagenesis (Thermo ScientificTM) in the FL WT caspase6 construct. Fully cleaved and active caspase-6 was also used in a form of a
constitutive two-chain (CT) (Vaidya et al., 2011), which was designed to
independently express the large and the small subunits of caspase-6 with the
prodomain (residues 1-23) and linker (residues 180-193) removed.

5.4.2 Caspase Protein Expression and Purification
All caspase-6 constructs used in this study were transformed into the
BL21(DE3) T7 express strain of E. coli (NEB). Overnight seed cultures were
initially grown in 2×YT media supplemented with 0.1 mg/mL ampicillin (Sigma) at
37°C. Dense cultures were then diluted 1000-fold with 2×YT media containing
0.1 mg/mL ampicillin at 37 °C until A600 reached 0.6. For the following caspase-6
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variants: FL procaspase-6 C163S (active-site knockout), FL procaspase-6
C163S/Y198A, FL S257D, FL Y198A, protein expression was induced by
addition of 1 mM IPTG (Anatrace) at 20°C for 18 h. Cells were centrifuged at
4,700 x g for 10 min at 4°C and stored at -20°C until use. Freeze-thawed cells
were lysed using a microfluidizer (Microfuidics, Inc.) in ice-cold lysis buffer (50
mM Tris, pH 8.5, 300 mM NaCl, 5% glycerol, 50 mM imidazole) and centrifuged
at 30,600 x g for 1 hour at 4 °C. The supernatant was loaded into a 5-mL HiTrap
nickel-affinity column (GE Healthcare) and washed with lysis buffer until the
absorbance returned to baseline. The protein was eluted with elution buffer (50
mM Tris, pH 8.5, 300 mM NaCl, 5% glycerol, 250 mM imidazole) and diluted 5fold with buffer A (20 mM Tris, pH 8.5, 2 mM DTT) to reduce the salt
concentration. This protein sample was then loaded into a 5-mL HiTrap Q HP
column (GE Healthcare). The column was developed with a linear NaCl gradient
and the protein was eluted in 20 mM Tris, pH 8.5, 200 mM NaCl, 2 mM DTT. This
eluted protein was stored at -80 °C until use. The purified caspases were
analyzed by SDS-PAGE to confirm identity and purity.
The expression and purification of the catalytically competent, N-terminally
(His)6 tagged procaspase-6 was similar to the expression and purification of other
caspase-6 variants described above except that the induction with 1 mM IPTG
was at 25°C for 30 min. The buffer systems for protein purification have been
slightly modified to optimize the production of the zymogen form of the enzyme.
The lysis and elution buffer components were similar except that the pH of both
buffer solutions was adjusted to pH 9 and DTT was excluded.
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5.4.3 ATP Probe Labeling and Mass Spectrometry
Caspase-6 variants (WT, Y198A, C163S, C163S/Y198A, S257D) were
expressed in E. coli BL21(DE3) cells (NEB). The samples were lysed and
prepared for ATP acyl phosphate probe labeling and mass spectrometric
analyses as described elsewhere (Patricelli et al., 2011; Patricelli et al., 2007).

5.4.4 Caspase Activity Assays
To measure caspase activity, 100 nM purified caspase was assayed over
7 min at 37°C in casp-6 activity assay buffer (100 mM HEPES, 120 mM NaCl,
0.1% CHAPS, 10% sucrose, 5 mM DTT). For substrate titration, a range of 0-500
μM

fluorogenic

substrate

VEID-AMC

[N-acetyl-Val-Glu-Ile-Asp-(7-amino-4-

methyl-coumarin), Enzo Life Sciences Inc.] was used. Fluorescence kinetic
measurements (λex/λem: 365nm/495nm) were performed in three independent
trials on three different days in 100-μL reactions in a 96-well format using a
microplate reader (SpectraMax M5, Molecular Devices). Initial velocities versus
substrate concentration were fit to a rectangular hyperbola using GraphPad
Prism (GraphPad Software, San Diego, USA) to determine the kinetic
parameters KM and kcat. Enzyme concentrations were determined by active-site
titration with the quantitative covalent inhibitor VEID-CHO (N-Acetyl-Val-Glu-IleAsp-aldehyde; Enzo Life Sciences Inc.). Protein was added to inhibitor solvated
in DMSO in 96-wells V-bottom plates at room temperature for 1.5 hours in
caspase activity assay buffer. Aliquots (90 μL) were transferred in duplicate to
black-well plates and assayed with 50-fold molar excess of substrate. The protein
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concentration was determined to be the lowest concentration at which full
inhibition was observed and was thus used to calculate kcat.

5.4.5 Effect of ATP on the Activity of Cleaved and Active Caspase-6
Cleaved and active caspase-6 ΔN D179CT (20 nM) was incubated with
increasing concentration of ATP (Fisher Scientific, S25123) (0–40 mM, 1.5-fold
dilution) in caspase-6 activity assay buffer (100 mM HEPES pH 7.5, 10%
sucrose, 0.1% CHAPS, 120 mM NaCl, and 5 mM DTT) at 37 °C for 1.5 h. VEIDAMC fluorescent substrate (Enzo Life Sciences Inc.) was then added to a final
concentration of 60 μM. The final volume was 30 μL in a 384-well black flat
bottom plate (BD Falcon™). Fluorescent kinetic measurements (λex/λem:
365nm/495nm) were performed over 7-min and the initial velocities were
calculated. The data was presented as percent activity of caspase-6 setting the
buffer-only control as 100%. The data represent an average of two independent
experiments (each run in duplicate) and the reported errors represent S.E.M.

5.4.6 Effect of ATP on the Proteolytic Cleavage of Procaspase-6 by Active
Caspase-6
To assess the susceptibility of full-length (FL) inactive procasapse-6
C163S and procaspase-6 C163S/Y198A to cleavage by fully cleaved and active
caspase-6 (ΔND179CT) in the presence or absence of 20 mM ATP, 3 μM of
each procaspase-6 variant was incubated with 0.3 μM of active caspase-6 in
caspase-6 assay buffer (100 mM HEPES pH 7.5, 10% sucrose, 0.1% CHAPS,
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120 mM NaCl, and 5 mM DTT) with or without 20 mM ATP at 37°C for a
specified time interval (hrs: 0, 0.25,1, 4). At each time point, SDS loading buffer
were added to the sample and boiled for 10 mins, then analyzed by 16% SDSPAGE to determine effect of ATP on the extent of cleavage of procaspase-6
variants by active caspase-6. The gels were imaged using ChemiDocTM MP
imaging system (Bio-rad) and band intensities were quantified using Image Lab
software (Bio-rad). The intensities of full-length procaspase-6 C163S and fulllength procaspase-6 C163S/Y198A were set at 100% and extent of cleavage
with or without ATP were reported as percent procaspase-6 remaining at each
time point. The average of 5 independent trials was reported. Statistical analysis
was performed using Mann-Whitney t-test (two-tailed) to determine if ATP has
significant effect on the proteolytic cleavage of procaspase-6 variants by active
caspase-6.

5.4.7 Effect of Nucleotides on the Self-Activation of Caspase-6
Catalytically competent procaspase-6 (3 μM) was incubated with varying
concentrations of ATP (0–60 mM), dATP (0–60 mM, Alfa Aesar™, J64045), GTP
(0–60 mM, Sigma-Aldrich, 10106399001), and Ap4A (0–10 mM), Sigma-Aldrich,
D1262) in caspase-6 assay buffer (100 mM HEPES pH 7.5, 10% sucrose, 0.1%
CHAPS, 120 mM NaCl, and 5 mM DTT) at 37°C for 6 h. SDS loading buffer were
added to the sample and boiled for 10 mins and analyzed by 16% SDS-PAGE.
The gels were imaged using ChemiDocTM MP imaging system (Bio-rad) and
band intensities were quantified using Image Lab software (Bio-rad). The

182

intensities of full-length procaspase-6 was set at 100% and extent of cleavage
with varying nucleotides concentration was reported as percent procaspase-6
remaining. The IC50 values were determined using nonlinear curve-fitting
algorithm (four-parameter equation) in GraphPad Prism (GraphPad Software,
San Diego, USA).
A time-point experiment (hrs: 0, 0.25,1, 2, 4, 6, 8) was also performed to
assess the extent of procaspase-6 activation in the presence or absence of 20
mM ATP.
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CHAPTER 6
DISCOVERY OF POTENT AND SELECTIVE INHIBITORS OF CASPASE-6
This chapter is being prepared for submission as: Narasimha Rao, Kevin B.
Dagbay,Yifei Pei, Elih M. Velazquez-Delgado and Jeanne A. Hardy. Discovery of
Potent and Selective Inhibitors of Caspase-6. KBD performed protein
purifications, biochemical assays including inhibition assay, mutagenesis, cellbased assay and mass spectrometry, wrote parts of the manuscript and prepared
all final figures. NR performed all synthetic works. YP performed biochemical
assay. EV performed initial screen and biochemical assays. JH initiated the work,
secured funding, directed the research project and was the principal author for
the manuscript.
6.1 Abstract
Caspase-6 is a cysteine aspartate protease that plays causative roles in
Alzheimer’s and Huntington’s Diseases. Although some industrial drug discovery
has focused on caspase-6, no caspase-6 inhibitors have progressed due to
issues of potency and most critically, lack of selectivity over the other twelve
human caspases, which are essential for normal development and homeostasis.
To date the most selective reported caspase-6 inhibitors are only 10-fold
selective over the most closely related caspases. We have discovered unique
caspase-6 inhibitors that are 500- and 10,000-fold selective over the two most
closely related caspases. These bis-N-oxide-based inhibitors are extremely
selective because they bind covalently to Cys–264, a non-conserved residue
found only in caspase-6. This cysteine-targeted mechanism of selectivity is one
that has been exploited recently by drugs such as ibrutinib, an irreversible,
covalent inhibitor of Btk. Our lead bis-N-oxide has an IC50 against caspase-6 of
~300 nM and also inhibits caspase-6 in neuronal cell lines with an IC50 of 20 μM.
The size of these bis-N-oxides (305 MW) and the other molecular properties are
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generally compatible with accepted guidelines for blood-brain barrier penetrance.
Thus, the chemical properties of these compounds are promising as therapeutic
leads for neurodegeneration.

6.2 Introduction
Caspases, a family of highly conserved cysteine aspartate proteases,
have been found to have critical roles in apoptosis and inflammation as well as in
development and neurodegeneration (for a review see (Lamkanfi et al., 2007)).
Caspases are produced as inactive procaspase zymogens comprising of a
connected prodomain, large subunit, intersubunit linker region, and small subunit.
Caspases are classified as either initiators (-2, -8, -9) or executioners (-3, -6, -7)
based on their function within the apoptotic cascade.

Initiator caspases are

expressed as monomers and become active upon dimerization facilitated by
formation of molecular platforms, e.g. apoptosome (Bao and Shi, 2007; Chu et
al., 2001; Muzio et al., 1996; Oberst et al., 2010; Pop et al., 2006).. In contrast,
executioner caspases are expressed as dimeric zymogens and become
activated by proteolytic cleavage by initiator caspases. The precise control of
activation of these caspases is essential to prevent unwanted apoptotic events
and detrimental cellular outcomes.
In the caspase family, caspase-6 is particularly highlighted for its
involvement in the critical pathways leading to neurodegeneration. Caspase-6
cleaves microtubule-associated protein Tau, which forms the neurofibrillary
tangles that are hallmarks of Alzheimer’s disease (AD). In postmortem AD brains,
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Tau cleaved by caspase-6 at Asp420 is the dominant form of Tau observed in
neurofibrillary (Albrecht et al., 2009; Albrecht et al., 2007; Guo et al., 2004).
Caspase-6 has also been reported to cleave polyglutamine expanded Huntingtin
(Htt) protein and be causative in the onset and progression of Huntington’s
disease (HD) (Graham et al., 2010; Riechers et al., 2016; Warby et al., 2008).
Because inhibition of caspase-6 can block cleavage of Tau and Htt, caspase-6
has

become

a

drug

target

of

significant

interest

for

treatment

of

neurodegeneration. One of the major stumbling blocks to exploiting caspase-6
therapeutically is that all 12 human caspases share similar active site chemistry.
Inhibition of apoptotic or inflammatory caspases will have a devastating effect on
homeostasis, so specific inhibition of caspase-6 is of the utmost importance.
Caspase-6 null mice are grossly normal and breed in the expected
Mendelian ratios without considerable apoptotic defects (Zheng et al., 2000),
Thus

physiologically,

caspase-6-associated

cellular

signaling

is

likely

dispensable to normal growth and development. As a promising therapeutic
target for neurodegeneration, several small-molecule (Chu et al., 2009; Leyva et
al., 2010; Pakavathkumar et al., 2017; Pakavathkumar et al., 2015) or peptidebased (Ekici et al., 2006; James et al., 2004; Nyormoi et al., 2003) competitive
inhibitors of caspase-6 have been reported. These covalent inhibitors possess
remarkable potency and neuroprotective effects in cells and in animal models of
neurodegenerative

diseases.

However,

due

to

overlapping

substrates

specificities in caspases (McStay et al., 2008), inhibitors directed at the active
site are quite promiscuous, inhibiting other caspases as well. Inhibition of other
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caspases, particularly caspase-3, -7, -8 and -9, are developmentally lethal as
reported in the knockout studies of these caspases in mice (Hakem et al., 1998;
Kuida et al., 1998; Kuida et al., 1996; Varfolomeev et al., 1998; Woo et al., 1998;
Zheng et al., 1999), suggesting the essential role of these caspases in normal
growth and development in mammals. Thus, efforts on the discovery and
development of an allosteric inhibitor are encouraging to come up with a specific
inhibitor of caspase-6.
To date, only three reports of allosteric or uncompetitive inhibitors of
caspase-6, either small molecules (Heise et al., 2012; Murray et al., 2014) or
peptide-based (Stanger et al., 2012), have surfaced in the literature. The first of
its class of uncompetitive inhibitor among caspase family and thus far the most
potent (11 nM IC50) caspse-6-specific inhibitor has been reported (Heise et al.,
2012). Unfortunately, this inhibitor has binding to the caspase-6-substrate
complex only when the substrate is a synthetic peptide substrate. This inhibitor
does not inhibit caspase-6 cleavage of natural protein substrates, including lamin
A/C because its activity is dependent on the type of P1’ residue within the
synthetic substrate used for in vitro activity assays. Thus, this compound has
absolutely no potential as a therapeutic lead. A phage display approach at
Genentech has been successful in identifying a peptide-based inhibitor (Pep419),
which

is

capable

of

binding

and

promoting

procasapse-6

zymogen

tetramerization, thus preventing further proteolytic activation of procaspase-6.
Despite its activity in neuronal cells and procaspase-6 isoform selectivity, pep419
has poor cell penetration properties. Pep419 requires electroporation for efficient
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cell uptake suggesting a clear threshold for its applications in cellular, animal and
human applications. Finally, a fragment-merging strategy was used to identify
nanomolar-affinity ligands that bind in the dimer interface and stabilize
procaspase-6 and thus prevents procaspase-6 activation (Murray et al., 2014).
These compounds have been shown to lock loop 2 (L2) in the inactive
conformation making L2 structural rearrangement impossible as part of the loop
assembly for a substrate-binding competent active site cavity. However, the
selectivity profiles of these inhibitors are unknown, thus the potential of these
inhibitors to progress as therapeutic leads are still uncertain. In addition, these
allosteric inhibitors that stabilize the procaspase-6 zymogen have less impact on
the activity of already activated caspase-6. Because active caspase-6 accrues
before the onset, particularly, of AD symptoms, allosteric inhibitors targeting
procaspase-6 form present a less effective treatment for neurodegeneration.
In this study, we employed a high-throughput screening strategy to identify
potent and selective inhibitors of active caspase-6. We have discovered a unique
class of potent and exquisitely selective inhibitors of active caspase-6 that
covalently modify Cys–264, a non-conserved residue only found in caspase-6.
More importantly, these compounds inhibit caspase-6 function in neuronal cells
and are amenable to structure-activity relationship (SAR) studies for further
improvement of its biochemical and cell-based potency. Notably, the molecular
properties of the identified lead bis-N-oxide compound are matched to the
accepted guidelines for blood-brain barrier penetrance, suggesting favorable
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chemical properties with a potential for use as caspase-6-specific inhibitor for
treatment of neurodegeneration.

6.3 Results and Discussion
6.3.1 Compound A is the Most Selective Caspase-6 Inhibitor to Date
Under the NIH molecular libraries program, we were performed a screen
of 359,786 compounds at the Broad Institute MLPCN site to identify caspase-6
specific and selective inhibitors (Figure 6.1A). All caspases share similar activesite chemistry so we expected that active site-binders would be eliminated based
on counter screening against related caspases. From this screen we identified 3
candidate lead compounds that showed the request selectivity over other
caspases: a bis-N-oxide, a piperazine and a sugar-like compound. We ultimately
selected compound A (Figure 6.1B) as our lead, due to it having the strongest
potency and its unparalleled selectivity. To date, the best selectivity of any
reported caspase-6 inhibitor is 10-fold selectivity for caspase-6 over the most
closely related caspases, caspase-3 and caspase-7 (Aharony et al., 2015; Chu et
al., 2009; Ekici et al., 2006; Heise et al., 2012; James et al., 2004; Murray et al.,
2014; Nyormoi et al., 2003; Pakavathkumar et al., 2017; Pakavathkumar et al.,
2015; Stanger et al., 2012). In contrast, compound exhibits 500-fold selectivity for
casp-6 over casp-7 and 10,000-fold selective for casp-6 over casp-3 (Figure 6.2).
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Figure 6.1 High Throughput Screen Identified Potent and Selective
Inhibitors of Caspase-6
(A) Results of caspase-6 screening. (B) Structure of Compound A, a bis-N-oxide,
the most selective inhibitor identified from the screen.

Figure 6.2 Compound A Shows Exquisite Selectivity for Caspase-6
(A) Compound A inhibits caspase-6 selectively over other initiator and
executioner caspases. Caspases were incubated with increasing dose of
compound A and activity assays were performed using peptide-based
fluorogenic substrates appropriate for each caspase. (B). The 500-fold or greater
selectivity is greater than of any reported casp-6 inhibitor.
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6.3.2 Compound A Stabilizes Caspase-6
Compounds that bind with sufficient affinity typically stabilize proteins
toward thermal and chemical denaturation. Active site inhibitors of caspase-6
such as the peptide-based inhibitor VEID-aldehyde (VEID-cho) stabilize it toward
thermal denaturation by 8°C (Figure 6.3). Compound A also stabilizes caspase-6
toward thermal denaturation, by 3°C suggesting that compound A binds to
caspase-6, and further suggesting that the inhibition is via a direct, bindingmediated mechanism, rather than via some not specific (e.g. denaturationmediated) mechanism. Notably 3°C is the same amount of stabilization that is
observed when caspase-6 adopts the canonical conformation relative to the
inactive helical conformation in which it rests prior to substrate binding (Vaidya et
al., 2011).

Figure 6.3 Compound A Binds and Stabilizes Caspase-6
Apparent thermal stability of caspase-6 (black solid line) in the presence of
compound A (brown solid line) and known active site inhibitor, VEID-CHO (blue
solid line) was determined using differential scanning fluorimetry. The dashed
lines represent the Boltzmann sigmoidal fit of the thermal shift data, where the
apparent melting point is determined as the midpoint of the melting curve.
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6.3.3 Compound A Inhibits Caspase-6 in Neuronal Cells
One of the most critical considerations in moving compound A forward is
its cell-based activity. To measure cell-based efficacy, we treated SK-N-AS
(ATCC® CRL-2137TM) human neuroblastoma cells with increasing concentrations
of compound A and monitored cleavage of a well-known caspase-6-specific
substrate, lamin A/C, after staurosporine-induced apoptosis. We observed that
increasing concentrations of compound A inhibited cleavage of lamin A/C by
caspase-6 with an IC50 of 20 μM (Figure 6.4). The fact that inhibition in cells was
observed suggests that compound A is somewhat cell penetrant, but the
increase in the cell-based IC50 relative to the enzyme-based inhibition, suggest
that cell permeability should be improved in future analogs of this compound.

Figure 6.4 Compound A Inhibits Caspase-6 Function in Neuronal Cells
(A) Compound A dose dependent inhibition of staurosporine-induced cleavage of
lamin A/C by caspase-6 in SK-N-AS neuroblastoma cells. Western blots were
performed for cleaved lamin A/C and GAPDH as protein loading control. (B)
Changes in lamin A/C cleavage are significant to the *95th and **99th confidence
intervals. One-way analysis of variance (ANOVA) with Bonferroni post hoc
(*p<0.05, **p<0.001) was performed. Error, represents the mean ± s.e.m of three
independent trials. Band quantification of cleaved lamin A/C was normalized to
GAPDH protein loading control.
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6.3.4 Intrinsic Chemical Reactivity Underlies Selectivity of Compound A
One of the notable features of compound A is that it contains two
potentially reactive N-oxide moieties, which could react with nucleophiles such as
thiols and amines. We found that these N-oxides are not intrinsically reactive with
typical cysteines or lysines. Caspase-6 is active as a dimer where each monomer
is cleaved one large and one small subunit. Caspase-6 has 10 cysteines (6
exposed) and 20 exposed lysine residues on each caspase monomer but our
denaturing mass spectrometry analysis of caspase-6 indicated that Compound A
reacts with only one cysteine on the small subunit of caspase-6 (Figure 6.5A) as
evidenced in the mass difference of the small subunit with or without compound
A equal to that of the molecular weight of the compound A (MW 305 g/mol). This
is striking because the active site cysteine Cys–163, which is on the large
subunit, has a substantially suppressed pKa due to the adjacent His–121. If the
activity of compound A was driven by its intrinsic electrophilicity, then Cys–163
on the small subunit would be the natural site of reaction. The fact that Cys–163
is not modified strongly suggests that other features of the compound such a
shape complementarity drive its binding and selectivity.
To determine where on the small subunit compound A binds, we
performed peptide mapping by tandem mass spectrometry. This analysis showed
a modified tryptic peptide that contained Cys–264 and Lys–265, both of which
could be the site of compound A reaction (Figure 6.5B). Sequence alignment
analysis of all caspases (Figure 6.5C) revealed that the putative binding sites,
Cys-264 or Lys-265, are located in the most diversified loop 4 (L4) of caspases
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Figure 6.5. Compound A Covalently Binds to a Unique and Non-Active Site
Cys–264
(A) The total ion chromatogram from the denaturing mass spectrometry of
caspase-6 bound to compound A suggests covalent modification of compound A
in the small subunit of casapse-6. Compared with unbound casapse-6, an
obvious mass shift could be detected in the caspase-6 + compound A, which has
a mass difference similar to the molecular weight of compound A (MW 305
g/mol). (B) MS/MS annotation of compound A-modified tryptic peptide (L4
residues 260–272). The b and y ions are colored red and blue, respectively. (C)
Sequence alignment of L4 residues in caspases. No cysteines are present in the
L4 loops region of any other caspases. The absence of cysteine in other
caspases underlies the compound A selectivity for caspase-6. (D) The
superimposition of unliganded (PDB code 2WDP, green) and VEID-bound (PDB
code 3OD5, orange) structures of caspase-6 highlighting the regions of the active
site, dimer interface and L4. Inset view shows the putative compound A binding
sites, Cys–264 and Lys–264, sit above the substrate-binding groove. (E) Kinetic
parameters of the substitution variants of the putative compound A binding sites,
Cys–264 and Lys-265. (F) Cys-264 is the site of covalent modification of
compound A in caspase-6.
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(Figure 6.5D). Importantly, Cys-264 and Lys-265 are unique to caspase-6, which
could explain the exquisite selectivity of compound A for caspase-6.
To confirm the specific modification site of compound A, we generated
substitutions of Cys-264 to alanine or serine and Lys–265 to alanine or arginine.
The kinetic parameters of caspase-6 compound A binding site variants
(C264A/S, K265A) showed similar activity to wild type (WT), with the exception of
C264A that showed a 15-fold decrease in catalytic efficiency (Figure 6.5E).
Mutagenesis of K265R or K265A had no impact on compound A function, but
mutagenesis of C264S or C264A dramatically desensitized caspase-6 to the
inhibitory effects of compound A (Figure 6.5F), indicating that compound A binds
covalently to caspase-6 at a unique Cys–264. In order for caspases to be active,
it is critical that all of the loops forming the substrate-binding groove are properly
ordered. Thus compound A is likely to bind in a way that prevents substrate
binding and may induce an alternate conformation of L4 and the substratebinding groove.

6.3.5 The Furoxan Moiety is Required for Compound A Reactivity
Compound A has two N-oxides, one on the triazole ring and one that is a
component of the furoxan of the central ring system. A priori it is not clear
whether the covalent modification of caspase-6 by compound A requires both Noxides, which would contribute to a large aromatic system spanning the entire
core of the compound, or whether a single N-oxide could convey the caspase-6
reactivity. We tested four compound A analogs that lack one of the N-oxides
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(Figure 6.6). Whereas compounds CASP-RT11-9 and CASP-6-III-18, which
maintain the furazan N-oxide in the furoxan ring, are still reactive, compounds
that maintain only the triazole N-oxide (compounds 4 and 5) are completely
inactive toward caspase-6 (Figure 6.6). This demonstrates that only one N-oxide,
the one in the furoxan, is required for compound A reactivity and selectivity. In
addition to providing a more in depth understanding of the reactivity of compound
A, these data also clear the path for development of new classes of compounds.
Future analogs of CASP6-III-18, which have only the furazan N-oxide represent a
departure from the bis-N-oxide core and are therefore representative of new
chemical entities.

Figure 6.6 The Furozan N-Oxide in the Furoxan Moiety is Required for
Reactivity, But the Triazole N-Oxide is Not Required for Function

199

6.3.6 The Phenyl Ring Composition Is Important for Affinity
Prior to this work no synthetic scheme for compound A had been
published. We developed a 7-step synthetic scheme to achieve compound A and
its derivatives. We synthesized compound A analogs with various substitutions at
the N2 position in the triazole ring (Table 6.1). We found that this position is very
sensitive to substitution and that many substitutions have a dramatic and
negative impact on the potency of compound A. From the pool of compound A
analogs we have made, 12 compounds exhibit an IC50 significantly more potent
than compound A. And further suggests that an SAR around the phenyl moiety is
a sensitive region that may enable synthesis of analogs of compound A highly
potent in both in vitro and in cell-based assays. The most potent analogue,
CASP-6-III-38, contains a diphenyl substituted amide moiety at the ortho position
(Table 6.1D) with an IC50 of 290 nM. We also tested one of the more potent
compounds (CASP-6-III-20, IC50~610 nM) and showed the same outstanding
selectivity profile as original compound A (Figure 6.7), further suggesting that
modifications around the phenyl ring retain the desired reactivity and selectivity.
The selectivity assay of other potent compound A analogs is an on-going work in
the Hardy Lab. Taken together, the dependence of the reactivity on the various
types of substituents around the phenyl ring suggests that there may be very
unique packing between compound A and caspase-6 L4 or an adjacent region.
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Table 6.1A Compound A Analogs With Substitutions at the Phenyl Ring on
the Triazole Moiety.
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Table 6.1B Compound A Analogs With Substitutions at the Phenyl Ring on
the Triazole Moiety.
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Table 6.1C Compound A Analogs With Substitutions at the Phenyl Ring on
the Triazole Moiety.

203

Table 6.1D Compound A Analogs With Substitutions at the Phenyl Ring on
the Triazole Moiety.

204

Table 6.1E Compound A Analogs With Substitutions at the Phenyl Ring on
the Triazole Moiety.

Figure 6.7. The Selectivity Profile of a Representative Compound A Analog
(CASP-6-III-20) Shows Potency Higher Than Compound A
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6.3.7 The Central Ring in Compound A Can Be Modified
We have developed a 6-step synthetic route that allowed us to install a
double bond in the central cyclohexane ring in compound A. Loss of saturation at
this position (CASP-6-RT-II-5) decreases affinity of the compound by ~30-fold
(Table 6.2). Nevertheless, we have observed that bromination of the double bond
(CASP-6-II-1) does not substantially further weaken the derivative’s ability to
inhibit casp-6 activity. Thus we hypothesize that substitution at this position on
the central ring may lead to new compounds that may have improved properties
for potency and cell penetrance.

Table 6.2 Compound A Analogs With Double Bond at the Central
Cyclohexane Ring.
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6.3.8 The Bis-N-Oxides are Predicted to Have Good Blood-Brain Barrier
Penetration
For casp-6 inhibitors to have clinical relevance in neurodegeneration, they
will need blood brain-barrier penetrance. Investigators at Pfizer have developed a
7-fold multi parameter optimization (MPO) scoring function for predicting blood
brain barrier penetrance (Wager et al., 2010) that has been highly successful.
Factors in the MPO calculation include: molecular weights between 250-350 Da,
LogD of less than 3, no more than two hydrogen bond donors, no more than 4
hydrogen bond acceptors, polar surface area between 25-75 Å2, fewer than 4
total rings, fewer than 2 aromatic rings, and fewer than 7 rotatable bonds. We
have assessed compound A for these properties. Compound A matches these
identified criteria and thus has an overall MPO score consistent with blood brain
barrier penetrance. Based on this analysis, we expect that compound A and its
derivatives to have blood brain penetrance.

6.4 Summary and Conclusion
We have discovered a series of bis-N-oxide compounds that offer the
greatest specificity of any caspase-6 inhibitors to date. This remarkable
specificity derives from the ability of these compounds to target a cysteine in the
most diverse loop, L4, in caspase-6. Cys–264 and the adjacent Lys-265 are not
present in L4 of any other caspases. The fact that the bis-N-oxides target this
cysteine is one of the key features that differentiate this series from all other
known caspase-6 inhibitors. Traditionally, covalent compounds have viewed
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skeptically by some within the pharmaceutical industry, but recently this view has
changed notably (Guterman, 2011; Singh et al., 2011), as the use of covalency
has been recognized to provide exquisite specificity for targets of interest. In
addition, market successes of compounds like ibrutinib, a covalent Bruton’s
tyrosine kinase (Btk) inhibitor described as having “outstanding clinical activity
and tolerability in B-cell malignancies” (Dubovsky et al., 2013) are changing the
covalent drug development paradigm. A Michael’s acceptor in Ibrutinib reacts
with a non-catalytic cysteine, providing both potency and specificity. The success
of ibrutinib led to the $21B acquisition of Pharmacyclics by AbbVie. Like Ibrutinib,
compound A forms a covalent bond to a unique, non-catalytic cysteine providing
unparalleled selectivity for caspase-6 inhibition. In conclusion, small covalent
inhibitor of caspase activation, such the ones presented here, might be advanced
into therapeutic leads for relevant human diseases including Alzheimer’s and
Huntington’s diseases as well as its use as molecular probes to investigate
mechanisms and functions of caspase activation and regulation.

6.5 Materials and Methods
6.5.1 Sources of Compound A and its Analogs
Prior to our synthesis of compound A, it was purchased from ChemDiv,
Inc., USA (compound ID: 3454-1844) or obtained from a screen library at the
Broad Institute of Harvard and MIT (compound ID: BRD-K32954333-001-11-0).
Compound 1

(compound ID: BRD-K55066264-001-01-9), compound 4

(compound ID: BRD-K68959369-001-01-4), and compound 5 (compound ID:
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BRD-K64914368-001-08-9) were obtained from a screen library at the Broad
Institute of Harvard and MIT. Compound 2 (compound ID: 3454-1837) and
compound 3 (compound ID: 3473-3473) were purchased from ChemDiv, Inc.,
USA. All other compounds reported here were synthesized in the Hardy Lab by
Narasimha Rao.

6.5.2 Site-Directed Mutagenesis of Caspase-6
The caspase-6 variants were derived from the synthetic, E. coli codonoptimized (His)6 C-terminally tagged caspase-6 gene (Celtek Bioscience), which
was ligated into the NdeI/BamHI sites of pET11a vector (Vaidya et al., 2011). All
caspase-6 variants used in this study were generated using caspase-6 ΔN
D179CT as template through Phusion® site-directed mutagenesis (Thermo
ScientificTM).

6.5.3 Caspase-3 Protein Expression and Purification
The gene for full-length wild-type caspase-3 in pET23b was transformed
into BL21(DE3) E. coli. Cultures were grown in 2xYT media with 100 µg/mL
Ampicillin at 37˚C with shaking until OD600=0.8. Protein expression was induced
by addition of 1 mM IPTG at 30˚C for 3 h and cells were harvested by
centrifugation at 4700 x g for 10 min at 4˚C. Cells were freeze-thawed, lysed in a
microfluidizer in a buffer containing 50 mM sodium phosphate pH 8.0, 300 mM
NaCl and 2 mM imidazole, and centrifuged at 30,600 x g for 50 min at 4˚C to
remove cellular debris. The supernatant was loaded onto a 5-mL HiTrap Ni-
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affinity column (GE Healthcare), washed with 50 mM imidazole and proteins
were eluted with 250 mM imidazole in lysis buffer. The eluted protein fraction was
diluted six-fold with 20 mM Tris pH 8.0 with 2 mM DTT (buffer A) and loaded onto
a HiTrap Q-column (GE Healthcare). Proteins were eluted by a linear gradient
from 0-500 mM of NaCl in buffer A. Casp-3 eluted in buffer A with 250 mM NaCl.
Peak fractions were analyzed by SDS PAGE for purity and were stored in -80˚C
until use.

6.5.4 Caspase-6 Protein Expression and Purification
The caspase-6 constructs were transformed into the BL21(DE3) T7
express strain of E. coli (New England Biolabs). Overnight seed cultures were
initially grown in 2xYT medium supplemented with 0.1 mg/ml ampicillin (Sigma)
at 37 °C. Dense cultures were then diluted 1,000-fold with 2xYT containing 0.1
mg/ml ampicillin and shaken at 37 °C until A600 reached 0.6. Protein expression
was induced by the addition of 1mM isopropyl 1-thio-β-D-galactopyranoside and
cultures were shaken at 20 °C for 18 h. Cells were centrifuged at 4,700 x g for
10 min at 4 °C and stored at −20 °C until use. Freeze-thawed cells were lysed
using a microfluidizer (Microfuidics, Inc.) in lysis buffer (50 mM Tris, pH 8.5, 300
mM NaCl, 5% glycerol, 50 mM imidazole) and centrifuged at 30,600 x g for 1 h at
4 °C. The supernatant was loaded into a 5-ml HiTrap nickel affinity column (GE
Healthcare) and washed with lysis buffer until the absorbance returned to
baseline. The protein was eluted with elution buffer (50 mM Tris, pH 8.5, 300 mM
NaCl, 5% glycerol, 250 mM imidazole) and diluted 5-fold with buffer A (20 mM
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Tris, pH 8.5, 2 mM DTT) to reduce the salt concentration. This protein sample
was then loaded into a 5-ml HiTrap Q HP column (GE Healthcare). The column
was developed with a linear NaCl gradient, and the protein was eluted in 20mM
Tris, pH 8.5, 200mM NaCl, 2mM DTT. This eluted protein was stored at −80 °C
until use. The purified caspases were analyzed by SDS-PAGE to confirm identity
and purity.

6.5.5 Caspase-7 Protein Expression and Purification
Plasmids encoding human casp-7 and all variants were transformed into
BL21(DE3) E. coli cells. Cultures were grown in 2xYT media with ampicillin
(100μg/mL, ThermoFisher) at 37°C until they reached an OD
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of 0.6. The

temperature was reduced to 18°C and cells were induced with 1 mM Isopropyl βD-1-thiogalactopyranoside (IPTG) for 18 hours. Cell pellets were stored at -80°C,
freeze-thawed and lysed in a microfluidizer (Microfluidics, Inc.) in a buffer
containing 50 mM sodium phosphate pH 8.0, 300 mM NaCl, and 2 mM
imidazole. Lysed cells were centrifuged at 27,000 rcf to remove cellular debris.
The supernatant was loaded onto a 5 mL HiTrap Ni-affinity column (GE
Healthcare). The column was washed with a buffer of 50 mM sodium phosphate
pH 8.0, 300 mM NaCl, and 50 mM imidazole. Casp-7 was eluted with a step
gradient to 300 mM imidazole. The eluted fraction was diluted 6-fold into a buffer
containing 20 mM Tris pH 8.5 and 2 mM DTT to reduce the salt concentration.
This protein was loaded onto a 5 mL Macro-Prep High Q column (Bio-Rad
Laboratories, Inc.). The column was developed with a linear NaCl gradient.
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Protein eluted in 120 mM NaCl and was assessed for purity by SDS-PAGE and
stored at -80°C in elution buffer.

6.5.6 Caspase-8 Protein Expression and Purification
The expression construct encoding human caspase-8 was transformed
into BL21(DE3) E. coli cells. Cultures were grown in 2xYT media with ampicillin
(100μg/mL, ThermoFisher) at 37°C until they reached an OD

600

of 0.6. The

temperature was reduced to 25°C and cells were induced with 1 mM Isopropyl βD-1-thiogalactopyranoside (IPTG) for 3 hours. Cell pellets were stored at -80°C,
freeze-thawed and lysed in a microfluidizer (Microfluidics, Inc.) in a buffer
containing 50 mM sodium phosphate pH 8.0, 500 mM NaCl, and 2 mM
imidazole. Lysed cells were centrifuged at 27,000 rcf to remove cellular debris.
The supernatant was loaded onto a 5 mL HiTrap Ni-affinity column (GE
Healthcare). The column was washed with a buffer of 50 mM sodium phosphate
pH 8.0, 500 mM NaCl, and 8 mM imidazole. Casp-8 was eluted with a step
gradient to 300 mM imidazole. The eluted fraction was diluted 6-fold into a buffer
containing 20 mM Tris pH 8.5 and 2 mM DTT to reduce the salt concentration.
This sample was loaded onto a 5 mL Macro-Prep High Q column (Bio-Rad
Laboratories, Inc.). The column was developed with a linear NaCl gradient.
Casp-8 eluted in 100 mM NaCl and was assessed for purity by SDS-PAGE and
stored at -80°C in elution buffer.
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6.5.7 Caspase-9 Protein Expression and Purification
The caspase-9 wild-type construct was transformed into BL21(DE3) strain
of E. coli. The cultures were grown in 2xYT media supplemented with 100 µg/mL
of ampicillin at 37˚C with vigorous shaking until they reached an optical density
(OD600) between 1-1.2. The temperature was lowered to 15˚C and protein
expression was induced by adding 1 mM of IPTG (Anatrace). Protein expression
was allowed to proceed for 3 h (except for C9 FL WT zymogen which was
expressed for only 30 min, C9FL S183A, C9FL S99A/S183A and C9FL
S195A/S183A which were expressed for 16 h) and cells were harvested by
centrifugation at 4700 x g for 10 min at 4˚C. Cell pellets were stored at -80˚C,
freeze-thawed and lysed in a microfluidizer (Microfluidics, Inc.) in lysis buffer (50
mM sodium phosphate pH 7.0, 300 mM NaCl and 2 mM imidazole). Cell lysates
were centrifuged at 30,600 x g for 50 min at 4˚C to remove cellular debris. The
supernatant was filtered through 0.45 µm PVDF (Millipore) filter and loaded unto
a 5-mL HiTrap Ni-affinity column (GE Healthcare). Proteins were eluted using a
linear gradient of 2-100 mM imidazole in lysis buffer. Protein fractions were
analyzed by SDS PAGE and fractions containing casp-9 were pooled and diluted
8x with a buffer containing 20 mM Tris pH 8.5 and 5 mM DTT (buffer A). The
protein solution was filtered through 0.45 µm PVDF filter to remove precipitates
and loaded onto a HiTrap Q-column (GE Healthcare). Proteins were eluted by a
linear gradient from 0-275 mM of NaCl in buffer A. Casp-9 eluted in buffer A at
180 mM NaCl. Peak fractions were analyzed by SDS PAGE for purity and were
stored in -80˚C until use.
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6.5.8 Caspase-6 Activity Assays
To measure caspase-6 activity, 100 nM purified caspase was assayed
over 7 min at 37°C in caspase-6 activity assay buffer (100 mM HEPES, 120 mM
NaCl, 0.1% CHAPS, 10% sucrose, 5 mM DTT). For substrate titration, a range of
0-500 μM fluorogenic substrate VEID-AMC [N-acetyl-Val-Glu-Ile-Asp-(7-amino-4methyl-coumarin), Enzo Life Sciences Inc.] was used. Fluorescence kinetic
measurements (λex/λem: 365nm/495nm) were performed in two independent trials
in 100-μL reactions in a 96-well format using a microplate reader (SpectraMax
M5, Molecular Devices). Initial velocities versus substrate concentration were fit
to a rectangular hyperbola using GraphPad Prism (GraphPad Software, San
Diego, USA) to determine the kinetic parameters KM and kcat. Enzyme
concentrations were determined by active-site titration with the quantitative
covalent inhibitor VEID-CHO (N-Acetyl-Val-Glu-Ile-Asp-aldehyde; Enzo Life
Sciences Inc.). Caspase-6 was added to inhibitor solvated in DMSO in 96-wells
V-bottom plates at room temperature for 1.5 hours in caspase-6 activity assay
buffer. Aliquots (90 μL) were transferred in duplicate to black-well plates and
assayed with 50-fold molar excess of substrate. The protein concentration was
determined to be the lowest concentration at which full inhibition was observed
and was thus used to calculate kcat.

6.5.9 Caspase-6 Inhibition Assay
Active caspase-6 (20 nM final concentration) was incubated with
increasing concentration of compound A and its analogs (0–500 μM, 2.5-fold
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dilutions) in caspase-6 activity assay buffer (100 mM HEPES pH 7.5, 10%
sucrose, 0.1% CHAPS, 120 mM NaCl, and 5 mM DTT) for 1.5 h at room
temperature. VEID-AMC fluorescent substrate (Enzo Life Sciences Inc.) was
then added to 60 μM final concentration. Each inhibition reaction was set up in
duplicate with the final reaction volume of 30 μL in a 384-well plate. Fluorescence
kinetic measurements (λex/λem: 365nm/495nm) were performed using a
microplate reader (SpectraMax M5, Molecular Devices) over 7-min period. Initial
velocities were generated from a rectangular hyperbola fit of the fluorescence
intensity versus time using the built-in equation in the SpectraMax analysis
software. The percentage VEIDase activity of caspase-6 was determined by
dividing the initial velocities of caspase-6 with inhibitor over the buffer-onlycontaining caspase-6 control. A plot of percentage VEIDase activity against the
log of the inhibitor concentration (in M) was generated and fitted into a non-linear
curve-fitting algorithm (4-parameter equation) using GraphPad Prism (GraphPad
Software, San Diego, USA) to determine the IC50 values. The data represent an
average of three independent experiments and the reported errors represent the
standard error of the mean (S.E.M).

6.5.10 Caspase Selectivity Assays
The inhibitory effect of compound A and its analogs were tested against a
panel of caspases (3, 6, 7, 8, 9). All enzymes used for the selectivity assay were
purified as described in the other parts of this Materials and Methods section.
The following enzyme and substrate concentrations were used: Caspase-3 (1
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nM), DEVD-AMC (3 uM); caspase-6 (10 nM), VEID-AMC (10 uM); caspase-7 (2
nM), DEVD-AMC (10 uM); caspase-8 (50 nM), IETD-AFC (10 nM); and caspase9 (800 nM), LEHD-AMC (100 uM). All fluorogenic substrates were purchased
from Enzo Life Sciences Inc. The following caspase activity assay buffers were
used: caspase-3 (25mM HEPES pH 7.5, 0.1% CHAPS and 50mM KCl, 10mM
DTT); caspase-6 (100 mM HEPES pH 7.5, 10% sucrose, 0.1% CHAPS, 120 mM
NaCl, and 5 mM DTT); caspase-7 (100 mM HEPES pH 7.5, 5 mM CaCl2, 10%
PEG 400, 0.1% CHAPS, 5 mM DTT); caspase-8 (10mM PIPES pH 7.2, 0.1 M
NaCl, 1mM EDTA, 10% sucrose, 0.05% CHAPS, 5 mM DTT); and caspase-9
(100 mM MES pH 6.5, 10% PEG 8000, 5 mM DTT). All caspases were incubated
with increasing concentrations of the inhibitor (0–500 μM or, 2.5-fold dilutions) in
each corresponding caspase activity assay buffer for 1.5 h at room temperature.
Fluorescent substrate (Enzo Life Sciences Inc.) was then added to the
caspase/inhibitor solution. Each inhibition reaction was set up in duplicate with
the final reaction volume of 30 μL in a 384-well plate. Fluorescence kinetic
measurements (λex/λem: 365nm/495nm) were performed using a microplate
reader (SpectraMax M5, Molecular Devices). Initial velocities were generated
from a rectangular hyperbola fit of the fluorescence intensity versus time using
the built-in equation in the SpectraMax analysis software. The percentage activity
of each caspase was determined by dividing the initial velocities of caspase with
inhibitor over the buffer-only-containing caspase control. A plot of percentage
caspase activity against the log of the inhibitor concentration (in M) was
generated and fitted into a non-linear curve-fitting algorithm (4-parameter
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equation) using GraphPad Prism (GraphPad Software, San Diego, USA) to
determine the IC50 values. The data represent an average of three independent
experiments and the reported errors represent the standard error of the mean
(S.E.M).

6.5.11 Denaturing Mass Spectrometry of Caspase-6:Compound A Complex
Caspase-6 wild-type (ΔND179CT) (5 μM) was incubated with 5-fold molar
excess of compound A for 1.5 h at room temperature in a buffer containing 20
mM Tris, pH 8.5, 120 mM NaCl, and 2 mM DTT. Mass spectra were acquired on
a QStar-XL (MDS Sciex, Toronto, Canada) hybrid quadrupole/time-of-flight with
reverse phase liquid chromatography (Agilent 1100 LC) using a PROTO 300 C4
column (Higgins Analytical, Inc.) to desalt the protein. The eluted protein was
injected into the ESI source at a rate of 0.5 mL/min using N2 as an ion source
gas. Protein was eluted from the column using a 30-minute gradient from 0–
100% acetonitrile and monitored using UV and TIC. A single peak containing
caspase-6 eluted between 10–15 minutes of chromatographic separation. Data
was analyzed using Analyst QS (Applied Biosystems) with BioAnalyst
extensions. Scanning was carried out between 700 - 1400 m/z and the final
spectra obtained were an average of 10 individual spectra. All spectra
deconvolutions were analyzed between 10 kD and 40 kD.
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6.5.12 Tandem Mass Spectrometry of Caspase-6:Compound A Complex
To identify the residues in caspase-6 covalently modified by compound A,
tandem MS was performed on the caspase-6/compound A complex. Caspase-6
wild-type (ΔND179CT) (28 µM) was incubated with 10-fold molar excess
compound A in 20 mM Tris, pH 8.5, 120 mM NaCl, and 2 mM DTT for 2 h at
room temperature. The sample was then pretreated with 10% acetonitrile for 45
min at 40 ˚C. The pretreated sample was digested with trypsin (sequencing
grade, Roche, Cat. #11418025001) in a 1:20 (w/w) trypsin:caspase-6 ratio for 18
h at 37 ˚C. The digestion reaction was quenched after addition of trifluoroacetic
acid to a final concentration of 0.2% (v/v). Trypsin (~23.3 kDa) was removed by
centrifugation using a microcon-10kDa centrifugal filter (EMD Millipore). One
microliter of ~25 µM tryptic peptides was subjected to tandem MS using an
Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific, MA) equipped with
ultra high pressure liquid chromatography (UHPLC), nano-LC systems,
quadruple mass filter, and CID with ion trap detection for MS/MS fragmentation.
MS spectra were analyzed using Proteome DiscovererTM (Thermo Scientific, MA)
software to identify the peptides modified with compound A.

6.5.13 Thermal Stability by Differential Scanning Fluorimetry
Caspase-6 wild-type (ΔND179CT) (10 µM) was incubated with either 5fold molar excess compound A or 5-fold molar excess of VEID-CHO in 20 mM
Tris, pH 8.5, 200 mM NaCl, and 5 mM DTT for 1.5 h at room temperature.
Fluorescence-based thermal shift assay was determined using 0.5x SYPROÒ
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Orange dye (ThermoFisher) in a CFX Connect Real-Time PCR detection system
(BioRad). Measurements were performed in a 96-well plate in 50-µL reactions.
Thermal-based fluorescence intensity was monitored from 25–95 ˚C at a heating
rate of 0.5 ˚C/min. The apparent thermal melting points (Tm,

apparent)

were

determined by curve fitting analysis using GraphPad Prism (GraphPad Software,
San Diego, USA).

6.5.14 Cell-Based Caspase-6 Inhibition Assay
Cell Culture. SKNAS human neuroblastoma cells (ATCC® CRL-2137TM)
were grown in high glucose Dulbecco’s Modified Eagles Medium (DMEM)
(GIBCOTM, Cat. No. 11960044) containing 1% penicillin-streptomycin (MP
Biomedicals, Cat. No. 1670049), 1% glutamax (GIBCOTM, Cat. No. 3505006), 0.1
mM non-essential amino acid (NEAA) (ATCC 30-2116), and 10% fetal bovine
serum (HycloneTM, Cat. No. SH30910.03). About 50,000 cells were seeded into a
6-well plate and allowed to attach overnight. Cells were treated with increasing
dose of inhibitor for 3 h. After incubation with inhibitor, apoptosis was induced by
adding 3 μM staurosporine for 4 h at 37 °C. Staurosporine-treated cells were
collected in cold phosphate-buffered saline PBS using a cell scraper (Falcon),
pelleted by centrifugation and lysed in RIPA lysis buffer at for 30 min at 4 ˚C on a
rotating platform. Supernatants were cleared by centrifugation (14,000 rpm at 4
˚C for 20 min) and protein concentrations were determined using BCA (Thermo
Scientific) assay.
Western Blotting. About 4 μg of protein was loaded per lane into a 12% SDS-
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PAGE gel and ran at 180 V for 55 min. Protein bands were transferred into a
PVDF membrane at 100 V for 2 hours. Membrane was then washed with 25 mL
of 1x Tris-buffered saline (TBS) (10 mM Tris pH8.0, 150 mM NaCl) for 5 mins
and blocked with 5% BSA in TBST (TBS with 0.1% Tween-20) for 1 h at room
temperature in a rotating platform. Blots were incubated with primary antibodies
to detect the expression of cleaved lamin A (1:1000, Cell Signaling Technologies
Cat. No. 2035) or GAPDH (1:1000, GAPDH, ThermoFIsher Scientific, Cat. No.
MA5-15738) for overnight at 4 ˚C. Blots were washed three times with 1X TBST
and incubated on a rocking platform for 1 h at room temperature with rabbit or
mouse horseradish peroxidase-conjugated secondary antibodies (1:50000,
Jackson Immuno Research). After washing three times with TBST, protein bands
were detected using SuperSignal West Dura Extended Duration Substrate for
HRP (ThermoFIsher Scientific, Cat. No. 34075) and imaged using ChemiDocTM
MP imaging system (Bio-rad). Band intensities were quantified using Image Lab
(Bio-rad) software and normalized to GAPDH control to determine the relative
level of cleaved lamin A in presence of increasing concentrations of the inhibitor.
One-way analysis of variance (ANOVA) with Bonferroni post hoc was applied to
three independent trials to determine the statistical significance between samples.

220

6.5.15 Synthetic Schemes
Scheme-1. Synthesis of Compound-A Analogs (8a-o).

Reagents and conditions: (a) Diethyl ether, methyl nitrite, 0o- 25 oC, 4h (90%); (b)
Na2CO3, NH2OH.HCl, EtOH: H2O (1:1), 6h (85%); (c) NaOBr aq Sol, H2O, 30 min
(85%); (d) HCHO, Con. HCl, 25 oC, 20 min (90%); (e) NaNO2, EtOH, AcOH, 25
o

C, 12h (90%); (f) Corresponding Hydrazines, EtOH, Cat. AcOH, 25 oC, 20-40

min (90%); (g) activated MnO2, Acetonitrile, 85 oC, 20-40 min (90%).
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Preparation of 2,6-Dioximinocyclohexanone (2): To a solution of 50 g. (0.509
moles) of cyclohexanone on 200 ml. of ether was added 11 ml. of con. HCl. The
reaction mixture was cooled to 10 oC, and nitrogen gas was passed slowly
through it for 15-20 min. Then methyl nitrite was passed slowly from an external
generator. The methyl nitrite gas was generated by adding a solution of 32 ml. of
con. H2SO4 in 58 ml. of H2O dropwise to a mixture of 86 g. of sodium nitrite, 41 g.
of methanol, and 76 ml. of H2O. The temperature was maintained at 5- 10 oC,
while the methyl nitrite was passed in over about 2 h until the methyl nitrite gas
was seized. A pale Yellow solid was precipitated as the reaction proceeded.
Then the reaction mixture was stirred at 25 oC for about 2h, the solid was filtered
on Buckner funnel and washed with (100 ml x 2) diethyl ether and dried
thoroughly to obtain pure product 2 as a pale yellow solid (70.8 g, 89% yield). 1H
NMR (400 MHz, DMSO-d6): δ (ppm): 2.69-2.65 (t, J = 6.5 Hz, 4H), 1.76-1.69 (m,
2H); 13C NMR (100 MHz, DMSO-d6): δ (ppm): 181.6, 154.6, 24.3, 17.9; MS (EI,
m/z): 156 [M]+.

Preparation of 1, 2, 3-Cyclohexane trioxime (3): To a solution of compound-2,
31.3 g. (0.2 moles) in 300 ml. of 50% aq Ethanol was added 12.9g. of Na2CO3,
followed by 17.4 g of Hydroxylamine hydrochloride at stirring. The stirring was
continued at 25 oC for about overnight. The precipitate obtained was filtered on
Buckner funnel and washed with (50 ml x 2) of H2O. The solid was dried
thoroughly to obtain compound-3 as a pale brown solid (27 g, 80% yield). 1H
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NMR (400 MHz, DMSO-d6): δ (ppm): 12.59 (s, 1H), 11.83 (s, 1H), 11.33 (s, 1H),
2.58-2.49 (m, 4H), 1.65-1.56 (m, 2H); 13C NMR (100 MHz, DMSO-d6): δ (ppm):
154.6, 153.1, 144.2, 25.2, 24.9, 18.1; MS (EI, m/z): 171 [M]+.

Preparation of 4-Hydroxyimino-4,5,6,7-tetrahydrobenzo[c][1,2,5]oxadiazole
1-oxide (4): To a solution of 10 g. (0.058 moles) of trioxime 3 in 35 ml. of 10%
NaOH was added at reaction temperature 5-10

o

C a solution of sodium

hypobromite prepared from 4.67 g. of NaOH in 44 ml. of water and 1.5 ml. of
bromine. The reaction mixture was stirred 1h at 25 oC and 8 ml. of con .HCl was
added drop wise over a period of 10 min. The precipitate obtained was filtered on
Buckner funnel and washed with (20 ml. x 2) H2O and dried to obtain compound4 as a pale yellow solid (8.1 g. 82% yield). 1H NMR (400 MHz, DMSO-d6): δ
(ppm): 12.26 (s, 1H), 2.71-2.61 (m, 4H), 1.89-1.81 (m, 2H); 13C NMR (100 MHz,
DMSO-d6): δ (ppm): 152.0, 145.3, 114.3, 22.6, 19.5, 19.2; MS (EI, m/z): 169 [M]+.

Preparation of 4-oxo-4,5,6,7-tetrahydrobenzo[c][1,2,5]oxadiazole 1-oxide
(5): To a stirred solution of 8g (0.04 moles) compound-4 in 70 ml. of 30%
formaldehyde was added 53 ml. of con HCl, slowly dropwise over a period of 20
min. Continued the stirring at 25 oC for about 20 min and extracted with
223

chloroform (2 x 100 ml). The organic layer was separated and washed with water
(2 x 100 ml) and dried over anhydrous Na2SO4 and concentrated on rota vapour
under reduced vacuum to give the product 5 as pale yellow solid (6.5g 90%
yield). 1H NMR (400 MHz, DMSO-d6): δ (ppm): 2.91-2.85 (t, J = 6.25 Hz, 2H),
2.78-2.73 (m, 2H), 2.30-2.21 (m, 2H); 13C NMR (100 MHz, DMSO-d6): δ (ppm):
183.9, 145.9, 108.7, 35.2, 16.2, 14.5; MS (EI, m/z): 154 [M]+.

Preparation

of

5-(hydroxyimino)-4-oxo-4,5,6,7-

tetrahydrobenzo[c][1,2,5]oxadiazole 1-oxide (6): To a stirred solution of 6g
(0.038 moles) compound 5 in 46 ml. of ethanol was added 46 ml. of acetic acid
and 2.95 g (0.042 moles) of sodium nitrite at 0 oC. The stirring was continues at 0
o

C for 4 h and at 25 oC for about overnight. The precipitate was filtered on

Buckner funnel and washed with (2 x 10 ml) water and dried thoroughly to obtain
product 6 as pale yellow solid. Evaporation of the filtrate gave a further amount of
product. (5g, 70% yield). 1H NMR (400 MHz, DMSO-d6): δ (ppm): 13.12 (s, 1H),
3.08-3.02 (t, J = 6.8 Hz, 2H), 2.88-2.83 (t, J = 7.0 Hz, 2H); 13C NMR (100 MHz,
DMSO-d6): δ (ppm): 175.2, 153.6, 152.3, 115.1, 20.4, 16.2; MS (EI, m/z): 183
[M]+.
General procedure for the preparation of (4)-4-(Substituted aromatic
hydrazono)-5-(hydroxyimino)-4,5,6,7-tetrahydrobenzo[c][1,2,5]oxadiazole 1oxides (7a-z): To a stirred solution of 500 mg (2.73 mmoles, 1equi) of compound
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6 in 10 ml. of ethanol was added corresponding hydrazine compounds (2.73
mmoles, 1 equi) and catalytic amount of acetic acid. The stirring was continued
at 25 oC for 30 min. The precipitate was filtered on Buckner funnel and washed
with (5 ml) of ethanol and dried thoroughly to obtain products (7a-z) as solids.
(70-85% yield).

(4Z)-4-(2-(2-chlorophenyl)hydrazono)-5-(hydroxyimino)-4,5,6,7
tetrahydrobenzo[c][1,2,5]oxadiazole 1-oxide (CMPD-A): To a stirred solution
of 500 mg (2.73 mmoles) compound 6 in 10 ml. of ethanol was added 387 mg
(2.73 mmoles) of 2-chlorophenyl hydrazine and catalytic amount of acetic acid.
The stirring was continues at 25 oC for 30 min. The precipitate was filtered on
Buckner funnel and washed with (5 ml) of ethanol and dried thoroughly to obtain
product 7 as yellow solid. (710 mg, 85% yield). 1H NMR (400 MHz, DMSO-d6): δ
(ppm): 13.33 (s, 1H), 12.4 (s, 1H), 7.71 (d, J = 9.1 Hz,3.08-3.02 (t, J = 6.8 Hz,
2H), 2.88-2.83 (t, J = 7.0 Hz, 2H);

13

C NMR (100 MHz, DMSO-d6): δ (ppm):

153.8, 153.6, 139.9, 129.9, 129.04, 123.9, 122.1, 119.1, 114.9, 113.3, 20.2, 15.9;
MS (EI, m/z): 307 [M]+.
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General procedure for Preparation of 7-(substituted aromatic)-5,7-dihydro4H-[1,2,3]triazolo[4',5':3,4]benzo[1,2-c][1,2,5]oxadiazole 3,6-dioxide (8a-o):
To a solution of corresponding hydrazones (1 equi) in acetonitrile (100 times),
activated MnO2 (7 equi) was added. The reaction mixture was stirred at 85 oC for
2-3 h. (until all the starting compound has disappeared, TLC monitoring). After
completion of the reaction the reaction mixture was cooled to 25 oC and filtered
on Buckner funnel over celite and washed with acetonitrile (2x 50 ml). The filtrate
was evaporated on rota vapour at reduced vacuum and the crude product was
purified

by

column

chromatography

(silica

gel

120-200

mesh)

using

Ethylaceate/n-Hexane as eluents to afford the compounds with high purity (8a-o).

7-(2-Chlorophenyl)-5,7-dihydro-4H-[1,2,3]triazolo[4',5':3,4]benzo[1,2c][1,2,5]oxadiazole 3,6-dioxide (CMPD-A): Compound A was prepared
according to the method described in general procedure. Employing compound
7A (500 mg, 1.62 mmol) in 50 ml. of acetonitrile and MnO2 (990 mg, 11.4 mmol)
to obtain compound-A as pale yellow solid (440 mg, 90% yield). 1H NMR (400
MHz, CDCl3): δ (ppm): 7.68-7.49 (m, 5H), 3.28-3.21 (m, 2H), 3.19-3.13 (m, 2H);
13

C NMR (100 MHz, CDCl3): δ (ppm): 147.9, 134.3, 133.4, 132.6, 131.4, 131.1,

129.1, 125.7, 17.1, 16.5; MS (EI, m/z): 305 [M]+.
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7-(3,4,5-Trimethoxyphenyl)-5,7-dihydro-4H[1,2,3]triazolo[4',5':3,4]benzo[1,2-c][1,2,5]oxadiazole

3,6-dioxide

(8a):

Compound 8a was prepared according to the method described in general
procedure. Employing compound 7a (500 mg, 1.37 mmol) in 50 ml. of acetonitrile
and MnO2 (838 mg, 9.59 mmol) to obtain 8a as brown solid (460 mg, 95% yield).
1

H NMR (400 MHz, DMSO-d6): δ (ppm): 7.30 (s, 2H), 3.94(s, 6H), 3.93 (s, 3H),

3.24-3.20 (m, 2H), 3.17-3.13 (m, 2H); 13C NMR (100 MHz, DMSO-d6): δ (ppm):
147.9, 134.3, 133.4, 132.6, 131.4, 131.1, 129.1, 125.7, 17.1, 16.5; MS (EI, m/z):
363 [M]+.

7-(3-(methylsulfonamido)phenyl)-5,7-dihydro-4H[1,2,3]triazolo[4',5':3,4]benzo[1,2-c][1,2,5]oxadiazole

3,6-dioxide

(8b):

Compound 8b was prepared according to the method described in general
procedure. Employing compound 7b (500 mg, 1.366 mmol) in 50 ml. of
acetonitrile and MnO2 (831 mg, 9.56 mmol) to obtain 8b as pale yellow solid (440
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mg, 90% yield). 1H NMR (400 MHz, DMSO-d6): δ (ppm): 10.21 (bs, 1H), 7.79 (s,
1H), 7.67 (d, J = 8.2 Hz, 1H), 7.60 (t, J = 8.1 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H),
3.32 (s, 3H), 3.01 (s, 4H); 13C NMR (100 MHz, DMSO-d6): δ (ppm): 147.8, 139.8,
135.2, 132.5, 130.9, 127.2, 120.7, 118.6, 113.9, 112.9, 17.1, 16.6; MS (EI, m/z):
366 [M]+.

7-(3-acetamidophenyl)-5,7-dihydro-4H-[1,2,3]triazolo[4',5':3,4]benzo[1,2c][1,2,5]oxadiazole 3,6-dioxide (8c): Compound 8c was prepared according to
the method described in general procedure. Employing compound 7c (500 mg,
1.5 mmol) in 50 ml. of acetonitrile and MnO2 (921 mg, 10.6 mmol) to obtain 8c as
pale yellow solid (457 mg, 92% yield). 1H NMR (400 MHz, DMSO-d6): δ (ppm):
10.31 (bs, 1H), 8.28 (s, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H),
7.55 (t, J = 8.1 Hz, 1H), 3.08 (s, 4H), 2.09 (s, 3H); 13C NMR (100 MHz, DMSOd6): δ (ppm):169.2, 147.8, 140.6, 134.8, 132.4, 130.1, 127.2, 120.3, 118.2, 114.0,
112.9, 24.5, 17.1, 16.6; MS (EI, m/z): 330 [M]+.
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7-(3-fluorophenyl)-5,7-dihydro-4H-[1,2,3]triazolo[4',5':3,4]benzo[1,2c][1,2,5]oxadiazole 3,6-dioxide (8d): Compound 8d was prepared according to
the method described in general procedure. Employing compound 7d (500 mg,
1.36 mmol) in 50 ml. of acetonitrile and MnO2 (1.04 g, 11.97mmol) to obtain 8d
as pale yellow solid (450 mg, 92% yield). 1H NMR (400 MHz, DMSO-d6): δ
(ppm): 7.91-7.87 (m, 1H), 7.82-7.80 (m, 1H), 7.51-7.46 (m, 1H), 3.09 (s, 4H);

13

C

NMR (100 MHz, DMSO-d6): δ (ppm):163.3, 160.8, 147.7, 135.6, 132.8, 131.9,
127.3, 119.9, 117.4, 112.9, 111.0, 17.0, 16.6; MS (EI, m/z): 289 [M]+.

7-(3-(methylcarbamoyl)phenyl)-5,7-dihydro-4H[1,2,3]triazolo[4',5':3,4]benzo[1,2-c][1,2,5]oxadiazole

3,6-dioxide

(8e):

Compound 8e was prepared according to the method described in general
procedure. Employing compound 7e (500 mg, 1.5mmol) in 50 ml. of acetonitrile
and MnO2 (921 mg, 10.6 mmol) to obtain 8a as pale yellow solid (457 mg, 92%
yield). 1H NMR (400 MHz, DMSO-d6): δ (ppm): 8.70 (bs, 1H), 8.35 (t, J = 1.84
Hz, 1H), 8.12-8.03 (m, 2H), 7.75 (t, J = 7.9 Hz, 1H), 3.09 (s, 4H), 2.82 (d, J = 4.5
Hz, 3H); 13C NMR (100 MHz, DMSO-d6): δ (ppm):; MS (EI, m/z): 328 [M]+.
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7-(2-fluorophenyl)-5,7-dihydro-4H-[1,2,3]triazolo[4',5':3,4]benzo[1,2c][1,2,5]oxadiazole 3,6-dioxide (8f): Compound 8f was prepared according to
the method described in general procedure. Employing compound 7f (500 mg,
1.71 mmol) in 50 ml. of acetonitrile and MnO2 (1.04g, 11.97 mmol) to obtain 8f as
pale yellow solid (450 mg, 92% yield). 1H NMR (400 MHz, CDCl3): δ (ppm): 7.687.59 (m, 2H), 7.42-7.35 (m, 2H), 3.26-3.22 (m, 2H), 3.17-3.13 (m, 2H); 13C NMR
(100 MHz, CDCl3): δ (ppm):158.5, 156.0, 147.8, 134.6, 133.7, 130.3, 126.0,
125.9, 121.4, 117.6, 112.9, 17.1, 16.6; MS (EI, m/z): 289 [M]+.

7-(2-carboxyphenyl)-5,7-dihydro-4H-[1,2,3]triazolo[4',5':3,4]benzo[1,2c][1,2,5]oxadiazole 3,6-dioxide (8g): Compound 8g was prepared according to
the method described in general procedure. Employing compound 7g (500 mg,
1.57 mmol) in 50 ml. of acetonitrile and MnO2 (960 mg, 11.04 mmol) to obtain 8g
as pale yellow solid (450 mg, 91% yield). 1H NMR (400 MHz, DMSO-d6): δ
(ppm): 13.42 (bs, 1H), 8.06 (d, J = 8.2 Hz, 1H), 7.87-7.76 (m, 2H), 3.07 (s, 4H);
13

C NMR (100 MHz, DMSO-d6): δ (ppm):; MS (EI, m/z): 315 [M]+.
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7-(2-(methylcarbamoyl)phenyl)-5,7-dihydro-4H[1,2,3]triazolo[4',5':3,4]benzo[1,2-c][1,2,5]oxadiazole

3,6-dioxide

(8h):

Compound 8h was prepared according to the method described in general
procedure. Employing compound 7h (500 mg, 1.5 mmol) in 50 ml. of acetonitrile
and MnO2 (921 mg, 10.6 mmol) to obtain 8h as pale yellow solid (450 mg, 92%
yield). 1H NMR (400 MHz, DMSO-d6): δ (ppm): 8.57 (bs, 1H), 7.80-7.69 (m, 4H),
3.12-3.02 (m, 4H), 2.69-2.65 (m, 3H);

13

C NMR (100 MHz, DMSO-d6): δ

(ppm):165.8, 147.9, 134.1, 132.0, 131.7, 131.6, 129.0, 128.9, 125.6, 112.9, 26.6,
17.1, 16.4; MS (EI, m/z): 328 [M]+.

7-(2-nitrophenyl)-5,7-dihydro-4H-[1,2,3]triazolo[4',5':3,4]benzo[1,2c][1,2,5]oxadiazole 3,6-dioxide (8i): Compound 8i was prepared according to
the method described in general procedure. Employing compound 7i (500 mg,
1.57 mmol) in 50 ml. of acetonitrile and MnO2 (956 mg, 11.0 mmol) to obtain 8i
as pale yellow solid (457 mg, 92% yield). 1H NMR (400 MHz, DMSO-d6): δ
(ppm): 7.68-7.49 (m, 5H), 3.28-3.21 (m, 2H), 3.19-3.13 (m, 2H); 13C NMR (100
MHz, DMSO-d6): δ (ppm):; MS (EI, m/z): 316 [M]+.
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7-(2-(trifluoromethyl)phenyl)-5,7-dihydro-4H[1,2,3]triazolo[4',5':3,4]benzo[1,2-c][1,2,5]oxadiazole

3,6-dioxide

(8j):

Compound 8j was prepared according to the method described in general
procedure. Employing compound 7j (500 mg, 1.46 mmol) in 50 ml. of acetonitrile
and MnO2 (892 mg, 10.26 mmol) to obtain 8j as pale yellow solid (462 mg, 93%
yield). 1H NMR (400 MHz, DMSO-d6): δ (ppm): 8.12 (d, J = 8.7 Hz, 1H), 8.01 (q,
J = 7.6, 7.1 Hz, 2H), 7.88 (d, J = 7.2 Hz, 1H), 3.10 (s, 4H); 13C NMR (100 MHz,
DMSO-d6): δ (ppm):156.6, 147.7, 134.1, 133.6, 132.1, 130.0, 128.2, 125.1,
112.9, 17.1, 16.5; MS (EI, m/z): 339 [M]+.

7-(o-tolyl)-5,7-dihydro-4H-[1,2,3]triazolo[4',5':3,4]benzo[1,2c][1,2,5]oxadiazole 3,6-dioxide (8k): Compound 8k was prepared according to
the method described in general procedure. Employing compound 7k (500 mg,
1.74 mmol) in 50 ml. of acetonitrile and MnO2 (1.06 g, 12.19 mmol) to obtain 8k
as pale yellow solid (460 mg, 92% yield). 1H NMR (400 MHz, CDCl3): δ (ppm):
7.55-7.51 (m, 1H), 7.45-7.37 (m, 3H), 3.28-3.21 (m, 4H), 2.28 (s, 3H); 13C NMR
(100 MHz, CDCl3): δ (ppm):146.3, 137.0, 132.8, 131.9, 131.8, 131.4, 127.9,
127.0, 124.4, 110.4, 17.8, 17.0, 16.5; MS (EI, m/z): 285 [M]+.
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7-(2,6-difluorophenyl)-5,7-dihydro-4H-[1,2,3]triazolo[4',5':3,4]benzo[1,2c][1,2,5]oxadiazole 3,6-dioxide (8l): Compound 8l was prepared according to
the method described in general procedure. Employing compound 7l (500 mg,
1.61 mmol) in 50 ml. of acetonitrile and MnO2 (892 mg, 10.26 mmol) to obtain 8l
as pale yellow solid (463 mg, 93% yield). 1H NMR (400 MHz, DMSO-d6): δ
(ppm): 7.95-7.86 (m, 1H), 7.59-7.51 (m, 3H), 3.10 (s, 4H); 13C NMR (100 MHz,
DMSO-d6): δ (ppm):159.8, 157.2, 136.1, 133.2, 125.9, 113.7, 13.6, 110.8, 17.0,
16.6; MS (EI, m/z): 307 [M]+.

7-(3-nitrophenyl)-5,7-dihydro-4H-[1,2,3]triazolo[4',5':3,4]benzo[1,2c][1,2,5]oxadiazole 3,6-dioxide (8m): Compound 8m was prepared according
to the method described in general procedure. Employing compound 7m (500
mg, 1.57 mmol) in 50 ml. of acetonitrile and MnO2 (950 mg, 11.0 mmol) to obtain
8m as pale yellow solid (467 mg, 94% yield). 1H NMR (400 MHz, DMSO-d6): δ
(ppm): 8.85 (s, 1H), 8.44-8.39 (m, 2H), 7.95 (t, J = 8.2 Hz, 1H), 3.11 (s, 4H); 13C
NMR (100 MHz, DMSO-d6): δ (ppm):148.3, 147.6, 135.0, 133.2, 131.6, 129.5,
127.5, 124.7, 118.7, 112.9, 17.1, 16.6; MS (EI, m/z): 367 [M]+.

233

7-(naphthalen-1-yl)-5,7-dihydro-4H-[1,2,3]triazolo[4',5':3,4]benzo[1,2c][1,2,5]oxadiazole 3,6-dioxide (8n): Compound 8n was prepared according to
the method described in general procedure. Employing compound 7n (500 mg,
1.54 mmol) in 50 ml. of acetonitrile and MnO2 (940 mg, 10.83 mmol) to obtain 8n
as pale yellow solid (450 mg, 91% yield). 1H NMR (400 MHz, DMSO-d6): δ
(ppm): 8.32 (d, J = 8.2 Hz, 1H), 8.15 (d, J = 8.6 Hz, 1H), 7.89 (d, J = 7.3 Hz, 1H),
7.77 (t, J = 7.9 Hz, 1H), 7.72-7.69 (m, 2H), 7.48 (d, J = 7.1 Hz, 1H), 3.14 (s, 4H);
13

C NMR (100 MHz, DMSO-d6): δ (ppm): 147.9, 134.3, 133.4, 132.6, 131.4,

131.1, 129.1, 125.7, 17.1, 16.5; MS (EI, m/z): 321 [M]+.

7-(3-carboxyphenyl)-5,7-dihydro-4H-[1,2,3]triazolo[4',5':3,4]benzo[1,2c][1,2,5]oxadiazole 3,6-dioxide (8o): Compound 8o was prepared according to
the method described in general procedure. Employing compound 7o (500 mg,
1.57 mmol) in 50 ml. of acetonitrile and MnO2 (960 mg, 11.04 mmol) to obtain 8o
as pale yellow solid (462 mg, 95% yield). 1H NMR (400 MHz, DMSO-d6): δ
(ppm): 13.21(bs, 1H), 8.46 (s, 1H), 8.12 (d, J = 7.9 Hz, 2H), 7.75 (t, J = 7.9 Hz,
1H), 3.09 (s, 4H); 13C NMR (100 MHz, DMSO-d6): δ (ppm): 147.9, 134.3, 133.4,
132.6, 131.4, 131.1, 129.1, 125.7, 17.1, 16.5; MS (EI, m/z): 315 [M]+.
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Scheme-II Synthesis of amides (9a-z):

Reagents and conditions: 8g/8o and Corresponding Amines (i) HATU, DIPEA
and Dry DMF 25 oC, 4h (90%).
Compound

R1

Compound

9a

9n

9b

9o

9c

9p

9d

9q
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R1

9e

9r

9f

9s

9g

9t

9h

9u

9i

9v

9k

9w

9l

9x

9m

9y

General procedure for synthesis of compounds (9a-z): To a solution of
compounds 8a/8o (1 equi) in Dry DMF (100 times), HATU (1 equi) and DIPEA (3
equi) was added. The reaction mixture was stirred at 25 oC for 2-3 h. (until all the
starting compound has disappeared, TLC monitoring). After completion of the
reaction, ethyl acetate (100 mL) was added and washed with sat. NaCl sol. (100
mL x 2) and water (100 mL) separated the organic layer and dried over
236

anhydrous Na2SO4. The solvent was evaporated on rota vapour at reduced
vacuum and the crude product was purified by column chromatography (silica gel
120-200 mesh) using Ethylaceate/n-Hexane as eluents to afford the compounds
with high purity (9a-z).

Scheme-III Synthesis of compound 15:

Reagents and conditions: (i) p-toluenesulfonylmethyl isocyanide (TOSMIC), tBuOK and Dry THF, 25 oC, 1h (85%); (ii) N-methyl-2-pyrrolidone (NMP), K2CO3,
2-Fluoroiodobenzene and Copper (I) bromide, 205 oC, 24h (40%); (iii) Isoamyl
nitrite, t-BuOK t-butanol 25 °C for 30 min (60%); (iv) NH2OH.HCl, MeOH, 70 oC
1h (80%); (v) NaOBr aq Sol, H2O, 30 min (85%).
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CHAPTER 7
UNIQUELY CASPASE-6: PROPOSITIONS OF THE DISTINCT STRUCTURAL
ARCHITECTURES ON FUNCTION AND TARGETED
REGULATION OF CASPASE-6

Figure 7.1 Visual Summary of PhD Research Projects
The various work done for this dissertation on probing the domain architecture
and structural dynamics of caspase-6 for its specific regulation.
A human being is a conglomerate of intricately woven cells packed into
tissues and organs with specific vital functions. Individual cells within tissues are
composed of biomolecules that associate in myriads of combinations within a
molecularly crowded environment, to come up with an organized molecular
ensemble that is poised to accomplish a specific cellular function. It takes a
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village of ingenious minds to comprehend the governing molecular machineries
within this tiny single cell. But this shared scientific knowledge amassed by the
collective efforts of scientific experts around the world over the years has built the
very foundation of the science behind the therapeutics that combat a range of
diseases—from cancer to neurodegeneration—that surfaced from the molecular
errors made by this tiny single cell along various cellular process.
Caspases are one class of molecular machines that direct programmed
cell death in multicellular organisms. Their function must be stringently regulated
to avoid the unwanted cellular consequences that result in mostly debilitating or
even fatal diseases. The dissertation presents series of careful investigations into
the structural dynamics and regulation of caspase-6, the function of which is
associated with neurodegenerative diseases. Thus, it is essential to understand
the fine and unique structural details of caspase-6, of which are often coupled to
its function and regulation. Only then we can precisely control its specific function
for therapeutic purposes.
Because of its association with neurodegeneration, caspase-6 has
become an increasingly popular molecular target for drug development that is
being pursued by both academic and pharmaceutical research laboratories.
Nevertheless, existing limitations regarding its structure, function, and specific
regulation need to be addressed. The visual summary of the body of work
narrated throughout this dissertation is presented in Figure 7.1. In the attempt to
relate structure-function relationships in caspase-6, Chapter II of this dissertation
presents the structural dynamic studies of caspase-6 that revealed the unique
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molecular switch at a potentially regulatory 130’s region. Chapter III narrates
further structural studies that uncovered the discrete and local dynamic
conformational changes in key regions of caspase-6 that can be exploited as a
complimentary scaffold for improved design of therapeutics. Meanwhile, the
studies on mutations in the CASP6 gene in several tumors (Chapter IV) took a
naturally provided tour of the functionally sensitive regions in caspase-6. This
study enabled the identification of stabilizing cation–π stacking interaction that
broadly being utilized by caspases to support the proper assembly of its active
site loops for substrate binding and catalysis. We have also uncovered another
level of regulation through nucleotide binding at the dimer interface that appears
to be procaspase-6 (zymogen) specific (Chapter V). The moderately conserved
dimer interface emerged as an exploitable region for targeted regulation of
caspase-6 as it can bind ligands from both natural and synthetic sources. Finally,
an activity-based high throughput screen of specific binders of caspase-6
enabled the discovery of the most potent and selective inhibitors of caspase-6 to
date. A series of careful experiments disclosed the specific covalent modification
of Cys–264 within the most diversified loop region in caspases that explains the
exquisite selectivity of bis-N-oxide inhibitors. Along with its favorable cell-based
and medicinal chemical properties, the exquisitely selective bis-N-oxide inhibitors
can potentially offer a targeted regulation of caspase-6 aimed to afford treatment
of neurodegeneration as well as molecular tools to discover mechanisms and
functions of caspase-6 activation in cells.
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7.1 Proposed Functional and Regulatory Roles of the Structural Switch
The mobile loops of caspases are crucial for the assembly of the
substrate-binding groove of binding and catalysis. Caspase-6 exists distinctly
from other caspases because it has additional mobile regions. Crystallography
(Vaidya, 2011; Wang et al., 2010) and the HDX-MS work (Dagbay et al., 2017)
presented in Chapter II have identified the two distinct conformational states of
the 130’s region in caspase-6. Detailed MD simulations, mutagenesis, and
thermal stability assays pinpointed Asp–135 within the 130’s region to be critical
in the helix-strand interconversion where the protonation of this residue
contributes to the favoring of the extended helical state of caspase-6. Only upon
substrate recruitment does this 130’s region exist exclusively in the canonical
strand conformation. Careful inspection of the residues on top of the 130’s region
shows patches of hydrophobic amino acids, e.i. tryptophan, tyrosine, and
phenylalanine, that might engage in substrate recognition as a possible exosite.
One can imagine the productive coupling of the protonation state of Asp-135 and
the hydrophobic patch to be taken advantage by caspase-6 in cellular scenarios
where a change in substrate preference is required, for example, under oxidative
stress conditions (Majdi et al., 2016) and global brain ischemia (Ding et al.,
2012), which both result in slight acidification. Probing the set of unique
substrates that employ these hydrophobic patch and extended helix tandem for
binding with caspase-6 is crucial in dissecting the specific protein–protein
interactions involved in caspase-6 signaling given the association of caspase-6 in
the multiple pathways to neurodegeneration (Wang et al., 2014). Recently, an
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MS-based approach to identify unique natural substrates of caspases in cellular
lysates was reported (Julien et al., 2016). Most substrates identified are novel
with significant variations in their rate of cleavage, by up to 500–fold. Using this
elegant approach, one can test the hypothesis that changes in substrate
preferences by the exosite couple helical caspase-6 (mimicked by E135Q
mutation) and the hydrophobic patch in relevant normal and disease neuronal
cell lysates. One can specifically aim to make substitution mutations of the
exposed hydrophobic patch residues and consider the changes on the substrate
specificity and protein-protein interaction of caspase-6 using a panel of known
protein substrates, i.e. microtubule-associated protein Tau, lamin A/C, by
proteolytic cleavage and pull-down assays, respectively. A broader approach will
be subjecting these hydrophobic patch mutation variants to the MS-based
approach as described by Julien et al. (2016) using relevant neuronal lysates and
determine the overall changes in the pattern of substrate recognition. One would
expect that if the hydrophobic patch on top of the 130’s helix plays a role in
molecular recognition, there would be observed changes in the proteolytic
cleavage pattern, protein-protein interaction, and substrate specificity profiles of
these hydrophobic patch mutation variants compared with the wild type caspase6. These approaches will ultimately reveal the relevance of the helix-strand
transition along with the possible uncovering of novel neuronal factors within the
caspase-6 signaling that may afford strategies for targeted regulation of caspase-6.
Moreover, the implication of the extended helical conformation in the
specific regulation of caspase-6 for therapeutic ventures is exceptional. When
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locked in the helical conformation, the Cys–His dyad is oriented in such a way
that renders caspse-6 catalytically inefficient to turnover substrates. As it has
been suggested before (Vaidya and Hardy, 2011; Vaidya et al., 2011), locking
caspase-6 in the helical state using small molecules may provide a means for
achieving caspase-6-specific inhibition. A continuing effort on the search for
caspase-6 helical state binders is an important yet challenging stride. But once
the proposed research goal of identifying the substrates that depend on the
helical/hydrophobic patch tandem on binding is satisfied, one can strategically
identify the caspase-6 binding epitope within the identified substrate through
HDX-MS, and use it as a scaffold to develop peptide-based inhibitors directed to
bind and lock the inactive helical state of caspase-6.

7.2 Implications of the Local Dynamic Changes and the Disordered
Prodomain
Uncovering the dynamic conformational changes in caspases upon
proteolytic activation and substrate binding (Chapter III) provides lasting
implications in structure-function studies and regulation of caspases. Over 226
structures of caspases have been reported to date, yet the complete depiction of
the underlying mechanisms of caspase activation remain inadequate due to the
missing information on conformational dynamics that is not quite satisfied by
protein crystallography. Our report on the accompanying dynamic conformational
changes along the proteolytic activation path of caspase-6 is the first of its kind
within the caspase family. One example of a seemingly global approach to
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determining the pattern of structural dynamics within protein family is that of Ras
superfamily

where

distinguishing

and

shared

signatures

of

dynamic

conformational changes were revealed among eight members of Ras and Rho
subfamilies (Harrison et al., 2016). Interestingly, the Ras superfamily members,
despite varied functions, have similar tertiary structures irrespective of its diverse
primary amino acid sequence. But the conformational dynamic profiles of Ras
superfamily suggest that tertiary structure conservation does not necessarily
result in the conservation of protein structural dynamics. This finding served as
an inspiration to use HDX-MS to assess the hypothesis that caspases, despite
their similarity in the overall protein fold, have diverse set of conformational
dynamics that can contribute to the distinct substrate specificity and unique
activation mechanism of each caspase. This will likely benefit future efforts on
the design of a caspase-specific regulator to be used in drug discovery or as
molecular probes to decipher additional caspase function in cells.
Along with the expected pattern of dynamic conformational changes in the
substrate binding loops of caspase-6, these studies revealed several striking
dynamic conformational changes in the regions of the prodomain, the directly
adjoining 26–32 region, and the linker region (Chapter III). The conformational
changes in the 26–32 region are dependent on the activation state of caspase-6.
Moreover, the 26–32 region happens to be in the same loop as the exosite for
substrate binding in caspase-7 (Boucher et al., 2012), the zinc ligands (Lys–36)
identified in caspase-6 (Velazquez-Delgado and Hardy, 2012), and the regulatory
phosphorylation site (Ser–30) in caspase-7, which modulates caspase-9 binding.
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It very tempting to speculate that a possible role of this region is in substrate
recruitment or binding of key regulators of caspase-6, since this region shows
variable conformational dynamics between its zymogen and active forms of the
enzyme. One plausible future direction is directly mutating this region and then
asses the propensity of this caspase-6 variant to bind a panel of protein
substrates or consider its effect on the overall structure of caspase-6. Moreover,
sequence alignment of all caspases suggests that the 26–32 is not conserved
across caspases, thus opens the possibility that it is a regulatory site that binds
to a select group of substrates in one caspase but not in any other caspases.
Finally, this work uncovered the intrinsically disordered nature of the
prodomain and a region in the linker, both of which are also computationally
predicted to be involved in protein binding. Moreover, a region in the linker is
predicted to be involved in protein binding only in caspase-6 but not in other
executioner caspases. One cannot avoid speculating that these regions are
important protein-binding regions that regulate caspase-6 function. Given the
reported roles of the prodomain in other caspases in protein–protein interactions
(see Chapter III Discussion Section) and armed with an MS-based approach
previously mentioned in a prior section 7.1 of this chapter, one can set out to test
the hypothesis that the prodomain and linker are involved in regulatory proteinprotein interactions by facilitating binding of caspase-6 to different cellular
substrates under certain cellular conditions. The substrate preference of
caspase-6 may vary depending on the presence of the prodomain or linker or
both. Moreover, the inhibitory effect of the prodomain is observed in cells but not
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under in vitro conditions (Klaiman et al., 2009) further suggesting that the
presumed regulatory protein–protein interaction can only occur in the permissive
environment of the cell. In addition, the fact that the prodomain in caspases is
one of the most distinctive regions highlights the plethora of unique possible
combinations of protein–protein interactions one caspase can make through its
prodomain region, thus suggesting a route to targeted regulation in caspases. In
fact, with the advent of the advanced antibody engineering technology, one could
develop an antibody against each caspase prodomain, in a targeted way that
would cater to a particular basic research or therapeutic ventures. This concept
has been imagined in the past and now has recently been realized in a recent
report on designing antibodies directed towards a specific epitope within
intrinsically disordered region using disordered proteins and peptides associated
with neurodegenerative and systematic misfolding diseases (Gao et al., 2009;
Sormanni et al., 2015).

7.3. Consequences of the Mutagenic Pressure in Caspases-6
The Catalogue of Somatic Mutations in Cancer (COSMIC) database
(Forbes et al., 2011) is a comprehensive resource of somatic mutations observed
in human cancer. In Chapter IV of this work, we have selected mutations in
CASP6 gene from the COSMIC database as well as from a mutational study in
CASP6 gene in colorectal and gastric carcinoma (Lee et al., 2006) to assess the
effect of these mutations in caspase-6 activity. Our results showed that these
tumor-associated mutations are deactivating, effectively slowing the ability of
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caspase-6 to process its substrates. One interesting observation that surfaced
from this work is the recognition that cation–π stacking interaction may be widely
used across the family of caspases to stabilize the mobile loops for proper
assembly of the substrate binding groove, thus productive enzyme catalysis. This
observation is suggested by the inactivating R259H mutation from a malignant
tumor in the colon. Although the inhibitory effect of the R259H mutation in vitro is
clear, its precise oncogenic contribution in cells is still unmasked. The cell-based
assay on the determination of the effect of R259H on the apoptotic index of the
normal and tumor-associated cells might be relevant to explore as well as those
of other observed mutations in caspase-6. The rational for this exploration is the
fact that caspase-6 expression profiling through immunohistochemistry showed
60–90% of the tumors tested showed expression of caspase-6 (Lee et al., 2006).
Likewise, aberrant regulation indicated by the presence of underexpressed or
overexpressed CASP6 gene across various tumor-associated tissue types has
been annotated in the COSMIC database (Chapter IV). Moreover, the hypothesis
that caspase-6 may be operational in select chemotherapeutic anti-cancer
mechanisms merits further investigation as it has been shown in several reports
that certain type of cancers can undergo caspase-6-mediated apoptotic cell
death (Martin et al., 2016; Shahzidi et al., 2013; Suboj et al., 2012; Yang et al.,
2014). In fact, a report has shown that the resistance of neoplastic cells to
chemotherapeutic insults is through inhibition of caspase-6 activation by survivin3B (Vegran and Boidot, 2013). And thus, downregulation of caspase-6 may
promote apoptotic resistance in some tumor cells. The association of caspase-6
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with cancer is another yet unexplored area with the potential to contribute cancer
therapeutics.

7.4 Caspase Dimer Interface, a Structural Hideout for Natural Ligands
Chapter V of this dissertation describes a collaborative project between
the Hardy Lab and ActivX Biosciences, Inc. to explore the regulatory role of
nucleotides on caspases. It was a surprise finding on the part of our ActivX
collaborators to observe that one of the peptides modified by their ATP acyl
phosphate probe was derived from procaspase-6. We then further explored the
ATP acyl phosphate probe binding characteristics and found that it binds to the
dimer interface in procaspase-6 requiring the critical Lys-198 residue possibly
binding through π-π stacking interactions. Moreover, other nucleotide probes can
bind to this dimer interface in procaspase-6. We also showed that inhibition of
procasapse-6 activation is a consequence of nucleotide binding to the dimer
interface. Thus, these data suggest that the dimer interface in procaspase-6 is a
regulatory nucleotide-binding site.
The question of why nucleotides bind procaspase-6 and possibly to other
caspases is remained unaddressed. I have provided some discussions to
address this question in Chapter V of this dissertation. One key realization from
this work and others is that nucleotides bind procaspase-6 to inhibit its apoptotic
function under cellular conditions that required nucleotides concentrations
greater than normal levels, presumably to promote cell survival in response to
various stress conditions, e.g. DNA damage. However, in the absence of a
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crystal structure, we can only propose a possible mechanism of action of
nucleotide binding to procaspase-6. Ishankumar Soni, a graduate student in the
Hardy Lab, is pursuing the co-crystal structures of procaspase-6 bound to
nucleotides with the goal of unraveling a possibly broad mechanism of nucleotide
binding to the dimer interface of procaspase-6.
Moreover, detailed cellular studies on the effect of varying endogenous
levels of nucleotides on procaspase-6 activation in cells through various reported
chemical and genetic tools may help further assess the functional role of
nucleotide binding to procaspase-6. Substitutions at the critical nucleotidebinding residue Lys-198 would be essential for assessing changes in the cellular
apoptotic index in the background of varying nucleotide concentrations in order to
further implicate the role of nucleotide binding to the apoptotic function of
caspase-6.
Meanwhile, the dimer interface residues of caspases are moderately
conserved thus provides a possible strategy to find caspase-specific binders that
take advantage of this cavity. The findings of the series of nanomolar affinity
binders of procaspase-6 identified through fragment-merging technology (Murray
et al., 2014) and the nucleotide binders of procaspase-6 provide the necessary
scaffolds for the future synthesis of a class of binders and activators specific to
bind to procaspase-6 dimer interface.
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7.5 Cys-264, a Perfect Anchor for the Specific Regulation of Caspase-6
With the discovery of the seemingly perfect inhibitor of caspase-6 that
covalently modifies Cys-264 in the most diversified loop of caspases, we now
have the capacity to interrogate the specific inhibition of caspase-6 and its impact
on the treatment strategies for neurodegeneration. Moreover, this inhibitor can be
developed as a powerful molecular probe to discover novel functions of caspase6 in both normal and disease state conditions.
However, there are still a lot of exciting strides to overcome including the
ongoing search for the most promising lead compound with improved potency in
both in vitro and in cell-based assays. The unwavering contributions of
Narasimha Rao, a postdoctoral fellow in the Hardy Lab, for all the synthetic
efforts for this work have seen unprecedented progress toward this goal with the
constant support of Yifei Pei, a graduate student in the Hardy Lab, who provides
expertise in both in vitro and in cell-based assays of the synthesized compounds.
In addition, despite several attempts to solve the co-crystal structure of caspase6 with compound A, there is still no available structure of caspase-6;compound A
complex that will definitely provide unparalleled contribution to the future design
of more potent analogs of compound A.
The current derivative of the bis-N-oxide lead compound with attached
biotin moiety can be a powerful chemical tool to facilitate the identification of
cellular off-targets of compound A through pull-down assays and mass
spectrometric analyses. Looking forward, this same technique can be applied to
identify protein and natural small molecule binders as well as other not yet
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identified post-translational modifications (PTM) of caspase-6. It would be
relevant to treat several types of cells from normal to diseased neuronal cells
with compound A–biotin to uncover some cell-specific interactors and novel
PTMs of caspase-6 between these cell types. One can also imagine the
synthesis of a compound A derivative with a fluorescent moiety to assess cellular
functions of caspse-6 in cells in terms of localization and distribution of caspase6 at various cellular conditions, e.g. inflammation and axonal degeneration.
Meanwhile, the assessment of the efficacy of the most potent compound A
derivatives in Alzheimer’s or Huntington’s mouse model will greatly impact the
potential of these caspase-6-specific inhibitors to be tested in humans with
neurodegenerative conditions.

In conclusion, the body of work presented in this dissertation is a
commencement of a thrilling future basic and applied research endeavors that
may impact the fields of apoptosis, cancer, and drug discovery efforts in
neurodegeneration.
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